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Abstract 
 
Type 2 diabetes (T2DM) is a complex disease, brought about by the 
interaction of genetic and environmental factors. Coupled with a 
growing obesity problem, the disease has reached epidemic 
proportions globally. Several heterogeneous metabolic disorders 
including hyperglycaemia and impaired insulin secretion and/or action 
play a part in the progression of the disease. Large-scale cohort studies 
have identified several biomarkers for diabetes risk and for glycaemic 
control. The current study focused on the sulphonylurea drug class, 
which is associated with poor response rates and significant adverse 
events including an increased risk of hypoglycaemia. This study aimed 
to validate existing markers and to identify new biomarkers that may 
aid in patient stratification, especially in response to sulphonylurea 
therapy. 500 participants with T2DM were recruited from the Western 
Health and Social Care Trust and formed the basis of the DIASTRAT 
cohort. Clinical and anthropometric data suggest that those receiving 
sulphonylureas had significantly worse outcomes in terms of glycaemic 
control and BMI, especially when this was combined with an 
exogenous insulin reparation. Genetic studies confirmed a role for 
ABCC8 and KCNJ11 in sulphonylurea response from beta cell (β-cell) 
lines. Furthermore, several SNPs in ABCC8, KCNJ11 and HNF1α were 
found to be significantly associated with glycemic control in 
participants receiving sulphonylurea therapy. A unique 75-protein 
signature was identified that correctly identifies those with T2DM to 
within 99.2% accuracy. Additionally, several of these proteins were 
found to correlate with glycaemic control in the DIASTRAT cohort. 
Overall, the work has identified several unique targets worthy of further 
validation in larger cohorts and secondary cohorts from other sites. 
Moreover, the work outlined in this thesis underlines the importance of 
considering both clinical and biological data for patient stratification. 
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1.1 The Endocrine pancreas 
The human pancreas comprises both the exocrine and endocrine 
compartments; it plays a role in the digestion and glucose homeostasis 
through its production of a range of enzymes and hormones (Bramswig and 
Kaestner, 2012). The endocrine pancreas in particular, constitutes only 2% of 
the entire pancreas mass, with around 1 million islets of Langerhans 
(Bramswig and Kaestner, 2012). The islets are principally made up of five 
endocrine hormone producing cell types: Glucagon producing alpha-cells 
(α-cells), insulin producing beta-cells (β-cells), delta-cells (δ-cells) responsible 
for somatostatin secretion, the ghrelin releasing epsilon-cells (ε-cells) and 
pancreatic polypeptide (PP) producing cells (Mastracci and Sussel, 2012). In 
rodents, the β-cells form a core in the islet with α-cells and δ-cells around the 
periphery, while in the human pancreas the β-cells are dispersed randomly 
throughout the islet (Kim et al., 2009) 
 
The endocrine pancreas receives between 5-15% of the organ’s blood 
supply, from several arterioles per islet, which split into capillaries producing 
a spherical network (Ballian and Brunicardi, 2007). Pancreatic islet cells are 
innervated by the autonomic nervous system. Parasympathetic innervation 
potentiates insulin secretion during hyperglycaemic excursions, controls the 
cephalic phase of insulin secretion, when the body is preparing to use 
glucose most efficiently, and stimulates β-cell proliferation (Thorens, 2014). 
The sympathetic nervous system is however involved in the response to 
hypoglycaemia, and the formation of islet architecture and maturation 
during development (Thorens, 2014).  
 
In type 2 diabetes there are some changes in the pancreas, particularly in 
relation to volume, which decreases, and the borders of the pancreas 
become more irregular when compared to a healthy pancreas (Al-Mrabeh 
et al., 2016). Type 2 diabetes is also marked by a decrease in functional β-
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cell mass and volume, and gradual β-cell failure, comparative to the 




1.2 Pancreatic Islet Hormones 
The pancreas is responsible for the production and the secretion of three 
important hormones involved in glucose homeostasis and insulin secretion: 
insulin, glucagon and somatostatin (Chandra and Liddle, 2009). There are 
also PP secreting cells. Some studies have shown that PP is involved in 
regulating food intake and energy balance (Inui, 1999), however, an 




Insulin is the peptide hormone released from the β-cells of the human 
endocrine pancreas; it is a 51-amino acid peptide with an A (21-amino 
acid) and B (30-amino acid) chain linked by 2 disulphide bonds (Wilcox, 
2005). Insulin is synthesized by a precursor, proinsulin, the gene encoding this 
precursor is found on short arm of chromosome 11 (Schroder and Zuhlke, 
1982). Proinsulin is synthesized, in the ribosomes of the rough endoplasmic 
reticulum from mRNA as pre-proinsulin, and then transported to the Golgi 
apparatus by secretory vesicles. Immature storage vesicles form here and 
proinsulin is converted to insulin and C-peptide by enzymes outside the 
Golgi apparatus (Wilcox, 2005). Insulin is stored in the lumen of the secretory 
vesicles and is released together with C-peptide and islet amyloid peptide 
in equal amounts (Fu et al., 2013). The insulin that is released goes to the 
portal venous system and 60% is removed during first pass through the liver 
(Wilcox, 2005). The liver is the principle site for the clearance of insulin, 
however the uptake and degradation of insulin occurs in all insulin sensitive 
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tissues (Duckworth et al., 1998). The kidney is another important site for 
insulin clearance and is responsible for removing around 50% of peripheral 
insulin, 50% of circulating proinsulin and 70% of C-peptide. This is achieved 
through glomerular filtration and reabsorption and degradation in the 
proximal tubule (Duckworth et al., 1998). All insulin sensitive cells are 
capable of removing and degrading insulin, the most notable after the liver 
and kidney is muscle (Duckworth et al., 1998).  
 
Insulin acts as an anabolic agent; it encourages the storage and 
production of carbohydrates, lipids and protein and hinders their 
breakdown and discharge into circulation (Chang et al., 2004). Insulin 
encourages the production of glycogen and lipids in muscle cells, and 
subdues lipolysis and gluconeogenesis from muscle amino acids. In the 
muscle cells in particular, the entry of glucose allows storage and synthesis 
of glycogen, meaning carbohydrates will be used as the primary source of 
energy, instead of fatty acids (Wilcox, 2005). Insulin is vital for the transport of 
glucose into the cell. It acts to increase glucose uptake through enrichment 
of GLUT4 transporter proteins at the plasma membrane (Chang et al., 2004) 
There are several factors that influence insulin synthesis and release, most 
notably, glucose. Insulin secretion can by impacted by changes in synthesis 
at the levels of gene transcription, translation and post-translational 
modification (Wilcox, 2005).  The synthesis of insulin is also affected by amino 
acids, acetylcholine, pituitary adenylate cyclase-activating polypeptide, 
glucose dependent insulinotropic polypeptide, glucagon-like peptide-1 







1.2.2 Glucagon  
 
The α-cells of the endocrine pancreas are responsible for the secretion of 
the 29-amino acid peptide hormone, glucagon. This peptide has a potent 
stimulatory influence on hepatic glucose production, which works to 
increase plasma glucose levels (Lund et al., 2014). Glucagon is encoded by 
the preproglucagon gene (Taborsky, 2010). This gene has six exons, one 
encoding the glucagon precursor and two that encode the precursors for 
glucagon-like peptide (GLP)-1 and GLP-2.  The products that come from this 
processing of proglucagon are tissue specific (Taborsky, 2010). When 
proglucagon is cleaved, only glucagon remains in its biologically active 
form, with the opposite being true for the GLP-1 and GLP-2 products. 
However, in the L-cells of the bowel, the opposite happens, with biologically 
active forms of GLP-1 and GLP-2 produced, and the inactive form of 
glucagon produced, also upon the cleavage of proglucagon (Taborsky, 
2010).  
 
Glucagon secretion is prompted during periods of low glucose; Ca2+ 
channels are opened following depolarization of the membrane, the 
subsequent influx of Ca2+ activates glucagon granule exocytosis from the 
cytoplasm (Briant et al., 2016). Glucagon acts to safeguard against a 
decrease in blood glucose (hypoglycaemia). This is achieved through its 
effects in the liver. Here, glucagon stimulates glycogenolysis and 
gluconeogenesis, causing a rapid increase in hepatic glucose output, and 
thus acting to restore normoglycaemia, (Briant et al., 2016). However, even 
a minor surge in glucose can induce long-lasting hyperglycaemia, for 
example a 10 pg/ml increase in glucagon can cause an upturn of hepatic 






Somatostatin is a polypeptide that is present in two main forms in humans, 
either as a 14-amino acid peptide (somatostatin 14) or the 28-amino acid 
form (somatostatin 28). Somatostatin 14-producing cells can be found in 
several peripheral organs – liver, lungs, immune system, urogenital tracts, 
kidneys, adrenals and the pancreas – while somatostatin 28 producing cells 
can be found along the gastrointestinal tract (Sliwinska-Mosson et al., 2014). 
This hormone has a regulatory role in the endocrine pancreas, where it is 
released from δ-cells following an increase in glucose concentrations. 
Somatostatin acts as an inhibitor of insulin, glucagon and pancreatic 
polypeptide release. However this is just one of many roles for somatostatin 
as it is also involved in inhibiting pain, the release of hypothalamic 




1.3 Regulators of pancreatic β-cell function 
 
1.3.1 Amino acids 
 
β-cell metabolism of different amino acids following ingestion and 
absorption of food can affect insulin secretion because of the consequent 
production of adenosine triphosphate (ATP) (Newsholme et al., 2005). The 
two most abundant amino acids found in circulation are L-glutamine and L-
alanine, followed by branched-chain amino acids (Newsholme et al., 2005).  
 
Amino acids play a role in the regulation of insulin secretion from the β-cell, 
which occurs via three distinct pathways (Keane and Newsholme, 2014). 
The first pathway involves the generation of ATP following tricarboxylic acid 
	 7 
metabolism. The second pathway involves the direct depolarization of the 
plasma membrane via interactions with amino acid transporters (Keane 
and Newsholme, 2014). The third pathway involves the depolarization of the 
plasma membrane, caused by the cotransport of Na+ ions with the amino 
acid (Keane and Newsholme, 2014).  
 
This suggests that amino acids can enhance glucose-stimulated insulin 
secretion, it has also been suggested that the effects of some amino acids 
can be damaging to β-cell function. For example, the metabolism of 
homocysteine can inhibit neuronal nitrous oxide synthase, this impacts the 
function of the β-cell because nitrous oxide synthase plays a key role in cell 
signaling and glucose uptake at low basal levels (Strain et al., 2004, Keane 
and Newsholme, 2014). This does not apply across the board for all amino 
acids however, with most having a positive effect on insulin release (Keane 
and Newsholme, 2014) 
 
1.3.2 Incretin Hormones 
 
There are two incretin hormones, both of which are found in the intestine. 
glucagon-like peptide 1 (GLP-1) is released from the L cells of the ileum, and 
glucose dependent insulinotropic polypeptide (GIP), is released from K cells 
in the duodenum (Kim and Egan, 2008). These hormones are released after 
ingestion of nutrients, with lipids and carbohydrates being the most 
effective macronutrient stimulants of incretin release (Phillips and Prins, 
2011). Both of the incretin hormones function by increasing insulin secretion. 
However, GLP-1 also inhibits glucagon release, gastric emptying and works 
to reduce postprandial glucose excursions (Phillips and Prins, 2011).  
 
G-protein coupled receptors for these two hormones are found on the 
pancreatic β-cell and when bound, they help promote the release of insulin 
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from the cells through the resulting production of 3’,5’-cyclic adenosine 
monophosphate (cAMP). cAMP prompts a glucose-dependent increase in 
intracellular calcium, ultimately triggering insulin release (Kim and Egan, 
2008, Phillips and Prins, 2011, Opinto et al., 2013). However, GLP-1 in 
particular has quite strong effects on the β-cell, as it also encourages the 
different stages of insulin biosynthesis and enhances β-cell function (Opinto 
et al., 2013).  Furthermore, both have been shown to improve β-cell function 
in addition to lowering β-cell apoptosis (Phillips and Prins, 2011, Vasu et al., 
2014).  However, this incretin effect is reduced in both type 2 diabetes and 
obesity (Opinto et al., 2013) 
 
GLP-1 and GIP are both rapidly degraded and inactivated by the enzyme 
dipeptidyl peptidase-4 (DPP-4), causing a reduction in their insulinotropic 
effects (Yabe and Seino, 2011). DPP4 hydrolyzes the final alanine residue of 
each of the hormones, resulting in the production of the metabolites GIP(3-
42) and GLP-1(9-37) these metabolites make up the most of the circulating 




Glucose, produced either through intestinal absorption, glycogenolysis or 
gluconeogenesis, is the primary regulator of insulin secretion from the β-cell 
(Roder et al., 2016). The pancreatic β-cell can act quickly to secrete insulin 
in response to changes in blood glucose levels. Insulin secretion is biphasic 
in nature with rapid release in the initial phase followed by a slower more 
sustained second phase of release (Rorsman et al., 2000, Roder et al., 2016). 
Glucose entry into the beta cell is facilitated by the membrane bound 
transporter GLUT2 (McClenaghan and Flatt, 1999). Glucose is then 
phosphorylated by glucokinase into glucose-6-phosphate, which is then 
metabolized to pyruvate and, following its oxidation through the 
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tricarboxylic (TCA) cycle, is converted to acetyl-CoA. This prompts closure 
of the ATP-sensitive potassium (KATP) channels due to the subsequent rise in 
the ATP:ADP ratio (McClenaghan and Flatt, 1999, Jensen et al., 2008). 
Closure of the KATP channel triggers membrane depolarization resulting in 
opening of voltage dependent Ca2+ channels (VDCCs). The ensuing rise in 
intracellular calcium triggers the exocytosis of insulin from secretory granules 
that fuse with the plasma membrane (McClenaghan and Flatt, 1999). 
 
When hyperglycaemia persists for many months or years, it can trigger a 
series of damaging effects on the functions of the pancreatic β-cell, known 
as glucose desensitization (Brock et al., 2002). Persistent hyperglycaemia 
leads to glucotoxicity resulting in a reduction in insulin biosynthesis, 
increased apoptosis and diminished glucose-stimulated insulin secretion 




1.4 Diabetes mellitus 
 
Diabetes Mellitus (DM) is a multifaceted, chronic metabolic disorder 
(Olokoba et al., 2012) that is ultimately characterised by hyperglycaemia 
resulting from insufficient insulin secretion or utilization (American Diabetes, 
2014a). 
 
DM is divided into the following main categories  - Type 1 Diabetes Mellitus 
(T1DM) and Type 2 Diabetes Mellitus (T2DM) (American Diabetes, 2014b). 
However, there are other secondary forms of DM such as gestational 
DM(American Diabetes, 2010) and DM caused by other factors such as 
genetic deficiencies in β-cell function or insulin action, cystic fibrosis-related 
diabetes (CFRD) (Stecenko and Moran, 2010), also monogenic diabetes in 
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the form of MODY (mature onset diabetes of the young) (Anik et al., 2015) 
or even drug or chemical-induced diabetes seen in those receiving care for 
HIV/AIDS or post organ transplant (Fathallah et al., 2015).  
 
T1DM occurs due to cell-mediated autoimmune destruction of the 
pancreatic β-cell (American Diabetes, 2014a) as a result of several genetic 
and environmental factors and the interactions between both (Wang et al., 
2014). This destruction, which occurs due to development of autoreactive T 
cells capable of destroying pancreatic β-cells, results in decrease insulin 
secretory function (Atkinson, 2012). Of all diabetes patients around 10% are 
made up of T1DM patients (American Diabetes, 2014a). A feature of T1DM 
is the sustained need for exogenous insulin replacement (Atkinson et al., 
2014). However, even with exogenous replacement, it does not necessarily 
mean that the metabolic regulation needed happens, thus management 
of T1DM can also include the use of insulin analogues or machine 
technology – insulin pumps being an example (Atkinson et al., 2014). When 
the necessary regulation does not occur through this form of treatment we 
see the rise in complications associated with T1DM. Complications can arise 
also due to a lack of adherence to medication, or from a non-response to 
treatment. Complications include, retinopathy, neuropathy, cardiovascular 
disease and hypoglycaemia (Atkinson et al., 2014). Other options for 
treatment include either whole pancreas, or islet-cell, transplantation. While 
outcomes for whole organ transplant are good, drawbacks remain due to 
the invasiveness of the procedure and the considerable perioperative risk 
(Ludwig et al., 2010). With islet-cell transplant, while preliminary reaction to 
transplantation is encouraging, typically after five years just 10% of patients 
stay free of exogenous insulin treatment (Atkinson et al., 2014). 
 
T2DM arises when the insulin producing pancreatic β-cell can’t produce 
enough insulin to deal with the rise in insensitivity (in certain tissues – muscle, 
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liver and fat) to the action of the insulin that has already been produced. 
Several factors play a role in this - age, obesity and lifestyle (Kahn, 2003, 
Scheen, 2003, Drong et al., 2012). Figure 1.1 details some contributing 
factors to T2DM. Around 90% of diabetes patients are made up of T2DM 
patients (American Diabetes, 2014a, Hex et al., 2012). The management of 
T2DM is complex and discussed later in section 1.5.2. 
 
Figure 1.1: Factors contributing to a hyperglycaemic state in T2DM 
This figure, adapted from De Fronzo, (2004), details a trio of metabolic defects that 
contribute to a hyperglycaemic state, which is a primary characteristic of T2DM. 
 
Current estimations put the number of global diabetes patients at over 300 
million and this number continues to rise (Alberti and Zimmet, 2014, Zimmet 
et al., 2014, Danaei et al., 2011). As of 2012, within the United Kingdom (UK) 
in particular there are and estimated 400,000 people with T1DM and 
3,400,000 with T2DM (Hex et al., 2012). The current projection is that those 
numbers will rise to 650,000 and 5,600,000 people respectively by 2035/36 












(Hex et al., 2012). The issue of not just treating diabetes but also the 
associated complications then worsens.  
 
Some of the complications associated with T2DM in particular include 
cardiovascular disease, cardiac failure, stroke, kidney failure, retinopathy, 
angina, diabetic foot ulcers (DFU) and subsequent amputation. For 
example, cardiovascular disease (CVD) is the most common complication 
associated with T2DM, and is the primary cause of death in >60% of 
diabetes patients (Howard and Magee, 2000). DFUs arise in 15% of diabetes 
patients and are followed by diabetes-related lower-leg amputations in 84% 
of the cases (Brem and Tomic-Canic, 2007). The foremost cause of blindness 
in people of working age in the UK is diabetes (Diabetes UK, 2012, Arun et 
al., 2003). As well as this, the numbers affected by these unnecessary 
complications in England alone is rising. Between 2006 and 2010 retinopathy 
increased by 118%, stroke increased by 87%, kidney failure increased by 
56%, cardiac failure by 43%, angina by 33% and amputations by 26% 
(Diabetes UK, 2012). 
 
 
1.5 Type 2 diabetes mellitus 
 
Glucose homoeostasis is controlled by a feedback loop, which is reliant 
upon interaction between the pancreatic β-cells and insulin sensitive tissues 
(Kahn et al., 1993). Insulin is released following the stimulation of the 
pancreatic β-cell. This in turn facilitates the acceptance of glucose, amino 
acids and fatty acids by these insulin sensitive tissues, after which the tissues 
then feed back information to the islet cells that they require insulin (Kahn et 
al., 2014). With patients who are obese, it is common to see insulin 
resistance (Kahn et al., 2014). This may result in the pancreatic β-cell 
upregulating insulin secretion as a way of trying to maintain a glucose 
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homeostasis. Conversely, if the pancreatic β-cell can’t produce enough 
insulin, plasma concentrations of glucose will increase (Kahn et al., 2014).  
 
1.5.1 Genetics of type 2 diabetes mellitus 
 
Over the last decade, with increasing numbers of genome-wide association 
studies (GWAS), there is mounting evidence of the influential role that 
genetic factors play in individual risk to T2DM and in response to therapy 
(Fuchsberger et al., 2016). The hope has been that with the use of modern 
DNA sequencing techniques these studies will identify genetic variants that 
increase risk of disease, risk of adverse events in treatment, or helping to 
determine disease phenotype (McCarthy, 2017). However, the complex 
nature of T2DM – the impact of environmental factors, a broad-spectrum 
phenotype and the influence of common low-impact risk variants – 
highlights the difficulty with approaching the disease in this manner 
(McCarthy, 2017). Studies of this type have produced results though, for 
example ~90 loci have been detected in which variation will affect insulin 
release (Rutter, 2016). 
 
Work has also shown how the rising global incidence of T2DM is inextricably 
linked to growing occurrence of obesity (Zimmet et al., 2001, McCarthy, 
2010). Although, there are a lot of environmental factors involved in 
whether or not a person becomes obese and develops T2DM, it has been 
shown that there are individuals who are genetically predisposed to obesity 
(McCarthy, 2010). A variety of GWAS have been conducted in order to 
scrutinize a wide range of body mass index (BMI) values, in doing so they 
have catalogued around 30 loci that influenced BMI and the risk of obesity 
(McCarthy, 2010). In particular variation in the FTO (fat mass and obesity 
associated) gene that can predispose someone to diabetes by affecting 
their BMI (Frayling et al., 2007, McCarthy, 2010), 16% of adults that were 
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homozygous for the risk allele had a 1.67-fold increased odds of obesity as 
opposed to those who did not have the risk allele, this was witnessed from 
age 7 upward and an increase in fat mass was also seen (Frayling et al., 
2007). The odds ratio (OR) is a way of quantifying how strongly the presence 
of one property is associated with the presence, or absence, of another (an 
OR = 1 suggests no additional risk of disease but a higher OR suggests a 
greater risk of disease). Visceral fat accumulation is known to have 
particularly negative health implications, with this in mind GWAS were 
conducted to analyse patterns of fat distribution resulting in the 
identification of 15 loci separate from those that influenced general 
adiposity, the loci have an impact on the wait to hip ratio, that is seen in 
women in particular more than men (Chambers et al., 2008, Lindgren et al., 
2009, Heard-Costa et al., 2009, Heid et al., 2010, McCarthy, 2010). 
 
Other large studies have shown a partial role for lower frequency variants in 
predisposition to T2DM, although not in as strong a fashion as common 
variants (Fuchsberger et al., 2016).  
 
Further work, using CRISPR-based gene editing in human embryonic stem 
cells (hESCs) has also provided fresh insight into the function of a variety of 
genes previously identified in GWAS studies (Rutter, 2016, Zeng et al., 2016). 
This genome editing tool, which is seeing a swift rise in popularity, allows 
hESCs to be genetically manipulated allowing for those studying to 
understand the contribution of genes, and their variants, to a disease (Teo 
et al., 2015). This work has potentially identified CDKAL1 – a gene that is 
important for first-phase insulin exocytosis in the β-cell, facilitating ATP 
generation, KATP channel closure and opening of Ca2+ channels as well as 
(Ohara-Imaizumi et al., 2010) – as a T2DM risk locus and a unique 
therapeutic target (previous work in mice and cells had failed to identify 
the importance of CDKAL1) (Zeng et al., 2016, Rutter, 2016).  
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1.5.2 Management of Type 2 diabetes mellitus 
 
The approach for the management and treatment of T2DM has been 
designed by the National Institute for Health and Care Excellence (NICE), 
and is briefly summarised in Figure 1.2.  
 
 
Figure 1.2:  NICE Guidelines for treatment of T2DM 
This figure, adapted from the NICE guideline 28, briefly describes the 
recommended treatment pathway in type 2 diabetes (SU, sulphonylurea,; DPP-4i, 
Dipeptidyl peptidase IV inhibitor,; SGLT-2i, sodium-glucose co-transporter 2 
inhibitor,; GLP-1 glucagon like peptide 1)  (National Institute for Health and Care 
Excellence (NICE), 2015). 
 
The NICE guidelines have some key points to consider when making 
decision for treatment of T2DM, they are as follows. 
 
Patient Education 
Educational intervention ensures every patient and their carer receive a 
structured education about diabetes. This should take place at the time of 














































education is a significant part of the patient’s care (Sibal and Home, 2009). 
In 2015 NICE recommended that any educational programme for patients 
must have clear aims and objectives, be evidence-base, and meet the 
patient’s individual needs. Trained educators should deliver a well-designed 




Nutritional management should provide the patient with dietary advice 
that is specific to them and should be updated regularly. Dietary advice 
should be combined with a personal diabetes management plan that 
should aim to increase the patient’s physical activity and target a loss in 
body weight of 5-10% (Sibal and Home, 2009). However it has still been 
shown that exercise, even in the absence of weight loss, can be beneficial 
for patients (Ripsin et al., 2009) as it can help to decrease their blood 
pressure. Raised blood pressure in T2DM patients is associated with 
cardiovascular disease (CVD), eye and kidney microvascular complications 
(UKPDS Group, 1998b, Sibal and Home, 2009). 
 
Blood Pressure Management 
Medications should be added that helps to reduce blood pressure if the 
patient is unable to make changes in lifestyle, or if changes in lifestyle are 
not effective in reducing blood pressure to below 140/80 mmHg. This should 
be monitored every 1-2 months and treatment can be intensified if the 
patients blood pressure is not consistently below that level ((NICE), 2015). 
 
Blood Glucose Management 
 
Part of managing blood glucose is the setting of targets for haemoglobin 
A1c (HbA1c). Doctors should encourage patients to achieve and maintain 
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their target HbA1c, unless adverse effects, like hypoglycaemia, or their 
efforts to achieve the target, damage their quality of life (National Institute 
for Health and Care Excellence (NICE), 2015). Glycaemic control is defined 
as a HbA1c of 48 mmol/mol, but where this is not realistically attainable, a 
target can be made with the patient so that reduction in HbA1c still occurs. 
If the patient is unable to maintain a HbA1c below 58 mmol/mol, drug 
treatment can be intensified and they should be advised to aim for a 
HbA1c of 53 mmol/mol. Some patients can be advised to self monitor blood 
glucose, but this shouldn’t be done routinely, rather only in cases where the 
patient is prescribed insulin, where hypoglycaemic episodes are occurring, 
if the patient is at increased risk of hypoglycaemic episodes while driving or 





NICE recommendations on drug prescribing in T2DM are summarized in 
Figure 1.2. Standard release metformin is the first-line therapy for T2DM 
((NICE), 2015). Metformin belongs to the biguanide class of drugs, which are 
and has been a drug of choice for use against T2DM for some time. They 
are an anti-hyperglycaemic class of drug that do not increase plasma 
insulin (Wrobel et al., 2017). Metformin is the only biguanide in clinical use. 
Metformin will diminish hepatic glucose production, decrease insulin 
resistance by allowing uptake and metabolism in skeletal muscle, lessen 
carbohydrate absorption, increase fatty acid oxidation, and decrease low-
density-lipoprotein (LDL) and very-low-density-lipoprotein (VLDL) (Patane et 
al., 2000, Giannarelli et al., 2003, Natali and Ferrannini, 2006). The main 
mechanism of action comprises the triggering in hepatocytes of AMP-
activated protein kinase (AMPK) that will impede the expression of genes 
essential for gluconeogenesis (Kim et al., 2008). The most common adverse 
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events seen with metformin use include anorexia, diarrhea and nausea 
(Bouchoucha et al., 2011), however there is significant interindividiual 
glycaemic response to metformin (Zhou et al., 2011). 
 
Where metformin is contraindicated or not tolerated there are other options 
for initial treatment, either a dipeptidyl peptidase-4 (DPP-IV) inhibitor, or 
pioglitazone, or a sulphonylurea. DPP-4 inhibitors are a class of synthetic oral 
hypoglycaemic drugs, often referred to as gliptins (e.g. sitagliptin, 
vildagliptin). They act to depress blood glucose concentrations by 
potentiating endogenous incretins (Deacon, 2011). Pioglitazone is a 
thiazolidinedione, which decrease hepatic glucose output and increase 
glucose acceptance in the muscle by boosting the efficiency of 
endogenous insulin (Inzucchi, 2002). This is achieved when the drug binds to 
peroxisome proliferator-activated receptor-γ (PPARγ), which is complexed 
with retinoid X receptor. The exogenous agonists thiazolidinedione then 
cause this complex to bind to DNA, encouraging transcription of genes key 
to insulin signaling (Inzucchi, 2002). Severe hepatotoxicity has been 
encountered with two thiazolidinediones, ciglitazone and troglitazone (Patil 
et al., 2010); conversely this has not been seen in clinical trials of 
pioglitazone (Einhorn et al., 2000).  Common adverse events seen with this 
particular thiazolidinedione include edema, heart failure, weight gain and 
fluid retention (Rizos et al., 2009). Other options include the insulin 
secretagogues, sulphonylureas. These drugs work by acting directly on the 
pancreatic β-cell to stimulate insulin secretion (Proks et al., 2002). They 
target the ATP-sensitive potassium (KATP) channel and subsequent inhibition 
of this channel triggers membrane depolarisation of the pancreatic β-cell. 
This prompts the opening of voltage-gated Ca2+ channels, which in turn 
provokes the entry of Ca2+ into the pancreatic β-cell, stimulating the 
exocytosis of insulin containing secretory granules (Proks et al., 2002). The 
most common adverse event observed with sulphonylureas is 
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hypoglycaemia. For some individuals, hypoglycaemia can be severe and 
persistent due to the duration of action of the drug, particularly with first 
generation sulphonylureas like tolbutamide and chlorpropamide 
(Aquilante, 2010). 
 
In some cases it is necessary to combine therapies. However, if triple 
therapy with metformin and two other oral drugs is not effective, or is not 
being tolerated, then NICE guidelines suggest adding a glucagon-like 
peptide-1 (GLP-1) mimetic to metformin and a sulphonylurea ((NICE), 2015). 
The GLP-1 mimetic Exenatide works by mimicking the effect of GLP-1, but is 
markedly more stable, and longer acting (Mann and Raskin, 2014). It can 
lower postprandial blood glucose concentrations by stimulating insulin 
secretion, subduing glucagon secretion and impeding gastric emptying 
(Mann and Raskin, 2014). It has been known to cause hypoglycaemia, and 
in rare cases even pancreatitis (Garg et al., 2010, Mann and Raskin, 2014). 
GLP-1 mimetics should only continue to be prescribed if the patient 
responds within 6 months. The response target set by NICE includes an 11 
mmol/mol reduction in HbA1c and weight loss of 3% of initial body weight 
((NICE), 2015).  
 
T2DM patients who have had combined therapy, but remain significantly 
hyperglycaemic are considered for exogenous insulin therapy (Sibal and 
Home, 2009). Modern insulin therapy uses almost completely human insulin, 
produced using recombinant DNA technology. Different formulations of 
insulin that are used also have varying time of peak effect and duration of 
action (Swinnen et al., 2009). Eventually nearly all T2DM patients will require 
insulin therapy (Niswender, 2009). Insulin works by binding to the insulin 
receptor, a large transmembrane glycoprotein complex from the tyrosine 
kinase-linked type 3 receptor superfamily, located on the plasma 
membrane of target cells (Wilcox, 2005, Lee and White, 2004). Binding to 
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the receptor allows adenosine triphosphate (ATP) to bind to the intracellular 
component of the receptor, causing phosphorylation of the receptor 
through tyrosine kinase activity (Wilcox, 2005). The result of this is the tyrosine 
phosphorylation of intracellular substrate proteins – insulin responsive 
substrates (IRS), which then bind other signaling molecules and promote 
further cellular actions of insulin (Wilcox, 2005). The internalised insulin is 
degraded in lysosomes, however the receptors are recycled to the plasma 
membrane (Lee and White, 2004). Some patients may continue to receive 
metformin while using insulin if there are not contraindications or intolerance 
((NICE), 2015). 
 
1.6 Response to treatment 
 
It is clear that in order for stratification of patients to take place, there needs 
to be an unambiguous definition of response to treatment. The marker used 
to determine the glycaemic control of a T2DM patient is glycated 
haemoglobin (HbA1c), which provides information on glycaemic control for 
the previous two to three months (Sherwani et al., 2016). Haemoglobin 
undergoes regular glycation, as part of normal physiological function and 
when this occurs, the most abundant fraction post-glycation is HbA1c 
(Sherwani et al., 2016). The amount of circulating HbA1c is directly 
proportional to the amount of circulating blood glucose (Sherwani et al., 
2016). The erythrocytes, which are rich in haemoglobin, typically have a two 
to three month lifespan, explaining why the HbA1c measurement gives such 
a long view of glycaemic control; typically this measurement is taken every 
three to six months in those with T2DM ((NICE), 2015, Sherwani et al., 2016). It 
is common to see response to treatment in T2DM defined in one of two 
ways: either as a magnitude of HbA1c change (DeFronzo et al., 2010), or a 
target HbA1c (Esposito et al., 2012). Some studies have shown that baseline 
HbA1c plays an important role in determining whether or not a patient 
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reaches their target HbA1c, or attains a desired magnitude of change. 
Essentially, those starting with a higher baseline HbA1c will see larger 
reductions, but they are also less likely to reach a 53 mmol/mol (6.9 %) 
target (DeFronzo et al., 2010, Esposito et al., 2012). This must be considered 
when assessing clinical efficacy of treatments. However there are two ways 
of potentially overcoming the effect caused by baseline HbA1c. The first 
involves altering the definition of response. Jones et al. (2014), showed that 
when different definitions of response are used, different groups of 
responders are identified. By way of example, a lower baseline HbA1c is 
associated with good response, when the definition of response is based on 
reaching target HbA1c. This group proposed a novel definition that 
combined both definitions, a change of < -21 mmol/mol with a HbA1c 
achieved of < 62 mmol/mol, and with the use of this novel definition were 
able to create a group of responders that did not vary as a result of 
baseline HbA1c (Jones et al., 2014). The second option has again been 
proposed by Jones et al. (2016), who after again demonstrating that 
baseline HbA1c is a major predictor of response, determined that adjusting 
data for baseline HbA1c was a successful method that can be used to 
reduce bias in studies where the aim is to identify a predictor of response, 
other than baseline HbA1c.    
 
 
1.7 Sulphonylureas: Response and adverse events 
As outlined above and in Figure 1.3, Sulphonylurea acts on the pancreatic 
β-cell to encourage insulin secretion.  
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Figure 1.3: Insulin release following sulphonylurea exposure 
This figure shows sulphonylurea binding to the SUR1 receptor on the KATP channel 
and the subsequent downstream effects that lead to insulin release from the 
pancreatic β-cell. Briefly, sulphonylurea binding causes closure of the KATP channel, 
membrane depolarisation, opening of voltage-dependent calcium channels, an 
influx of calcium into the β-cell, and as a final consequences, insulin exocytosis. 
(GLUT2, glucose transporter 2,; ATP, adenosine triphosphate,; ADP, adenosine 
diphosphate,; KATP, ATP sensitive potassium channel,; SUR1, sulphonylurea receptor 
1,; Kir6.2, inwardly rectifying potassium channel,; VDCC, voltage dependent 
calcium channel) 
 
The normal activity of the β-cell KATP channel is governed by intracellular 
adenosine nucleotide; ATP causes an inhibitory effect on channel activity 



































(Proks et al., 2010). The KATP channel is a hetero-octameric complex 
comprising two types of protein subunit – Kir6.2, and sulphonylurea receptor 
1 (SUR1) (Ashcroft and Gribble, 1999, Proks et al., 2002). Kir6.2 is a member of 
the family of inwardly rectifying K+ (Kir) channels, it assembles as a tetramer 
forming the channel pore (Proks et al., 2002).  The Kir6.2 subunits have a 
binding site for adenine nucleotides; the pore will close when either ATP or 
ADP binds to one or more of these sites (Proks et al., 2010). The Kir6.2 
subunits are complexed with SUR1 subunits, each containing ER retention 
signals, which will inhibit their movement to the plasma membrane when 
the partner subunit is absent (Proks et al., 2010). SUR1 is part of the ABC 
transporter family, with 17 transmembrane helices (TMs). The TMs are 
organized as a single group of 5 TMs, with two repeats of 6 TMs, followed by 
a large cytosolic loop with consensus sequences for nucleotide binding and 
hydrolysis (Proks et al., 2002). The Kir6.2 pore achieves sensitivity to the 
stimulatory effects of nucleotides, and activation or inhibition by 
therapeutic drugs from SUR1 (Nichols et al., 1996, Gribble et al., 1997a, 
Gribble et al., 1998a, Proks et al., 2010). SUR1 has two nucleotide-binding 
domains (NBDs) that take part in binding and hydrolysis of Mg-nucleotides 
(Proks et al., 2010). The NBDs combine in a head-to-tail fashion, the Walker 
motifs of one interact with the linker domain of the other and form 2 
composite ATP-binding sites (Proks et al., 2010). Although the events taking 
place at site 1 are not clear, it is known that the channel can be activated 
whenever MgADP occupies site 2 (Zingman et al., 2001, Proks et al., 2010).  
 
There are two groups of KATP channel activity inhibitors – one group that 
includes Imidazolines and antimalarials which bind directly to Kir6.2 to block 
KATP channel activity, or the other group which bind with high affinity to SUR 
causing closure of K channels (for example sulphonylureas or benzamido 
derivatives) (Proks and Ashcroft, 1997, Gribble et al., 1997b, Mukai et al., 
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1998, Gribble et al., 1998b, Gribble and Ashcroft, 1999, Gribble et al., 2000, 
Proks et al., 2002).  
 
There are three main types of sulphonylurea receptor subunit, SUR1 - shapes 
part of the KATP channel in endocrine cells and brain, SUR2A – is found in 
heart and skeletal muscle, SUR2B encompasses the smooth muscle KATP 
channel (Proks et al., 2014). Sulphonylureas will bind to their particular 
receptor with high affinity prompting the pore to shut (Proks et al., 2014). This 
inhibition though, is incomplete and reaches a maximum of around 50-80%, 
this is as a result of KATP channels with bound sulphonylurea still being open 
to some extent (Gribble et al., 1997b, Barrett-Jolley and Davies, 1997, Proks 
et al., 2014). Therefore, sulphonylureas are considered partial antagonists of 
the KATP channel (Proks et al., 2014).  
 
The position of the binding site for sulphonylureas on the KATP channel has 
yet to be fully elucidated. However, some evidence suggests that residues 
within the intracellular loop between transmembrane domains 5 and 6, and 
a residue in the intracellular loop between transmembrane domains 15 and 
16, play a role (Ashfield et al., 1999, Vila-Carriles et al., 2007, Proks et al., 
2014). Sulphonylureas can also interact with Mg-nucleotides to regulate KATP 
channel activity (Proks et al., 2014). An example being the obstructive 
effect that MgATP and MgADP have on glibenclamide’s ability to bind to 
either SUR1 or SUR2 (Hambrock et al., 2002). Equally, MgADP can enrich the 
sulphonylurea inhibition of β-cell KATP channels (Proks et al., 2002).  
 
A difficulty with sulphonylurea treatment is interindividiual variation in 
response to the drug. While different studies use different definitions of 
failure to respond, 10-20% of patients will suffer from primary sulphonylurea 
failure. That is, upon initial sulphonylureas administration, they will have less 
than a 20-mg/dl reduction in fasting plasma glucose (DeFronzo, 1999, 
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Aquilante, 2010). Whereas, in the region of 50-60% of patients will ultimately 
fail to reach the required glycaemic control following a primary decrease in 
fasting plasma glucose of greater than 30mg/dl (DeFronzo, 1999, Aquilante, 
2010). There is no clear reason why the failure rate is so high. Secondary 
sulphonylurea failure is also an issue in around 5-7% of patients who have a 
good response to the drug class initially (DeFronzo, 1999, Aquilante, 2010). 
This varying response has also been replicated in large-scale randomized 
trials; in particular the A Diabetes Outcome Progression Trial (ADOPT) 
revealed that sulphonylurea monotherapy failure was 34%, contrasted with 
15% for rosiglitazone and 21% for metformin (Kahn et al., 2006, Aquilante, 
2010). In addition to this variation in the successfulness of sulphonylurea 
treatment, variation is also seen in the adverse events experienced as a 
result of sulphonylurea treatment. Approximately, 31% of patients suffer mild 
hypoglycaemia in the first year of glibenclamide treatment (UKPDS Group, 
1998a). However, the frequency of severe hypoglycaemia is estimated at 
1% per year (UKPDS Group, 1998a). The UKPDS study defined a mild 
hypoglycaemic event as one where the patient could treat the event 
unaided, and severe was defined as when the patient needed help from a 
third party or medical assistance. There are clinical factors involved in the 
failure of sulphonylurea treatment including deteriorating β-cell function, 
long-standing diabetes, elevated baseline glucose levels and an elevated 
degree of insulin resistance (Aquilante, 2010). The same could also be said 
when it comes to sulphonylurea induced hypoglycaemia, there are clinical 
factors involved like - the duration of sulfonylurea action, mild baseline 
hyperglycemia, irregular eating patterns, excessive alcohol intake and age 
(Aquilante, 2010). However, these clinical factors are not the only factors at 
play in variation to sulphonylurea response, disposition and side effects 
(Aquilante, 2010). There is evidence suggesting that genetic polymorphisms 
are involved in the interindividual variation (Aquilante, 2010). 
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Genes involved in response to sulphonylureas, and risk to T2DM, include the 
ATP Binding site cassette, subfamily C, member 8 (ABCC8). ABCC8 encodes 
for the sulphonylurea receptor 1 (SUR1) protein, it is positioned at 11p15.1 
and contains >100kb of genomic DNA (Kapoor, 2010, Haghverdizadeh et 
al., 2014). The ABCC8 gene contains 39 exons, and some 2318 common 
and rare SNPs (Haghverdizadeh et al., 2014). From this large number some 
SNPs have received more notice in the literature, 9 are present in coding 
regions, the rest in non-coding (Haghverdizadeh et al., 2014).  
 
Another important gene to note is the potassium inwardly rectifying 
channel, subfamily J, member 11 (KCNJ11) gene, which encodes for Kir6.2 
an essential part of the KATP channel which is found in pancreatic β-cells, it is 
located at 11p15.1 (Qin et al., 2013). Polymorphisms of this gene have been 
shown to predispose individuals to T2DM (Gloyn et al., 2005) as well as 
affecting the therapeutic response to sulphonylurea treatment (Aquilante, 
2010, Javorsky et al., 2012). Additionally, there is hepatocyte nuclear factor-
1α (HNF-1α), a gene located at 12q24.2, the protein encoded by this gene is 
HNF-1α transcription factor, involved in the regulation of the tissue specific 
expression of different genes in pancreatic islet, the liver and the kidney 
(Hansen et al., 1997, McDonald et al., 2012).  This gene has been identified 
as having a part to play in the pathogenesis of T2DM (Giuffrida et al., 2009), 
however it is more commonly known as mutations in this gene are the most 
common cause of Maturity Onset Diabetes of the Young (MODY) in the UK 
(McDonald et al., 2012). Finally, the potassium voltage-gated channel, KQT-
like subfamily, member 1 (KCNQ1) gene encodes for the pore-forming 
subunit of a voltage gated potassium channel (KvLQT1) that can be found 
in the pancreatic β-cell (Travers et al., 2013, Schroner et al., 2011). The gene 
is located at 11p15.5 and it has been acknowledged as being a risk gene 
associated with T2DM (Kong et al., 2009, Travers et al., 2013), as well as a 
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gene that is involved in the therapeutic response to sulphonylureas 
(Schroner et al., 2011). 
 
 
1.8 Stratification: Patient Benefit and Healthcare Economics 
 
Stratified medicine is defined as the division of patients into groups based 
on either their risk of disease or their response to a given treatment 
(Lonergan et al., 2017).  The intention then is that drug dosages can be 
refined or more suitable treatments identified for specific patient groups. 
This decision is brought about through the use of biomarkers and different 
measures of the advantages and the cost for treatment of each group 
(Lonergan et al., 2017).  The benefit then of stratifying treatment comes 
from the patient receiving an improved treatment at an earlier stage and a 
reduction in waste for the health service provider (Lonergan et al., 2017).  
 
Placing that knowledge within the context of the cost of treating T2DM 
shows the importance of stratification in the wider picture. With the large 
numbers of patients with T2DM, there is a sizeable cost burden placed on 
the health service. As of 2010/11 the burden of direct patient care was 
estimated at £9.8bn and indirect costs associated with diabetes estimated 
at £13.9bn (Hex et al., 2012). The direct costs have been divided between 
treatment/intervention and complications/adverse events, with the former 
costing over £2bn and the latter costing £7.7bn (Hex et al., 2012). It is clear 
from these figures that the liability, in terms of costs, to the NHS is significant, 
accounting for approximately 10% of total NHS resource expenditure, a 
number which is again expected to rise (Hex et al., 2012). 
 
It is well understood that HbA1C is an important indicator of long-term 
glycaemic control (Sherwani et al., 2016) and that raised HbA1c is greatly 
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associated with an increased risk of T2DM associated complications 
(principally CVD) and mortality (Sherwani et al., 2016). Improving glycaemic 
control has a positive impact on risk to further complications (UKPDS Group, 
1998a). It has been shown that a HbA1c of 53 mmol/mol (7.0%) instead of 63 
mmol/mol (7.9%), for example, sees a 25% reduction in microvascular 
complications (UKPDS Group, 1998a, Baxter et al., 2016).  
 
In the context of stratifying treatment, initiation of the correct therapy at the 
earliest possible opportunity will not only improve outcomes for the patients 
but also have a great impact on cost burden to the NHS. Recent work has 
shown that getting the right treatment sooner to diabetes patients could 
save the NHS around £340 million in the first five years and around £5.5 
billion after 25 years (Baxter et al., 2016). Most of these savings are as a result 
of the reduction in microvascular complications. With T2DM in particular, 
the savings are seen through the reduction in foot ulcers, amputations and 
neuropathy (Baxter et al., 2016).  
 
 
1.9 Aims of this thesis 
 
Large-scale cohort studies have identified several biomarkers for T2DM risk 
and for sulphonylurea response. This study aimed to validate existing 
markers and to identify new biomarkers that may aid in patient 
stratification, especially in response to sulphonylurea therapy. Specific 
objectives include: 
1. Identify and validate existing markers of sulphonylurea response in 
two pancreatic β-cell lines. 
2. Establish a biobank of 500 T2DM patients (DIASTRAT cohort) with 
associated clinical, anthropometric, and biochemical data. 
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3. Conduct proteomic screens for novel inflammatory or metabolic 
markers associated with glycaemic control and sulphonylurea 
response in the DIASTRAT cohort 
4. Assess the prevalence of potentially important SNPs among the 
DIASTRAT cohort and assess the relationship with glycaemic control 










































Reagents of analytical grade and deionized water (obtained from Elga, 
High Wycombe, UK) were used. Sources of each reagent are as follows: 
Sigma Aldrich (Irvine, UK): Dimethylsulfoxide (DMSO) “for molecular 
biology”, PAP Pen for immunostaining, 4-didget hand-held tally counter, 
Poly-prep slides – poly-L-lysine coated glass slides, Sodium chloride 
(NaCl), Potassium chloride (KCl), Calcium chloride (CaCl2), Magnesium 
sulphide (MgSO4.7H20), Magnesium chloride hexahydrate BioXtra 
(MgCl2.6H20), Sodium phosphate dibasic BioXtra (Na2HPO2H20), 
Monobasic potassium phosphate (KH2PO4), D-Glucose, Bovine Serum 
Albumin (BSA), Tween 20, ethanol, Triton X-100, , beta-actin monoclonal 
antibody mouse, C,N-diphenyl-N’-4,5-dimethyl thiazol 2 yl tetrazolium 
bromide (MTT), Goat serum, Hydrochloric acid (HCl) and 
paraformaldehyde (PFA). Thermo Fisher Scientific (UK): Pierce protease 
and phosphatase inhibitor mini tablets, RIPA lysis and extraction buffer, 
Platinum TAQ DNA polymerase, Trackit 100 bp DNA ladder, 100 MM DNTP 
set, Roswell Park Memorial Institute (RPMI) 1640 cell culture media with L-
glutamine and supplemented with Penicillin/Streptomycin and Fetal 
Bovine Serum (FBS) South American, Dulbeccos Modified Eagle Medium 
(DMEM) supplemented with Penicillin/Streptomycin, Fetal Bovine Serum 
(FBS), 2-β Mercaptoethanol and sodium pyruvate, Trypsin 0.5% EDTA, 
Agarose, Gel Red Stain loading dye, Trackit Cyan/Yellow loading buffer 
and black clear-bottomed 96 well plate for fluorescence.  Roche 
Diagnostics (West Sussex, UK): Lightcycler 480 Probes Master Mix, 
Lightcycler plates 480 Multiwell plate, Transcriptor First Stand cDNA 
synthesis kit, Transcriptor Reverse Transcriptase, Protector RNase Inhibitor, 
Deoxy-NTP set. Abcam (Cambridge, UK): .ALPCO/Stratech Scientific 
(Newmarket, UK): Rat Insulin ELISA kit. Santa Cruz Biotech (Dallas, US):. 
Mercodia (Uppsala, Sweden): Ultrasensitive Mouse Insulin ELISA kit and 
Insulin ELISA Mouse kit. Merck Millipore (Watford, UK):. Qiagen 
(Manchester, UK): RNeasy Mini Kit (250) and Premix FlexiTube siRNA – 
predesigned siRNA directed against ABCC8, KCNJ11, KCNQ1 and HNF1α 
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PHE Culture Collection (Salisbury, UK): General Cell Collection: BRIN-




2.2     Methods 
 
2.2.1 Culture of β-cell lines 
 
The pancreatic β-cell line BRIN-BD11 is a glucose responsive insulin-
secreting cell line of rat origin. The cell line was created at Ulster 
University through the electrofusion of primary rat islets and the RINm5F 
cell line. Prior reports show that BRIN-BD11 cells are useful for analyzing 
the molecular mechanisms by which β-cells regulate insulin secretion 
(McClenaghan et al., 1996). The pancreatic β-cell line MIN6 is insulinoma-
derived from transgenic mice containing the human insulin promoter 
gene connected to the SV40 T-antigen hybrid gene (Miyazaki et al., 
1990, Ishihara et al., 1993). These cells have levels of glucose-induced 
insulin secretion that are similar to cultured mouse islet cells and are 
regarded as a valuable tool in the analysis of the molecular mechanisms 
by which β-cells regulate insulin secretion in response to extracellular 
glucose (Miyazaki et al., 1990). Both cell lines grow as adherent 
monolayers with epithelial-like appearance as shown in Figure 2.1, and 
were chosen due to their reported expression of genes of interest, which 
is discussed later. While both cell lines produce insulin in response to 
glucose and are recognised as good models for studying pancreatic β-
cells, they of course are not the same as a primary human pancreatic β-
cell, a caveat that is important to remember when interpreting any 






Figure 2.1: Pancreatic β-cell lines in culture.  
 
(A) x4 magnification of MIN6 cell monolayers; (B) x20 magnification of BRIN-
BD11 cell monolayers. 
 
All cells were stored at the NI Centre for Stratified Medicine, Ulster 
University, in 1.5 ml vials (Sterilin Ltd, Hounslow, UK) containing freezing 
media with a final composition of 10 % DMSO, 10 % tissue culture 
medium, and 80 % foetal bovine serum (FBS). The cells were stored at -20 
°C for 4 h, before being moved for further storage at -80 °C. Cells were 
removed from the freezer and thawed in a water bath maintained at 37 
°C. The contents of the vials were suspended in 5 ml of warmed tissue 
culture medium and centrifuged for 5 min at 900 rpm (10,000 g). The cell 
pellet was re-suspended in fresh culture medium to give a single cell 
suspension, which was placed in a tissue culture flask and stored in an 
incubator at 37 °C, at an atmosphere of 5% CO2 and 95% air. MIN6 cells 
were maintained in 75 cm2 tissue culture flasks containing DMEM tissue 
culture medium with 4.5 g/L D-Glucose, 580 mg/L L-Glutamine, and 
supplemented with 10% (v/v) heat inactivated FBS, 
Penicillin/Streptomycin (5000 IU/l), 1x Sodium Pyruvate and 0.05 mM β-
mercaptoethanol. BRIN-BD11 cells were maintained in 175 cm2 tissue 
culture flasks containing RPMI tissue culture medium supplemented with 
10% (v/v) FBS and Penicillin Streptomycin (5000 IU/l). 
 
The following procedure was used to routinely passage the cells: culture 
medium was aspirated from the flask and cells washed twice with 5 ml of 
phosphate buffered saline solution (PBS). A total of 2 ml of trypsin-EGTA 
(1x) was used to detach cells from the tissue culture flask. After addition 
A B 
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of trypsin, cells were returned to the incubator at 37 °C, at an 
atmosphere of 5% CO2 and 95% air, for 3-5 min. The flask was gently 
tapped to aid dissociation and cells were then re-suspended in 3 ml of 
tissue culture medium and transferred to a polypropylene Sterilin tube 
(Sterilin Ltd, Hounslow, UK). Cells were then pelleted by centrifugation at 
900 rpm (10,000 g) for 5 min. The supernatant was discarded and fresh 
culture medium was added to the cells to create a single cell suspension 
for experimental use. Aliquots of the cell suspension were counted using 
a Neubauer haemocytometer (Scientific Supplies Co., UK). Cells were 
returned to culture and allowed to attach overnight as monolayers or 
utilized for experiments. 
 
2.2.2 Induction of insulin secretion 
 
Acute, static, 20 min incubations with sulphonylureas were conducted to 
assess insulin secretion from the BRIN-BD11 and MIN6 cell lines. A total of 
1.5 x 105 BRIN-BD11 cells/well, or 1 x 105 MIN6 cells/well, were seeded in 
24 well plates and allowed to attach overnight. Following this an Acute 
insulin response test designed to mimic first phase insulin secretion was 
performed. Firstly, media was removed from each well and cells were 
treated with Krebs-Ringer Bicarbonate (KRB) Buffer (115 mM NaCl, 4.7 
mM KCl, 1.28 mM CaCl2 1.2 mM MgSO4, 0.1% BSA, pH 7.20) 
supplemented with 1.1 mM glucose. The plate was then returned to the 
incubator at 37 °C, at an atmosphere of 5% CO2 and 95% air for 40 min, 
after which the 1.1 mM glucose was removed and replaced with 1 ml of 
test solution (KRB buffer supplemented with 5.6 mM glucose ± 200 µM 
Glibenclamide or Tolbutamide). The plate was returned to the incubator 
for a further 20 min. Following incubation the supernatant was transferred 




2.2.3 Insulin ELISA for analysis of cell culture supernatants 
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Insulin release from BRIN-BD11 or MIN6 cells into the surrounding culture 
medium in response to sulphonylurea treatment was assessed using rat 
(ALPCO, Salem, NH, USA), or mouse (Mercodia, UK) specific insulin ELISA 
kits according to the manufacturers’ instructions.  
 
In brief, assessment of rat insulin concentrations (ALPCO, Salem, NH, USA) 
involved adding 10 µl of each calibrator, sample and control to wells of 
a supplied 96 well plate treated with primary antibody against insulin. 
Following the addition of samples, 75 µl of enzyme conjugate was 
added; the plate was covered in foil and placed on a plate shaker at 
900 rpm for 2 h at room temperature. Enzyme conjugate was diluted 1:10 
with conjugate stock provided in the kit. Each well was then washed 6 
times with 350 µl of wash buffer. Working strength wash buffer was 
prepared by diluting wash buffer concentrate that had been supplied 
with 20 parts distilled water. Substrate TMB (100 µl) was added to each 
well, and the plate further incubated at room temperature for 15 min. 
Finally, 100 µl of stop solution was added and absorbance was read 
immediately at 450 nm using an Epoch Microplate Spectrophotometer 
(BioTek, UK). A typical standard curve is illustrated in Figure 2.2.  
 
Figure 2.2: Typical rat Insulin ELISA standard curve 
 
























Assessment of mouse insulin concentrations was conducted by adding 
25 µl of each calibrator, sample and control to the appropriate well of a 
supplied 96 well plate coated with primary antibody against insulin. 
Following the addition of samples, 100 µl of enzyme conjugate was 
added; the plate was covered in foil and placed on a plate shaker at 
900 rpm for 2 h at room temperature. Each well was then washed 6 times 
with 350 µl of wash buffer. Working strength wash buffer was prepared by 
diluting wash buffer concentrate that had been supplied with 20 parts 
distilled water. Substrate TMB (200 µl) was added to each well, and the 
plate further incubated at room temperature for 15 min. Finally, 50 µl of 
stop solution was added to each well and absorbance was read 
immediately at 450 nm using an Epoch Microplate Spectrophotometer 
(BioTek, UK). A typical standard curve is illustrated in Figure 2.3.  
 
 
Figure 2.3: Typical Mouse Insulin ELISA standard curve 
 




2.2.4 Extraction and quantification of RNA 
 
Total RNA was extracted from BRIN-BD11 and MIN6 cells using the 
QIAGEN RNeasy® Mini Kit (QIAGEN, West Sussex, UK).  This kit allows up to 
100 µg of RNA longer than 200 bases to bind to the RNeasy silica 
membrane using a specialized high salt buffer system. Disruption of cell 




















pellets was achieved through the addition of 350 µl of Buffer RLT. A total 
of 350 µl of 70 % molecular-grade ethanol (Sigma Aldrich, UK) was then 
added to the lysates and mixed, providing a suitable binding condition 
for the silica membrane. The lysates were pipetted onto an RNeasy Mini 
spin column, placed in a 2 ml collection tube and centrifuged at 10,000 
rpm (8,000 g) for 15 s in a microcentrifuge. Buffer RW1 (700 µl) was 
added, and samples were further centrifuged to clean the spin column 
membranes for 15 s at 10,000 rpm (8,000 g). Buffer RPE (500 µl) was 
added to the spin columns, which were centrifuged again for 15 s at 
10,000 rpm (8,000 g). This step was then repeated with an additional 
minute of centrifugation at 10,000 rpm (8,000 g). The spin columns were 
placed into new 2 ml collection tubes and centrifuged for 1 min at 
10,000 rpm (8,000 g). Following this step, the spin columns were placed in 
new 1.5 ml collection tubes and 50 µl RNase-free water was added. RNA 
was eluted from the spin column following centrifugation for 1 min at 
10,000 rpm (8,000 g). Spin columns were discarded at this point, and the 
collection tubes capped and immediately transferred to ice. RNA 
samples were quantified using a NanoDrop™ 2000 spectrophotometer 




2.2.5 cDNA Synthesis 
 
Total RNA (100 ng) was reverse transcribed into cDNA using the 
Transcriptor First Strand cDNA Kit (Roche Diagnostics Ltd., UK).  The RNA 
was added to a thin walled PCR tube on ice and the following reagents 
are added to generate a 20 µl reaction: Random Hexamer primer 2 µl 
(60 µM); transcriptor reverse transcriptase reaction buffer (5X) 4 µl; 
Protector RNase Inhibitor (40 U/µl) 0.5 µl; Deoxynucleotide mix 2 µl; 
Transcriptor reverse transcriptase (20 U/µl) 0.5 µl. The volume was 
increased to 20 µl with RNAse-free as required. Cycling conditions are 
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shown in Table 2.1. On completion of the cDNA reaction, samples were 
stored at -20 °C until needed for further experimentation.  
 
Temperature (°C) Time (Minutes) Description 
25 10 Annealing 
50 60 Elongation 
85 5 Reverse Transcriptase 
Inactivation 
Table 2.1: Cycling Conditions for generation of cDNA 
 
 
2.2.6 Quantitative real-time PCR (qPCR) 
 
Custom designed probes were generated, via Roche’s RealTime ready 
Configurator (Roche Diagnostics, West Sussex, UK) (see Table 2.2). qPCR 
was performed on a Lightcycler 480 system (Roche Diagnostics Ltd., UK). 
Beta-actin was selected as a house-keeping gene after optimizing 
against a panel of potential genes. To do this, 2 µl of cDNA was added 
to each well of a 96-well plate, along with 5 µl of Master Mix (Roche 
Diagnostics Ltd., UK), 2 µl of RNase-free water and 1 µl of the relevant 
probe, final concentration of probe is 2x, to make a total reaction 
volume of 10 µl. The plate was then sealed with clear plastic film and 
centrifuged at 1500 rpm (226 g) for 2 min at 18 °C. The plate was read 
according to an optimized protocol for monocolour hydrolysis probes 
provided by Roche, UK (see Table 2.3). 
 
Table 2.2: qPCR Primer Probes  
Gene Species Assay ID 
ABCC8 R. norvegicus 506195 
M. musculus 300187 
KCNJ11 R. norvegicus 506200 
M. musculus 317283 
KCNQ1 R. norvegicus 506506 
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M. musculus 307946 
HNF-1α R. norvegicus 500240 
M. musculus 315865 
 
Table 2.3: Cycling conditions for monocolour hydrolysis probes  
Program Name Cycles Target °C Analysis Mode 
Pre Incubation 1 95 None 
Amplification 55 95 Quantification 
60 
72 





BRIN-BD11 and MIN6 cells were seeded onto sterile Poly-L-lysine slides at 
a density of 4 x 104 cells/slide, and maintained in a 90 mm vented a Petri 
dish. Cells were allowed to attach for 4 h at 37 °C, in an atmosphere of 5 
% CO2 and 95 % air, at this point media was added to the dish for 
overnight incubation. Following this, cells are washed 3 x 5 minutes with 
PBS. Cells were incubated at room temperature for 20 min with 200 µl of 
ice-cold 4 % paraformaldehyde (PFA) to ensure cellular attachment. 
Cells were washed 3 x 5 min in PBS, and permeabalised using 0.3 % Triton-
X for 15 min (for analyses of intracellular proteins). Cells were washed for 
a further 3 x 5 min in PBS. Cells were incubated for 10 min in blocking 
serum comprising 15 µl blocking serum in 1 ml PBS. Cells were then 
incubated overnight at 4 °C with primary antibody. Slides were not 
washed between the blocking stage and the addition of primary 
antibody, although tissue was used to drain any excess blocking serum 
from the slides. Primary antibody was diluted 1:100 of buffer containing 
1.5 % blocking serum. Diluted antibody (200 µl) was added to each slide 
and covered with a piece of parafilm, cut to fit the slide, to ensure even 
antibody coverage and to prevent slide from drying. Primary antibody 
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against SUR1, Kir6.2, KCNQ1 and HNF-1α (Santa Cruz Biotechnology, UK) 
were used. 
 
After overnight incubation, slides were washed 3 x 5 min in PBS and 200 µl 
secondary antibody (Alexa Fluor® 488 goat anti-mouse IgG or Alexa 
Fluor® 488 goat anti-rabbit IgG – Life Technologies, UK) was added. 
Secondary antibody was diluted in PBS (1:400) and slides incubated for 
45 min at 37 °C in a humidified chamber (place tissue soaked in PBS in 
corner of dish). The dish was also covered in tin foil to prevent leaching 
of the fluorescent signal. Slides are again washed 3 x 5 min in PBS. A total 
of 100 µl DAPI (stock diluted in water to give a final concentration of 125 
ng/µl) was added to each slide and left at room temperature for 20 min 
after which a drop of Vectashield mounting medium (Vector 
Laboratories, Inc., Burlingame, CA, USA) was added, then covered with 
a coverslip. Slides were allowed to dry and sealed with nail polish. Slides 
were viewed using a fluorescent light source and images stored as TIFF 
files. Microscope used was Axio imager A.2 with an Axio MRM camera 
(Zeiss Group, UK).  
 
 
2.2.8 Potassium Channel Inhibition 
 
BRIN-BD11 cells were seeded into 24 well plates at a density of 15 x 104 
cells/well and allowed to attach over night at 37 °C, in an atmosphere of 
5% CO2 and 95% air. 25 µl of antibody was then added to the applicable 
wells. Antibodies against SUR1, Kir6.2 and KCNQ1 (Santa Cruz,	
Heidelberg, Germany) were used; these are potassium channel proteins 
on the surface of the β-cell. After a further 24 h incubation an acute 
insulin response test was performed, as detailed in section 2.2.2, and 
samples were then stored at -80 oC for further analysis. By inhibiting 
potassium channels a simple assessment can be made of their 
importance to insulin secretion from the β-cell, thus validating further 
examination of their role.  
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2.2.9 Transfection with siRNA 
 
BRIN-BD11 cells were seeded at a density of 5 x 104 cells/well/24 well 
plate, whilst MIN6 cells were seeded at a density of 8 x 104 cells/well/24, 
and allowed to attach overnight at 37 °C, in an atmosphere of 5 % CO2 
and 95 % air. Following overnight incubation, media was removed from 
the cells and replaced with 500 µl fresh media prior to transfection.  
 
Custom FlexiTube siRNA (QIAGEN, Manchester, UK) was designed against 
SUR1, KIR6.2, HNF-1α and KCNQ1 (see Table 2.4 for details). The likelihood 
of success of the siRNA was assessed using an online tool SpliceCenter-
siRNA Check (Ryan et al., 2008). Following an extensive optimization 
process, which is summarized in Table 2.5, 100 nM siRNA was added to 
an eppendorf tube containing 100 µl of serum-free culture medium, 
along with 2.5 µl Lipofectamine Transfection Reagent (Invitrogen, UK). 
The mixes were incubated for 15 min at room temperature to allow 
transfection complexes to form. These complexes were then added 
drop-wise onto the cells (to give a final volume of 600 µl per well), which 
were then incubated under normal growth conditions for 48 h (BRIN-
BD11) or 72 h (MIN6). Mock transfections and scrambled siRNA were used 
























Control (non-sil.) siRNA 1022076 













100,000 24 10 3 20 
120,000 24 50 3 35 
120,000 48 50 3 40 
120,000 72 100 3 40 
50,000 72 100 2.5 80-90 
80,000 72 100 3.5 60-90 
Table 2.5: siRNA optimization  
 
2.2.10 Determination of cell viability by colorimetric 3-(4,5-
Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide (MTT) assay 
 
An MTT assay was used to assess cell metabolic activity. The tetrazolium 
dye MTT is added to cells and taken up by the mitochondria in viable 
cells, where it is reduced to purple formazan. Following the addition of 
the solubilisation solution DMSO, the purple formazan is dissolved into a 
coloured solution. The absorbance of this solution can then be read and 
quantified (Stockert et al., 2012). BRIN-BD11 cells were seeded and 
transfections performed as per section 2.2.8. The calorimetric MTT assay 
was then used to determine cell metabolic activity following siRNA 
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transfection at 24, 48 and 72 h. The media was removed from the cells, 
and replaced with 400 µl of media containing 40 µl of 12 mM MTT stock 
solution. The cells were further incubated for 2 h at 37 °C. MTT-containing 
media was then removed from each well, and replaced with 400 µl of 
DMSO, and the plate was returned to the incubator for a further 45 
minutes. Absorbance was then read at a wavelength of 570 nm with 




2.2.11 Cellular protein extraction 
 
Cells were harvested and pelleted as described in Section 2.2.1. The 
supernatant was then removed and 100 µl of ice-cold protein extraction 
buffer (RIPA Buffer (Sigma Aldrich, UK)) supplemented with Pierce™ 
Protease and Phosphatase Inhibitor mini tablets (1 tablet per 10 ml RIPA 
buffer) was used to resuspend the cell pellet, followed by incubation on 
ice for 20 min with vortexing of the lysate every 5 min. The lysate was 
then centrifuged at 12,700 rpm (18,213 g) for 15 min at 4 °C. Supernatant 
containing the cellular protein was then transferred to a fresh tube and 
stored at -80 °C for future use.  
 
 
2.2.12 Protein quantification 
 
Total protein was determined using the Thermo Scientific Pierce BCA 
Protein Assay Kit (Thermo Fisher Scientific (UK). This assay uses the 
reduction of Cu2+ to Cu1+ by protein in an alkaline medium with the 
highly sensitive and selective colorimetric detection of the cuprous 
cation (Cu1+) by bicinchoninic acid (BCA). The intensity of the colour is 




Protein samples were thawed on ice and 10 µl of each was added into a 
clean, dry, 96-well microplate. A total of 200 µl of working reagent was 
added to all samples and standards. Working reagent was prepared by 
combining 50 parts of BCA reagent A with 1 part BCA reagent B (50:1, 
Reagent A:B). The plate was then gently agitated for 30 seconds, after 
which it was covered and placed in an incubator at 37 °C for 30 min.  
After the plate had cooled to room temperature, the absorbance was 
measure at 562 nm on a plate reader. A typical standard curve is shown 
below in Figure 2.4 
 
Figure 2.4 – Typical BCA assay standard curve 
 
A standard curve was created ranging from 0 - 2,000 µg/ml using bovine serum 
albumin (BSA) standards provided.  
 
 
2.2.13  Patient Recruitment to the DIASTRAT cohort 
 
The Stratified Medicine optimizing treatment for Diabetes (DIASTRAT) 
study is a pilot observational study, investigating the incidence of 
variation of candidate biomarkers within a local type 2 diabetes 
population. A total of 500 people were asked to participate in the study 
and were recruited from the Western Health and Social Care Trust. 
Criteria for inclusion on the study were as follows: aged between 18 and 
80 years; diagnosed with type 2 diabetes. Those outside the age limits, or 
with other forms of diabetes (type 1; secondary diabetes) were excluded 



















from participation. Those approached to participate had been 
previously diagnosed with T2DM and were identified by the consultant 
doctors at Altnagelvin hospital as being eligible to participate and then 
were contacted by those working on DIASTRAT to be asked to 
participate, or were brought to the DIASTRAT team while attending their 
diabetes clinic at Altnagelvin hospital having seen their consultant 
doctor that day. All participants were recruited from secondary care. 
The majority of participants were recruited from the same area, with a 
large proportion residing within one postcode area of Derry City.  All 
participants provided informed written consent and the study was 
approved by the Office for Research Ethics Committees Northern Ireland 
(ORECNI) on 12/11/2014. (ORECNI Ref: 151917; NHS/HSC Trust Ref: WT 
14/25 151917; HSC Rec Ref: 14/NI/1123). The Invitation letter, participant 
information sheet and study protocol are provided in Appendix 1. The 
recruitment process relied on input from others, applying for ethical 
approval for the study, identifying or contacting participants, collecting 
and processing samples, and finally to collating participant information 
stored in their medical records. As such recruitment was performed by 
this author (Declan McGuigan), Andrew English (PhD student, Ulster 
University), Dr Catriona Kelly (Ulster University) Dr Paula McClean (Ulster 
University), Dr Geraldine Horrigan (C-TRIC), Dr Maurice O’Kane (WHSCT), 
Dr Neil Black (WHSCT), Dr Athinya Thiraviaraj (WHSCT). 
 
 
2.2.14 Processing blood samples 
 
Consented participants each provided 2 x 9 ml tubes (containing EDTA) 
and 1 x 8 ml tube serum separating tube. One 9 ml EDTA tube was frozen 
at – 80 oC, while the second EDTA tube and the serum separating tube 
were processed immediately. The blood samples were centrifuged for 15 
min at 3000 rpm at 4 oC. Serum, from the serum separating tubes, was 
removed and aliquoted into individually labeled 1.5ml eppendorf tubes 
and stored at -80 oC. Centrifugation of the tubes containing EDTA, 
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produced 3 layers: an upper plasma layer, a middle buffy coat layer 
(containing leukocytes and white platelets) and a lower red blood cell 
layer. The plasma layer was taken and aliquoted into individually labeled 
1.5ml eppendorf tubes and stored at -80 oC. The middle buffy coat layer 
was removed into a separate 1.5 ml eppendorf tube, to which 1 ml of 
PBS was added, and the contents then split evenly between two 1.5 ml 
eppendorf tubes. The buffy coat in each tube was washed twice with 
PBS, and the remaining red blood cells removed. RNALater (1 ml; 
Ambion) was added to one buffy coat tube, and 1 ml of M-PER™ 
Mammalian Protein Extraction Reagent (ThermoFisher Scientific) was 
added to the other buffy coat tube. Samples were then stored at -80 oC 
until needed for further analysis.  
 
 
2.2.15 DNA extraction from buccal swabs 
 
Buccal swabs were collected from consenting participants using a 
Dacron swab to brush the inside of the cheek. This was then collected in 
a 15ml Falcon tube and processed. To extract DNA, the Qiagen QIAmp 
DNA Mini kit (Qiagen (Manchester, UK) was used. 600 µl of PBS was 
added to the tube containing the swab, along with 20 µl Qiagen 
Protease stock solution and 400 µl Buffer AL. The sample was then 
immediately mixed by vortexing for 15 s. The sample was then incubated 
at 56 oC for 10 min. Ethanol (400 µl) was then added, and the sample 
mixed again by vortexing. Following this, 700 µl of the sample was 
carefully removed to a QIAmp mini spin column and centrifuged at 8000 
rpm (6000 x g) for 1 min. The column was then placed in a fresh 
collection tube, and 400 µl of ethanol was again added to the swab and 
mixed. A total of 700 µl of the remaining sample from the Falcon tube 
was added to the spin column. Buffer AW1 (500 µl) was then added to 
the spin column and centrifuged at 8000 rpm (6000 x g) for 1 min. The 
column was placed in a fresh collected tube, and 500 µl of Buffer AW2 
added. Subsequently the column was centrifuged at full speed (14,000 
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rpm or 20,000 x g) for 3 min. The spin column was finally placed in a 
clean 1.5 ml microcentrifuge tube, and 150 µl of Buffer AE added. This 
was then kept at room temperature for 1 min before a last centrifuge at 
8000 rpm (6000 x g) for 1 min. Samples were quantified using a 
NanoDrop™ 2000 spectrophotometer (Thermo Fisher Scientific Inc.) 
 
 
2.2.16 DNA extraction from whole blood 
 
The extraction of DNA from whole blood was performed using the 
Qiagen Gentra Puregene Blood Kit. A total of 300 µl of either fresh or 
frozen whole blood can be used. Initially, 900 µl of RBC lysis solution was 
added to a 1.5 ml microcentrifuge tube, followed by 300 µl of whole 
blood. This was then mixed by inverting ten times, and incubated for 1 
min at room temperature, inverting at least once during incubation. The 
sample was then centrifuged for 20 s at 13,000 – 16,000 x g to pellet the 
white blood cells. The supernatant was then carefully discarded through 
pipetting or pouring, leaving approximately 10 µl in the tube, and the 
white blood cell pellet. The tube was then vortexed vigorously to 
resuspend the pellet in the residual liquid to aid cell lysis, which was 
achieved through the addition of 300 µl of cell lysis solution. The liquid 
was pipetted up and down to lyse the cells, followed by vigorous 
vortexing for 10 s. To give an RNA-free DNA sample, 1.5 µl of RNase A 
solution was added, and the sample incubated for 15 min at 37 oC. The 
sample was then quickly cooled on ice for 1 min. A total of 100 µl of 
protein precipitation solution was added, followed by 220 s of vortexing 
at high speed. The sample was centrifuged for 1 min at 13,000 – 16,000 x 
g, with the precipitated protein forming a tight, dark brown pellet. 
Isopropanol (300 µl) was added to a clean 1.5ml microcentrifuge tube, 
to which the supernatant from the previous step was added, with 
caution taken to not dislodge the protein pellet.  
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Next the sample was then mixed by inverting 50 times, until the DNA was 
visible as threads or a clump. This was followed by another centrifugation 
step for 1 min at 13,000 – 16,000 x g, producing a small white DNA pellet. 
The supernatant was then carefully discarded and the tube carefully 
drained onto clean absorbent paper, making sure the pellet remains in 
the tube. At this point, 300 µl of 70% ethanol was added and the sample 
inverted several times to wash the pellet, followed by a further 
centrifugation step for 1 min at 13,000 – 16,000 x g. Again, the 
supernatant was discarded, the tube drained onto clean absorbent 
paper, with care taken not to dislodge the pellet, and the pellet left to 
air dry for 5 min. Then 100 µl of DNA hydration solution was added, and 
vortexed for 5 s at a medium speed to mix, and incubated at 65 oC for 5 
min to dissolve the DNA. Finally, the sample was incubated overnight at 
room temperature, with gentle shaking, after which the sample was 
briefly centrifuged and transferred to a storage tube before being 
quantified, samples were quantified using a NanoDrop™ 2000 
spectrophotometer (Thermo Fisher Scientific Inc.) 
 
 
2.2.17 Human Insulin ELISA for analysis of plasma samples 
 
The Mercodia Insulin ELISA (Mercodia, Uppsala, Sweden) was used for 
the quantitative determination of insulin from human plasma samples. 
The Mercodia Insulin ELISA is a solid phase two-site enzyme immunoassay. 
It is based on the direct sandwich technique in which two monoclonal 
antibodies are directed against separate antigenic determinants on the 
insulin molecule. To begin, 25 µl of each calibrator, sample and control 
was added to the appropriate well. Following the addition of samples, 
100 µl of enzyme conjugate was added; the plate was covered in foil 
and placed on a plate shaker at 900 rpm for 1 hour at room 
temperature. Each well was then washed 6 times with 350 µl of wash 
buffer. Working strength wash buffer was prepared by diluting wash 
buffer concentrate that had been supplied with 20 parts distilled water. 
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Substrate TMB (200 µl) was added to each well, and the plate further 
incubated at room temperature for 15 min. Finally, 50 µl of stop solution 
was added and absorbance was read immediately at 450 nm using an 
Epoch Microplate Spectrophotometer (BioTek, UK). A typical standard 
curve is illustrated in Figure 2.5.  
 
 
Figure 2.5: Typical Human Insulin ELISA standard curve 
 




2.2.18 Human C-peptide ELISA for analysis of plasma samples 
 
The ALPCO (Newmarket, UK) C-peptide ELISA was used for the 
quantitative determination of C-peptide in human plasma samples. The 
96-well microplate is coated with a monoclonal antibody specific for C-
peptide. To start, 25 µl of each standard, control and sample was 
pipetted into their respective wells. Assay buffer (50 µl) was then added 
to each well.  The microplate was then covered with a plate sealer and 
incubated at room temperature for 1 hour, with shaking at 700 – 900 rpm. 
After this, the contents of the plate were decanted and the plate 
washed 6 times with 350 µl of working strength wash buffer in each well. 
Following this, 100 µl of working strength conjugate was added to each 




















well, the plate was then covered again, and placed on a shaker at 700 – 
900 rpm for 1 hour at room temperature. The plate was again washed 6 
times with 350 µl of wash buffer. 100 µl of TMB substrate was then added 
to each well, and the plate was incubated for 15 min at room 
temperature on a shaker at 700 – 900 rpm. Finally, 100 µl of stop solution 
was added to each well, and absorbance was read immediately at 450 
nm using an Epoch Microplate Spectrophotometer (BioTek, UK). A typical 
standard curve is illustrated in Figure 2.6.  
 
 
Figure 2.6: Typical Human C-peptide ELISA standard curve 
 
A C-peptide standard curve ranging from 0 – 3000 pmol/L was created with the 
standards provided.  
 
 
2.2.19 Database construction 
 
Following recruitment of participants, clinical, anthropometric and 
biochemical information was collected for each patient. This included a 
lipid profile, HbA1c history, and all current prescribing information. This 
information was collected from two sources within the Western Health 
and Social Care Trust (WHSCT). The DIAMOND database and the 
Northern Ireland Electronic Care Record (NIECR) database were both 
consulted to give a full history. DIAMOND is a database used in the 
WHSCT to collect all relevant clinical information specifically from 




















diabetes patients’ electronic records. Whereas NIECR is the electronic 
care record system for all patients in NI, and houses all clinical 
information – details of hospital visits, test results etc – in one place for 
authorized personnel to access. Where possible data was entered in 
binary form, and where it was needed internationally recognised 
standard units were used. Figure 2.7 below shows select parts of the 
database, to provide a better understanding of the volume of data that 
























































Figure 2.7: Database Construction 
 
Above are screenshots of the DIASTRAT patient information database, showing 
just some of the anthropometric and clinical data that was collected for 


























Figure 2.8: Database Construction 
 
Above are screenshots of the DIASTRAT patient information database, showing 
just some of the anthropometric and clinical data that was collected for 
participants in this study.  
 
 
2.2.20 OLINK Proximity Extension Assay 
 
Proximity extension assay (PEA) work was outsourced to Olink Bioscience, 
Uppsala, Sweden. They use high-multiplex immunoassays for targeted 
human protein biomarker discovery. The technology involved can 
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measure 92 proteins across 96 samples simultaneously from 1 µl of 
plasma. A pair of oligonucleotide-labeled antibodies, Proseek probes, 
are allowed to pair-wise bind to the target protein present in the sample 
in a homogeneous assay. When the two Proseek probes are in close 
proximity, a new PCR target sequence is formed by a proximity-
dependent DNA polymerization event. The resulting sequence is 
subsequently detected and quantified using standard real-time PCR. 
Each of the 96 oligonucleotide antibody-pairs contains unique DNA 
sequences allowing hybridization only to each other. Subsequent 
proximity extension creates 96 unique DNA reporter sequences that are 
amplified by real-time PCR. Cross-reactive events are not detected with 
Olink’s panels since only matched DNA reporter pairs are amplified with 
real-time PCR. 
 
As described above in Section 2.2.16, plasma was separated from blood 
taken from participants in this study, 50 µl of plasma from each 
participant was then loaded into one well of a 96 well plate. These plates 
were then shipped to Olink, Uppsala, Sweden for analysis.  
 
 
2.2.21 SNP genotyping using the Affymetrix UK Biobank array 
 
DNA extracted from whole blood was quantified using the Qubit 
Fluorometric Quantitation (ThermoFisher Scientific Inc.). The Qubit allows 
for quantitation of dsDNA using fluorescence-based quantitation assays. 
As quality control, a subset of samples were also run on a 1% agarose gel 
to check for any degradation prior to sending for sequencing (Figure 
2.8). These sample were also measured using the NanoDrop™ 2000 
spectrophotometer (Thermo Fisher Scientific Inc.) to confirm the 
OD260/OD280 ratio was between 1.8 and 2.0 and the OD260/OD230 
was greater than 1.5.  
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Samples were required to have an input mass of 100 ng, gDNA 
concentration of 5 ng/µl, with a final volume of 20 µl. DNA samples were 
diluted using reduced EDTA TE buffer (10mM Tris-HCL pH 8.0, 0.1 mM 
EDTA), which was supplied by Affymetrix. Samples were aliquoted into 
ABgene 96 Square Well Storage (Thermo Fisher Scientific Inc.) and sealed 
with caps mats (Thermo Fisher Scientific Inc.). Samples were shipped on 
dry ice to Cambridge Genomics Services (CGS) for analysis on the 
Affymetrix UK Biobank array. CGS is a core facility within the Department 
of Pathology at Cambridge University that offer genomics technologies 




















Figure 2.9: DNA Gel 
 
A subset of DNA samples were run on a 1% agarose gel to assess DNA quality 
prior to being sent for sequencing.  
 
 
2.2.22 Statistical Analyses 
 
Data are presented as mean ± standard error of the mean (SEM) or 
standard deviation (SD) for a given number of observations (N) as 
indicated in the Figures. Comparison of gene and protein expression 
between groups was compared by two-tailed unpaired Student t test 
(for data standardized against a control) or one-way ANOVA with 
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posthoc test (for non-standardised data) using either Graphpad, (PRISM 
Software, USA) or SPSS Statistics (IBM software). Correlations were 
interrogated using Pearson’s or Spearman’s coefficient (SPSS) as 
appropriate. Significance was accepted at P<0.05. 
 
Analysis of Olink data was completed in Matlab with bespoke scripts 
written by Dr Steven Watterson (Stratified Medicine, Ulster University).  
Proteins falling below the level of assay detection were excluded from 
the analysis. Expression of the remaining proteins between control and 
DIASTRAT groups were compared using an unpaired two-sample t test 
with significance accepted at P<0.05. The proteins that passed this test 
were ranked, with the smallest overlap in the distributions between the 
patient groups at the top of the list and the proteins with the largest 
overlap at the bottom. The top 75 proteins were selected and the linear 
combination sought to enable calculation of a pseudo-protein with the 
smallest possible overlap in the distributions between the two participant 
groups.  
 
Analyses of UK Biobank array genotyping data was performed using 
Axiom’s Genotype Console software. Samples failing quality control (SNP 
call rate <97.2% and QC<0.82) were excluded from further analysis. 
Variant calling was performed following creation of SNP lists against 
each gene of interest. Using XLSTAT, comparisons between genotypes 
were assessed using a two-sample t test for two proportions following 
conversation of percentages positive for each genotype to proportions 
(where 100% = 1) and 95% confidence interval (CI). Significance was 
accepted at P<0.05.  Clustering of genotypes of interest was performed 






































Sulphonylureas (SU) are a commonly used treatment in T2DM. They work 
by acting directly on the pancreatic β-cell to stimulate insulin secretion 
(Proks et al., 2002). They target the ATP-sensitive potassium (KATP) channel, 
which is a hetero-octameric complex comprising two types of protein 
subunit – an inwardly rectifying potassium subunit (Kir6.2), and 
sulphonylurea receptor 1 (SUR1) (Ashcroft and Gribble, 1999, Proks et al., 
2002). Subsequent inhibition of this channel triggers membrane 
depolarisation of the pancreatic β-cell, prompting the opening of 
voltage-gated Ca2+ channels, which in turn allows entry of Ca2+ in to the 
pancreatic β-cell, and stimulates the exocytosis of insulin from secretory 
granules (Proks et al., 2002). The most common adverse event observed 
with SU is hypoglycaemia. For some individuals this can be severe and 
persistent due to the duration of action of the drug. This is particularly 
troublesome with first generation sulphonylureas like tolbutamide and 
chlorpropamide (Aquilante, 2010). 
 
With SU treatment, interindividiual variation in response is a concern. It is 
estimated that 10-20% of patients will suffer from primary SU failure; that 
is, they will have less than a 20 mg/dl reduction in fasting plasma glucose 
(DeFronzo, 1999, Aquilante, 2010). Roughly 50-60% of patients will 
ultimately fail to reach the required glycaemic control following a 
primary decrease in fasting plasma glucose of greater than 30 mg/dl 
(DeFronzo, 1999, Aquilante, 2010). Secondary SU failure is also an issue in 
around 5-7% of patients who have a good response at the start 
(DeFronzo, 1999, Aquilante, 2010). This varying response has also been 
replicated in large-scale randomized trials; in particular the A Diabetes 
Outcome Progression Trial (ADOPT) revealed a sulphonylurea 
monotherapy failure of 34% contrasted with 21% for metformin (Kahn et 
al., 2006, Aquilante, 2010). 
 
	 59 
Along with this variation in the response to treatment, variation is also 
seen in occurrence of adverse events. Approximately 31% of patients 
suffer mild hypoglycaemia in the first year of glibenclamide treatment, 
with the frequency of severe hypoglycaemia estimated at 
approximately 1% per year (UKPDS Group, 1998). There are clinical 
factors involved in the failure of SU treatment including deteriorating β-
cell function, long-standing diabetes, elevated baseline glucose levels 
and an elevated degree of insulin resistance (Aquilante, 2010). There are 
also some factors that affect severity of SU induced hypoglycaemia, 
including the duration of sulphonylurea action, mild baseline 
hyperglycemia, irregular eating patterns, excessive alcohol intake and 
age (Aquilante, 2010). 
 
Clinical factors are not the sole regulators of variation to response. There 
is evidence suggesting certain single nucleotide polymorphisms (SNPs) 
are involved (Aquilante, 2010). However, there is little consensus in the 
literature as to what SNPs are at play. This is highlighted in the work of 
Song et al. (2017), who identified SNPs in ABCC8, KCNJ11, which have 
evidence showing, or not, an association with T2DM (Meirhaeghe et al., 
2001, Zychma et al., 2002, Ragia et al., 2012, Li et al., 2014). Similar effects 
were observed for KCNJ11 alone, with Haghvirdizadeh and colleagues 
citing multiple SNPs involved in SU response, which was again supported 
and contrdicted by other studies (Haghvirdizadeh et al., 2015). The lack 
of consensus and among these groups perhaps highlights difference of 
effect of SNPs among different populations. 
 
The aim of this study therefore was to assess the effect of ABCC8, 
KCNJ11, KCNQ1, HNF1α and TCF7L2 deficiency on SU (glibenclamide 
and tolbutamide) response from single β-cells using two β-cell lines: MIN6 
and BRIN-BD11. The hypothesis therefore being tested was that 
deficiency, or knockdown in expression, would cause a reduction in 
insulin output from the two cell lines. 
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3.2 Materials and Methods 
 
3.2.1 Chemicals 
Reagents of analytical grade and deionized water were used. All other 
chemicals used are listed in Chapter 2, Section 2.1 
 
3.2.2 Culture of β-cell lines 
Two pancreatic β-cell lines, MIN6 and BRIN-BD11, were grown and 
maintained in DMEM and RPMI tissue culture medium respectively, as 
described in Chapter 2, Section 2.2.1. 
 
3.2.3 RNA extraction and Quantification 
Total RNA was extracted from monolayers and quantified as described in 
Chapter 2, Section 2.2.4. 
 
3.2.4  cDNA synthesis 
Total RNA (100 ng) was reverse transcribed into cDNA using the 
Transcriptor First Strand cDNA Kit (Roche Diagnostics Ltd., UK) as 
described in Chapter 2, Section 2.2.5. 
 
3.2.5 Quantitative real-time PCR (qPCR) 
Quantitative real-time PCR (qPCR) was performed as described in 
Chapter 2, Section 2.2.6. 
 
3.2.6 Immunocytochemistry 
Immunocytochemistry was performed using primary antibodies for SUR1, 
Kir6.2, KCNQ1 and HNF1α according to the protocol described in 
Chapter 2, Section 2.2.7. 
 
3.2.7 Assessment of acute insulin release from Pancreatic β-cells 
Release of insulin from MIN6 and BRIN-BD11 cells, directly, or following 
transfection with siRNA, was assessed using the method described in 
Chapter 2, Section 2.2.3. Following 40 min preincubation with 1.1 mM 
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glucose, cells were acutely exposed to 16.7 mM glucose with 200 μM SU 
(Tolbutamide or Glibenclamide) for 20 min. 
 
3.2.8 Protein Extraction and Quantification 
Total protein was extracted as described in Chapter 2, Section 2.2.12. 
Protein was measured using the quantitative BCA assay, described in 
Chapter 2, Section 2.2.12. For the purposes of these experiments, protein 
concentrations were determined following acute tests and insulin 
secretory data standardized for protein content. 
 
3.2.9 Potassium Channel Inhibition  
BRIN-BD11 potassium channel inhibition was performed following 
addition of 25 µl antibodies again SUR1 (encoded by ABCC8), Kir6.2 
(Encoded by KCNJ11) and KCNQ1 as described in Chapter 2, Section 
2.2.8. 
 
3.2.10  siRNA Transfection 
Pancreatic β-cell lines MIN6 and BRIN-BD11 were transfected with siRNA 
against ABCC8, KCNJ11, KCNQ1 and HNF1α as described in Chapter 2, 
Section 2.2.9. 
 
3.2.11 Statistical Analyses 
Results are presented as mean ± SEM for a given number of observations 
(n) as indicated in the Figures. Groups of data were compared using 
unpaired Student’s t-tests or One-way ANOVA with posthoc tests. 
Significance was accepted if P<0.05. 
 
 
3.3 Results  
 
3.3.1 BRIN-BD11 and MIN6 pancreatic β-cell lines secrete insulin following  
exposure to sulphonylureas 
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BRIN-BD11 (Figure 3.1A) and MIN6 (Figure 3.1B) cells were exposed to 16.7 
mM glucose and tolbutamide or glibenclamide (200 µM) for 20 min. BRIN-
BD11 cells displayed a 319.16 ± 12.3% increase (P<0.005) and a 568.99 ± 
10.3% increase (P<0.0001) in insulin secretion in response to tolbutamide 
and glibenclamide respectively (Figure 3.1A). Similar data was obtained 
from MIN6 cells where insulin secretion was significantly enhanced in 
response to both sulphonylureas (Figure 3.1B) 
 
 
Figure 3.1:  Sulphonylurea-potentiated insulin secretion in β-cell lines 
 
BRIN-BD11 (A) and MIN6 (B) cells were exposed to 16.7 mM glucose and 200 µM 
tolbutamide or glibenclamide for 20 min and insulin secretion assessed by ELISA. 
Data are presented as mean ± SEM (n = 3).  **P<0.005, ***P<0.001 ****P<0.0001 
compared with control (16.7 mM Glucose). 
 
 
3.3.2 BRIN-BD11 and MIN6 pancreatic β-cell lines express candidate 
biomarkers at both the mRNA and protein level 
 
Candidate genes reported to enhance T2DM risk and to be involved in 
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literature and phenotypes validated using the Type 2 Knowledge Portal. 
Evidence in support of each gene is summarised in Table 3.1 Expression 
of each of the candidate genes was assessed using qPCR (Roche 
Lightcycler 480) with β-actin serving as a house-keeping reference gene. 
ABCC8, KCNJ11, HNF-1α and KCNQ1 were expressed in BRIN-BD11 and 
MIN6 cells (Figure 3.2). Expression of each candidate was confirmed at 
the protein level as shown in Figure 3.3.  
 
Despite reports showing its important role in insulin production, and 
expression in the MIN6 cell line (da Silva Xavier et al., 2009, Zhou et al., 
2014), TCF7L2 expression was not observed in either cell line in this study. 
Several primer-specific probes against both rat and mouse TCF7L2 
sequences were employed. However, cp values were not observed in 
any instance. Given this, investigation of the role of TCF7L2 was not 




Table 3.1: Supporting evidence for causal involvement in T2DM risk or  
sulphonylurea response. 
 
A literature search was conducted to identify evidence of an association with 
either risk of T2DM or an effect on response to sulphonylurea. The Type 2 
Diabetes Knowledge portal was also used to identify phenotypes that had 













(Hani et al., 1997, Hansen et al., 
1998, Hart et al., 1999, Hart et al., 
2000, Rissanen et al., 2000, Reis et 
al., 2002, Florez et al., 2007, 
Hamming et al., 2009, Fatehi et al., 
2012, Sokolova et al., 2015)
(Aquilante, 2010, Song et al., 
2017, Feng et al., 2008, 
Pollastro et al., 2015)
T2DM; Height; BMI; Subcutaneous 
adipose tissue volume; 
Microalbuminaria; Proinsulin levels
(Eftychi et al., 2004, van Dam et 
al., 2005, Florez et al., 2007, 
Aquilante, 2010, Gong et al., 2012, 
Li, 2013, Qin et al., 2013, Qiu et al., 
2014, Haghvirdizadeh et al., 2015, 
Rastegari et al., 2015)
(Sesti et al., 2006, Holstein et 
al., 2009, Aquilante, 2010, El-
Sisi et al., 2011, Javorsky et al., 
2012, Li et al., 2014, Song et 
al., 2017)
T2DM; BMI; Height; Two-hour 
glucose
(Grant et al., 2006, Hattersley, 
2007, Pearson et al., 2007, Cauchi 
and Froguel, 2008, Gloyn et al., 
2009, Villareal et al., 2010, Holstein 
et al., 2011, Schroner et al., 2011b, 
Wang et al., 2013)
(Pearson et al., 2007, 
Schroner et al., 2011b, 
Holstein et al., 2011, Song et 
al., 2017)
T2DM; Fasting glucose
(Yasuda et al., 2008, Unoki et al., 
2008, Saif-Ali et al., 2011b, Saif-Ali 
et al., 2011a, van Vliet-
Ostaptchouk et al., 2012, Sun et 
al., 2012, Sun et al., 2014, Ma et al., 
2015, Riobello et al., 2016)
(Aquilante, 2010, Ohshige et 
al., 2010, Schroner et al., 
2011a, Li et al., 2017)
T2DM; Height; Serum creatinine; 
Fasting glucose; Serum cystatin c; 
HOMA-B; Insulin at 30min OGTT; 
Schizophrenia; Insulin at 30min 
OGTT adj BM; Precardial adipose 
tissue volume; visceral adipose 
tissue attenuation
(Gill-Carey and Hattersley, 2007, 
Billings and Florez, 2010, Voight et 
al., 2010, Estrada et al., 2014, 
Prasad and Groop, 2015)
(Ellard and Colclough, 2006, 
Pearson et al., 2000, Khelifa et 
al., 2016)
T2DM; Cholesterol; LDL 
cholesterol; Coronary artery 
disease; Two-huor glucose; 





Figure 3.2:  Candidate gene expression in pancreatic β-cell lines 
 
Total RNA was extracted from (A) BRIN-BD11 and (B) MIN6 cells and reverse 
transcribed into cDNA. Expression of candidate genes was then determined 
through qPCR, with β-actin used as the house keeping gene. Data are 




























































Figure 3.3: Expression of candidate biomarkers at protein level in MIN6 and 
BRIN-BD11 cell lines 
 
The expression of candidate biomarkers in MIN6 cell line was confirmed by 
immunocytochemistry. SUR1, Kir6.2, KCNQ1 and HNF1α were expressed. Images 





















3.3.3  Potassium channel inhibition affects sulphonylurea-induced insulin 
secretion 
 
An initial assessment of the role of candidate biomarkers on 
sulphonylurea response was conducted using simple antibody blocking 
experiments. To assess the impact of cell surface potassium channel 
proteins on sulphonylurea-induced insulin secretion, BRIN-BD11 cells were 
exposed to antibodies against SUR1, Kir6.2 and KCNQ1 prior to 
sulphonylurea treatment. The resulting effect on sulphonylurea-induced 
insulin secretion was measured by ELISA and is shown in Figure 3.4. 
Unsurprisingly, blockage of SUR1 inhibited sulphonylurea-induced insulin 
secretion in response to both tolbutamide (54.63 ± 0.02% reduction, 
P<0.0001) and glibenclamide (50.53 ± 0.04% reduction, P<0.0001). 
However, blockage of Kir6.2 only inhibited insulin secretion in response to 
glibenclamide (49.47 ± 0.04% reduction, P<0.0001). This is consistent with 
the proposal that glibenclamide may have some affinity for Kir6.2 (Selvin 
and Renuad 2015). Blockage of KCNQ1 had no effect on sulphonylurea 
induced insulin secretion. However, KCNQ1 does not host a 
sulphonylurea binding site and the reported role of KCNQ1 in response to 







Figure 3.4: Effect of potassium channel inhibition on BRIN-BD11 response to 
sulphonylureas. 
 
Following addition of 5 µg of antibody against SUR1, Kir6.2 or KCNQ1, BRIN-BD11 
monolayers were incubated for 24 h. Following this, insulin secretion in response 
to 200 µM Tolubitamide or Glibenclamide was tested by ELISA. Data are 
presented as mean ± SEM. (n = 3).  ***P<0.001, ****P<0.0001 compared with 
corresponding control (5.6 mM Glucose). ΔP<0.05, ΔΔ P<0.01, ΔΔΔΔ P<0.0001 
compared with equivalent treatment in the absence of blocking antibody. 
(GLU, glucose; Tol, tolbutamide; Glib, glibenclamide) 
 
 
3.3.4  siRNA transfection has no significant impact on pancreatic β-cell 
line viability 
 
Concerns regarding transfection reagent induced toxicity prompted the 
decision to assess the impact, of rising concentrations of transfection 
reagent on the number of proliferating BRIN-BD11 cells. This was assessed 
at 3 different time points following exposure to transfection reagent using 
an MTT assay. As seen in Figure 3.5, at both the 24 and 48-hour time 
points there is no significant difference between the 3 groups. At 72 h, 
absorbance is higher in cells treated with the transfection reagent when 
compared to the control group (P<0.05) suggested that, at these 
concentrations, transfection reagent does not adversely affect the 
number of proliferating cells. Although we do see a rise in absorbance 
between 24 and 48 h this is most likely due to the increased number of 
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was most likely due to cells becoming over confluent in the wells, and 
starting to strip off. The result confirmed that these high amounts of 
transfection reagents were not having an impact of BRIN-BD11 cell 
viability, and based on these observation 6 µl of transfection reagent was 
used in future transfections.  
 
 
Figure 3.5: siRNA transfection has no significant impact on viability of BRIN-
BD11 cells 
 
Following addition of transfection reagent, the effect on cell viability in this cell 
line was studied using an MTT assay. Data are presented as mean ± SEM (n=3), 
*P<0.05, **P<0.01 compared with control at the corresponding time point.  
 
 
3.3.6  Transfection efficiency using siRNA in pancreatic β-cell lines  
 
The expression of candidate biomarkers was silenced in both BRIN-BD11 
and MIN6 cells using 100 nm siRNA against the rat or mouse sequences 
(for BRIN-BD11 and MIN6 respectively) of ABCC8, KCNJ11, KCNQ1 and 
HNF1α. Gene silencing was quantified by qPCR as shown in Figure 3.6. 
 
Silencing of ABCC8 in BRIN-BD11 cells was 41.98 ± 9.623% of scrambled 
control (P<0.005, Figure 3.6A). However, ABCC8 silencing in MIN6 cells 
was less efficient with expression levels post transfection 74.05 ± 12.26% of 
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Silencing of KCNJ11 in BRIN-BD11 cells was 40.30 ± 9.35% of scrambled 
control (P<0.005, Figure 3.6A). Consistently, KCNJ11 silencing in MIN6 cells 
was less efficient with expression levels post transfection at 28.57 ± 14.67% 
of scrambled control (NS, Figure 3.6B). 
 
Silencing of KCNQ1 in BRIN-BD11 cells was 54.14 ± 5.91% of scrambled 
control (P<0.0001, Figure 3.6A). KCNQ1 silencing in MIN6 cells was 
comparable with BRIN-BD11 cells with expression levels post transfection 
at 51.26 ± 11.37% of scrambled control (P<0.005, Figure 3.6B). 
 
Finally, silencing of HNF1α in BRIN-BD11 cells was 2.47 ± 1.35% of 
scrambled control (NS, Figure 3.6A). Knockdown of HNF1α was not 
achieved in BRIN-BD11 despite attempts to optimize four different siRNAs; 
therefore these experiments were excluded from further insulin secretion 
assays. Conversely, HNF1α silencing in MIN6 cells was more successful 
with expression levels post transfection at 56.74 ± 7.99% of scrambled 







Figure 3.6: Candidate biomarker knockdown using siRNA in BRIN-BD11 and 
MIN6 cell lines 
 
Candidate biomarker knockdown at the mRNA level, using 100nm siRNA, 
against ABCC8, KCNJ11, KCNQ1 and HNF1α in BRIN-BD11 (A) and MIN6 (B) cells 
was assessed using qPCR. The figure shows the percentage knockdown in 
comparison to the scrambled siRNA used for each cell line. Data are presented 
as mean ± SEM with n=7-8 for BRIN-BD11 and n=6-9 for MIN6. ***P<0.001, 
****P<0.0001 compared with the corresponding scrambled siRNA. 
  
 
3.3.7  ABCC8 drives sulphonylurea response in pancreatic β-cell lines 
 
Following knockdown of expression of each candidate biomarker, the 
impact on insulin secretion from pancreatic β-cell lines was assessed 
using ELISA, and is represented as a % of control (Scrambled siRNA), in 
BRIN-BD11 (Figure 3.7A) and MIN6 (Figure 3.7B) cells.  
 
Following ABCC8 knockdown in BRIN-BD11 cells (Figure 3.7A), significant 
reductions in insulin secretion were observed in response to 1.1 mM 







































































glibenclamide (49.02 ± 7.47% reduction, P<0.0001) when compared with 
the scrambled siRNA control. In the MIN6 cell line (Figure 3.7B) the 
subsequent effect on insulin secretion following ABCC8 knockdown was 
not replicated.  
 
KCNJ11 knockdown in the BRIN-BD11 cell line (Figure 3.7A) caused a 
significant reduction in insulin secretion in response to 16.7 mM glucose + 
glibenclamide (26.08 ± 7.15% reduction, P<0.005) compared to 
scrambled control. Again, this finding was not replicated in the MIN6 cell 
line (Figure 3.7B). 
 
Significant reductions in tolbutamide (29.00 ± 9.27% reduction, P<0.01)  
and glibenclamide (37.00 ± 8.86% reduction, P<0.005)-potentiated insulin 
secretion were observed in BRIN-BD11 cells, following KCNQ1 knockdown 
(Figure 3.7A). Consistent with observations following ABCC8 and KCNJ11 
knockdown in MIN6 cells, KCNq1 knockdown did not significantly alter 




Figure 3.7: Effect of candidate biomarker knockdown on insulin secretion 
from BRIN-BD11 cells 
 
Insulin secretion in response to glucose and sulphonylureas from BRIN-BD11 (A) 
or MIN6 (B) cells following knockdown of candidate biomarkers using 100 nm 
siRNA was assessed by ELISA. Tolbutamide and glibenclamide where added in 
combination with 16.7mM glucose. Data are presented as mean ± SEM with 
n=3-5 for BRIN-BD11 and n=4-6 for MIN6. *P<0.05, **P<0.01, ****P<0.0001 
compared with the corresponding scrambled siRNA. 
  
 
3.4  Discussion 
 
It is known that inter-individual response to sulphonylurea treatment exists 
and that a genetic component is likely to play a role in varying response 
rates. Several genes have been highlighted as having a significant 
impact on sulphonylurea response including ABCC8, KCNJ11, KCNQ1, 
HNF1α and TCF7L2 (Glamoclija and Jevric-Causevic, 2010, Schroner et 



























































However, individual studies have identified different loci within each of 
these genes that are deemed to be important in terms of response 
(Pearson et al., 2000, Meirhaeghe et al., 2001, Schroner et al., 2011, Li et 
al., 2014). Furthermore, little consistency exists within the literature as to 
which SNPs are causative in sulphonylurea failure. Much of this variation 
may result from differences in cohort characteristics. For example, 
different ethnic groups have worse macrovascular complications of 
diabetes (Golden et al., 2012). However, there are a significant number 
of loci linked with increased risk to T2DM irrespective of ethnicity 
(Spanakis and Golden, 2013). This study therefore endeavored to 
investigate the role of each of these candidate genes on sulphonylurea 
response from single β–cells in an effort to better understand the 
mechanisms behind sulphonylurea response.  
 
Two β–cell lines were chosen for the study in an attempt to ensure that 
any observed changes in sulphonylurea response did not result from the 
nuances of one particular cell line. Additionally, first and second 
generation sulphonylureas (tolbutamide and glibenclamide respectively) 
were employed to determine if drug chemistry had an effect on 
response.  The BRIN-BD11 and MIN6 cell lines have previously been shown 
to be sulphonylurea responsive (Brennan et al., 2006, Morioka et al., 
2012), which was again confirmed in the current study where significant 
enhancements in sulphonylurea-induced insulin secretion were 
observed. Furthermore, the cell lines were found to express four of the 
five candidate genes of interest, namely ABCC8, KCNJ11, KCNQ1 and 
HNF1α consistent with reports in the literature (Blumenfeld et al., 1991, 
Gloyn et al., 2006, Yamagata et al., 2011). TCF7L2 expression was not 
observed in either cell line in this study contrary to some reports in the 
literature (Migliorini and Lickert, 2015, Dong et al., 2016). It is possible that 
TCF7L2 is expressed at low levels in these cell lines and that this accounts 
for the lack of determination of mRNA expression in this study. However, 
having employed numerous species-specific and primer-specific probes 
to examine expression, we excluded TCF7L2 from further study. 
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The potassium sensitive KATP channel comprises two subunits, SUR1 and 
Kir6.2. ABCC8 encodes the pancreatic β–cell surface protein SUR1, a key 
component of the KATP channel, and also the direct target for 
sulphonylureas. The effect of SUR1 inhibition was assessed following 
exposure to an antibody against SUR1. Unsurprisingly, the blockage of 
SUR1 prevented sulphonylurea binding, inhibiting subsequent 
downstream effects and hampering insulin release from the BRIN-BD11 
pancreatic β–cell line. Following this ABCC8 specific siRNA were used in 
transfections of both pancreatic β–cell lines. A clear and obvious effect 
on sulphonylurea-induced insulin secretion was observed in the BRIN-
BD11 cell line after ABCC8 silencing especially in response to 
glibenclamide. However, a significant effect was not observed in the 
MIN6 cell line following ABCC8 silencing. This discrepancy may be 
explained by the poor transfection efficiency observed in the MIN6 cell 
line, which proved difficult to transfect in all instances in this study.  
 
The second subunit of the KATP channel is the inwardly rectifying Kir6.2, 
encoded by KCNJ11. Kir6.2 is also a target of sulphonylurea action 
especially for second-generation drugs like glibenclamide (Kuhner et al., 
2012, Proks et al., 2014). Following exposure of the BRIN-BD11 cell line to 
an antibody against Kir6.2, sulphonylurea-induced insulin secretion was 
impacted, but only in response to glibenclamide. Glibenclamide is 
known to carry some affinity for the Kir6.2 subunit of the KATP channel that 
is not associated with tolbutamide (Kuhner et al., 2012). This was 
supported by experiments in which KCNJ11 was silenced in the BRIN-
BD11 cells. As with the antibody blocking experiment, glibenclamide-, 
but not tolbutamide-induced insulin secretion was significantly impaired. 
As mentioned above, glibenclamide does carry affinity for the Kir6.2 
subunit, and given that second generation sulphonylureas are typically 
more potent than first (tolbutamide) this result is perhaps not surprising 
(Aquilante, 2010). Consistently, a significant effect in sulphonylurea-
induced insulin secretion was not observed following attempts to silence 
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KCNJ11 in the MIN6 cell line, likely reflecting the poor transfection 
efficiency in this model.  
 
KCNQ1 encodes a voltage-gated K+ channel in the pancreatic β–cell. As 
a cell surface protein, the effect on sulphonylurea-induced insulin 
secretion following exposure to KCNQ1 antibody was assessed, prior to 
undertaking siRNA transfections in the cell line models. Following 
antibody blocking of the channel, no impact on sulphonylurea-induced 
insulin secretion from BRIN-BD11 cells was observed. However, this was 
not a result replicated following transfection with KCNQ1 specific siRNA 
where highly significant reductions in both tolbutamide- and 
glibenclamide-induced insulin secretion were observed. The antibody 
blocking experiments hamper channel activity by occupying the binding 
site on KCNQ1. However, it is possible that the effect on sulphonylurea-
induced insulin secretion observed in the BRIN-BD11 cell line following 
KCNQ1 knockdown highlights an important role for KCNQ1 expression 
and not just channel activity in the regulation of this process. Once 
again, poor transfection efficiency in the MIN6 cell line was observed 
and attempts at KCNQ1 silencing were associated with a limited effect 
on insulin secretion in this instance. Yamagata et al. (2011) showed that 
overexpression of KCNQ1 could regulate insulin secretion in the MIN6 β–
cell line, with insulin secretion in response to tolbutamide significantly 
impaired. It was proposed that the increase in channel density lowered 
the rate of action potentials and decreased insulin release from the β–
cell. Collectively, KCNQ1 appears to play an important role in insulin 
secretion from the pancreatic β–cell, which warrants further 
investigation.  
 
Prior work has shown that mutations in HNF1α causes sensitivity to 
sulphonylureas (Ashcroft and Rorsman, 2012). As HNF1α is not a cell 
surface protein it was not possible to conduct an antibody blocking 
experiment in this study. However, multiple attempts were made to 
assess the effect of HNF1α deficiency on sulphonylurea-induced insulin 
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secretion in the BRIN-BD11 and MIN6 cell lines. Despite optimization of 
four independent siRNAs against HNF1α, knockdown at the gene level 
was not achieved in the BRIN-BD11 cell line. Although good transfection 
efficiency was achieved in the MIN6 cell line, a limited effect on insulin 
secretion was observed.  
 
To summarise, while transfection efficiency was better in the BRIN-BD11 
cell line compared with the MIN6 cell line. In the BRIN-BD11 cell line, 
ABCC8, KCNJ11 and KCNQ1 all significantly impaired insulin secretion in 
response to glibenclamide. Our data suggests that ABCC8, KCNJ11, and 
KCNQ1 may have a role to play in the direct control of SU-driven insulin 
secretion suggesting that genes beyond the KATP channel are important 








































Treatment of T2DM involves changes in lifestyle and pharmacological 
treatment (National Institute for Health and Care Excellence (NICE), 
2015). There is typically a focus on educating the patients about their 
disease and how to self manage the disease along with dietary advice 
(National Institute for Health and Care Excellence (NICE), 2015). Priorities 
thereafter involve blood pressure management and blood glucose 
management, with specific targets for each (140/80 mmHg and 48 
mmol/mol respectively) (National Institute for Health and Care 
Excellence (NICE), 2015). If lifestyle and dietary changes are insufficient 
to meet these targets then pharmacological interventions are indicated 
(National Institute for Health and Care Excellence (NICE), 2015).  
 
Diabetes control is monitored by measuring a patient’s glycated 
haemoglobin (HbA1c), giving an insight into glycaemic control over the 
previous two to three months (Sherwani et al., 2016). As part of normal 
physiological function, haemoglobin is regularly glycated, with the most 
abundant fraction formed being HbA1c (Sherwani et al., 2016). The 
amount of circulating HbA1c is directly proportional to the amount of 
ambient blood glucose; therefore, as blood glucose increases, so too 
does HbA1c (Sherwani et al., 2016). As the lifespan of an erythrocyte is 
typically two to three months, when HbA1c is measured it gives an insight 
into how well the patient’s glycaemia has been controlled over that time 
period (Sherwani et al., 2016). In the diabetic population, HbA1c should 
be routinely monitored every 3-6 months (National Institute for Health 
and Care Excellence (NICE), 2015). The target set by the NICE guidelines 
for good glycaemic control is 48 mmol/mol. If the first line 
pharmacological therapy, metformin, is not tolerated, or if HbA1c does 
not fall below 58 mmol/mol, additional therapies will be introduced. 
Amongst these is the sulphonylurea drug class, which acts to enhance 
insulin secretion from the pancreatic β-cells. This drug class is associated 
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with poor response rates and will be the primary focus of the current 
study, 
 
Given the complex aetiology of the disease, the T2DM population is 
notoriously heterogonous in terms of clinical characteristics and response 
to treatment. Much of the variation relates to metabolic capabilities, 
socioeconomic differences, environmental influences, ethnicity and 
differences in severity of disease (Cantrell et al., 2010). Response to 
therapy is further complicated by the significant level of polypharmacy 
observed in the T2DM population (Noale et al., 2016). Polypharmacy 
describes the phenomenon of multiple medications prescribed 
concurrently, and typically increases with age (Peron et al., 2015), in 
T2DM it’s not uncommon to see patients with more than one anti-
diabetic treatment, for example an SU and INS concurrently, with 
perhaps a statin for stating to combat high cholesterol too. 
Polypharmacy-related complications typically arise due to increased risk 
of nonadherence to drug, drug-drug interactions and adverse drug 
events (Peron et al., 2015). Among older patients with T2DM the factors 
that contribute to polypharmacy include micro- and macro-vascular 
complications including diabetic nephropathy and retinopathy, 
coronary artery disease, geriatric syndromes and cognitive impairment 
(Peron et al., 2015).  
 
Given the above, thorough characterization of cohort characteristics 
and clinical information (to include prescribing information) are an 
important part of any cohort study in the T2DM population.  As such, the 
aims were clear - to firstly characterise participant demographics within 
a T2DM cohort (DIASTRAT) recruited from the Western Health and Social 
Care Trust through collecting clinical, anthropometric and biochemical 
information. To understand the prevalence of polypharmacy among the 
cohort. To garner an initial impression of glycaemic control within the 
cohort through studying HbA1c levels and finally, to assess plasma c-
peptide and insulin levels as an indicator of residual β-cell function.  
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4.2 Materials and Methods 
 
4.2.1 Chemicals 
Reagents of analytical grade and deionized water were used. All other 
chemicals used are listed in Chapter 2, Section 2.1. 
 
4.2.2 Participant Recruitment 
Participants were recruited onto the Stratified Medicine, optimizing 
treatment for Diabetes (DIASTRAT) study as described in Chapter 2, 
Section 2.2.15. 
 
4.2.3 Database Construction 
Participant clinical, anthropometric and biochemical information was 
collated into a database, full detail are provided in Chapter 2, Section 
2.2.21 
 
4.2.4 Processing blood samples 
Blood samples taken from consented participants was processed using 
the method described in Chapter 2, Section 2.2.16.  
 
4.2.5 Plasma insulin levels 
Participant plasma insulin levels were assessed using the Mercodia 
Human Insulin ELISA kit as described in Chapter 2, Section 2.2.19. 
  
4.2.6 Plasma C-peptide levels 
Participant plasma c-peptide levels were assessed using the ALPCO C-




Data are presented as mean ± SD for a given number of participants (N). 
Comparisons of clinical, anthropometric and biochemical data between 
subgroupings were assessed by One-way ANOVA with post-hoc test. 
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Significant correlations between HbA1c, or c-peptide (as markers of 
glycaemic control and residual β-cell function respectively) and other 
characteristics, were identified using Spearman’s coefficient (p). 





4.3.1 Baseline characteristics of the DIASTRAT cohort 
 
Demographic information on the cohort is collated in Table 4.1. Of the 
500 participants recruited, 10 were eventually excluded for exceeding 
the maximum age range of the cohort (18 – 80 years). The cohort was 
predominantly male (63%) with a mean age of 63 (± 11.12) years. Mean 
weight was 96.08 (± 20.70) kg, BMI was 33.93 (± 7.77) and height was 
168.50 (± 10.30) cm. Where data was available, the average alcohol 
consumption for the cohort was 0.36 (± 1.06) units/day. However, the 
data for alcohol consumption is unlikely to be fully representative of the 
cohort as a whole, as alcohol consumption data was recorded for just 
57% of all participants, with the majority of those recording zero alcohol 
consumption. 
 
For analyses, the cohort was sub-grouped based on their use of 
exogenous insulin (INS) or sulphonylureas (SU). Significant differences 
(P<0.05) in weight and BMI were observed between those received INS in 
the absence of SU and those receiving SU in the absence of INS (Figure 
4.1). In both instances, values for those in the SU+/INS- group (weight: 
100.10 ± 22.24 kg; BMI: 34.85 ± 7.70) were significantly higher than those in 








































5.1  Introduction 
 
Inflammation is the biological process responsible for protecting against 
pathogens and controlling repair and healing after cell damage 
(Kraakman et al., 2014). If inflammation is not contained following an 
acute exacerbation, the continuous activation of the immune system 
can trigger tissue damage and disease (Kraakman et al., 2014). With 
both obesity and T2DM there is evidence of persistent low-grade 
inflammation, with a rise in circulating inflammatory cytokines and 
acute-phase proteins (Touch et al., 2017). In obese individuals this low-
grade inflammation contributes to insulin resistance, the main 
pathological change that links both obesity and T2DM (Zhao et al., 
2014). The low grade inflammation typically seen in obesity and T2DM is 
characterised by an increase in circulating TNF-α, as well as inflammatory 
mediators like C-reactive protein (CRP), serum amyloid A (SAA), the pro-
inflammatory cytokine interleukin-6 (IL-6), and the chemokine’s IL-8, C-C 
chemokine ligand 2 (CCL2)/monocyte chemoattractant protein-1 (MCP-
1) and CCL5/RANTES (regulated on activation, normal T cell expressed 
and secreted). However, the circulating levels of all of these proteins can 
be reduced following weight loss (Hotamisligil et al., 1995, Dalmas et al., 
2011). It has also been reported that increased interleukin-1β (IL-1 β), IL-6 
and CRP is predictive of T2DM (Pradhan et al., 2001, Spranger et al., 
2003, Donath and Shoelson, 2011).  
 
Tumor necrosis factor-alpha (TNF-α) can facilitate insulin resistance in 
obesity and diabetes, it does this, in part, by inhibiting the tyrosine kinase 
activity of the insulin receptor (Schenk et al., 2008). The inhibition of 
nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) 
and c-Jun N-terminal kinases (JNK) can also enhance obesity associated 
insulin resistance (Eguchi and Manabe, 2013). Obesity can also change 
cytokine secretion from adipose tissue and modify gene expression in 
adipocytes causing activation of inflammatory processes within the 
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adipose tissue (Eguchi and Manabe, 2013). In those who are obese, 
adipose tissue will secrete lower amounts of anti-inflammatory 
adipokines and higher amounts of proinflammatory cytokines, like IL-6 
and TNF-α (Eguchi and Manabe, 2013). Also, due to activated lipolysis in 
obesity, free fatty acids are released, causing the activation of 
inflammatory signalling and the release of proinflammatory mediators; 
this response provides the link between obesity and insulin resistance 
(Eguchi and Manabe, 2013).  Adipose tissue also contains macrophages, 
which produce a large amount of pro-inflammatory factors that are 
upregulated in obesity. The number of macrophages increases with 
increasing obesity, and alters the activation status of the cells (Donath 
and Shoelson, 2011).  
 
Those with T2DM can also present with histological changes in the 
pancreas, in the form of amyloid deposits (Westermark, 1972), immune 
cell intrusion (Ehses et al., 2007) or cell death/fibrosis (Yoon et al., 2003), in 
the pancreatic islets perhaps caused by inflammation (Eguchi and 
Manabe, 2013). This is perhaps indicative of a role for inflammation in the 
progress of pancreatic β-cell dysfunction (Eguchi and Manabe, 2013). 
Inflammation also plays a role in atherosclerotic plaque formation, a key 
step in atherosclerosis, which is instrumental in the progression of 
cardiovascular disease – a common comorbidity seen in T2DM (Martin-
Timon et al., 2014, Golia et al., 2014)  
 
Despite the body of evidence in support of a role for inflammation in the 
progression from obesity to diabetes, a unique protein signature 
associated with the diabetic state is not well defined. Therefore, this 
study sought to examine the inflammatory profile within a T2DM cohort 
(DIASTRAT) using large-scale screens for proteins associated with 
inflammation and cardiovascular outcomes, with a view to determining 




5.2 Materials and Methods 
 
5.2.1 Chemicals 
Reagents of analytical grade and deionized water were used. All other 
chemicals used are listed in Chapter 2, Section 2.1. 
 
5.2.2 Participant Recruitment 
Participants were recruited onto the Stratified Medicine, optimizing 
treatment for Diabetes (DIASTRAT) study as described in Chapter 2, 
Section 2.2.15. 
 
5.2.3 Processing Blood samples 
Blood samples taken from consented participants was processed using 
the method described in Chapter 2, Section 2.2.16. 
 
5.2.4 Proximity Extension Assay (PEA) 
Plasma samples were used for PEA. This work was outsourced to Olink 




Comparison of protein marker expression between those with T2DM and 
apparently healthy controls was conducted using unequal t tests as 
described in detail in Chapter 2, Section 2.2.22. Dr Steven Watterson 
(Ulster University) wrote the scripts used to undertake this analysis. 
Comparison of protein expression within subgroupings of the T2DM 
cohort was conducted by one-way ANOVA with posthoc test. Data are 
presented as mean ± min/max. Pearson’s correlation of normalized 
expression data with clinical parameters was conducted on the entire 
cohort (‘All participants’) or those receiving a sulphonylurea (‘SU+’). In all 






Olink proximity assays were conducted on the following 4 panels: 
Cardiovascular II panel, Cardiovascular III panel, Immune response 
panel and the Inflammation panel. Each panel comprised 92 proteins 
leading to an initial analysis of 368 proteins across the 4 panels. These 
panels contained a small number of proteins repeated across multiple 
panels (i.e. IL-6 is present on 3 of the 4 panels), which has been ignored 
for initial analysis and thereafter removed from the results data.  
 
Initially, the data comprised 374 patients with diabetes and 20 control 
participants, each of whom had measurements taken across 368 
proteins. Any patient sample that failed QC, this QC value is set by Olink, 
was removed from the analyses. Similarly, several proteins across all four 
panels fell below the level of meaningful detection and have been 
excluded from the analyses for all participants. Following these 
exclusions, the cohort consisted of 20 control samples, 354 samples from 
people with diabetes and measurements across 292 proteins.  
 
 
5.3.1 Identification of a protein signature indicative of a T2DM 
phenotype in the DIASTRAT cohort 
 
The aim of this analysis was to generate a formula that would yield a 
single number for each participant that can be applied to a threshold to 
robustly identify the cohort to which they belong. 
 
To this end, differential expression of all 292 detectable proteins was 
evaluated between cohorts using an unequal t-test and those with p-
values below 0.05 were highlighted. This yielded 75 proteins in which 





Table 5.1 Proteins with significant differential expression from healthy 
controls. 
 
Proteins that were significantly altered in participants with T2DM when 
compared with the control cohort are listed above. Significance was accepted 
at P<0.05 following an unequal t-test.  
 
Combination of these 75 proteins correctly identified those with T2DM to 
within 99.2% accuracy (3 misclassified participants; Table 5.2A). To 
increase accuracy to 100%, additional proteins would be required to 
Protein P value Protein P value
KLRD1 0.0001 HAOX1 0.0140
KIM1 0.0004 t-PA 0.0151
TNFRSF14 0.0005 REN 0.0163
FGF-21 0.0005 GLB1 0.0178
EGLN1 0.0006 LILRB4 0.0183
MMP7 0.0009 PRDX5 0.0194
CD84 0.0009 VSIG2 0.0194
CCL4 0.0009 CLEC4D 0.0204
AGRP 0.0010 CCL17 0.0214
DCBLD2 0.0011 ITGB2 0.0216
CLEC4A 0.0016 LAP TGF-beta-1 0.0230
FGF-23 0.0017 LIF-R 0.0238
FGF-23 0.0025 TR 0.0239
U-Par 0.0028 MMP12 0.0243
TNFRSF9 0.0030 HGF 0.0251
FGF-21 0.0032 IL-18R1 0.0266
IL-4RA 0.0033 PAR-1 0.0272
Gal-4 0.0034 TNFRSF11A 0.0287
LPL 0.0035 FCRL6 0.0296
TRAIL-R2 0.0041 TNFR1 0.0298
PD-L1 0.0045 CKAP4 0.0313
CTSL1 0.0047 TFF3 0.0321
SORT1 0.0053 PCSK9 0.0325
HSP 27 0.0059 CD83 0.0336
PRSS8 0.0070 VEGFA 0.0343
PA1 0.0073 CXCL6 0.0361
HO-1 0.0075 JAM-A 0.0366
HB-EGF 0.0085 CDCP1 0.0399
CLEC6A 0.0090 SLAMF1 0.0401
TNFSF14 0.0093 CASP-3 0.0402
IDUA 0.0097 ANG-1 0.0429
AREG 0.0097 TNFSF13B 0.0434
CCL3 0.0108 MMP-9 0.0443
NCR1 0.0109 PON3 0.0448
IL-18 0.0117 PDGF subunit A 0.0452
BTN3A2 0.0120 IL-1RT1 0.0470
TREM1 0.0130 AXL 0.0479





strengthen the signature. However, in the DIASTRAT cohort, only 75 
proteins displayed differential expression when a P value of 0.05 was 
applied. To attempt to enhance accuracy, the selection cut-off was 
relaxed to include a P value of less than 0.09. This yielded 100 proteins 
that were differentially expressed between those with T2DM and the 
control cohort. However, an improvement in the accuracy of 
classification was not observed (Table 5.2B). 
 




25 37 90.1 
50 10 97.3 





Table 5.2 Identification of a T2DM phenotype based on protein signature. 
 
(A) Application of a P value threshold of 0.05 lead to the identification of a 75 
protein signature that could accurately identify someone with T2DM to within 
99.2% accuracy. (B) Relaxing the P value threshold to 0.09 increased the 




5.3.2 Macrophages drive the inflammatory response in the  
DIASTRAT cohort 
 
The 75 proteins that displayed significant differential expression between 
T2DM participants and those in the control cohort were further analysed 
to understand the ontology of cell types and tissues involved.  
 




100 3 99.2 
 112 
 
Gene names were entered into the Enrichr database (Chen et al., 2013, 
Kuleshov et al., 2016) and significant associations with cell types 
examined based on data from the All RNA-seq and CHIP-seq Sample 
Search Space (ARCHS4). ARCHS4 mines RNA-seq and CHIP-seq datasets 
available on the Gene Expression Omnibus (GEO). The programme 
analyses the aligned reads mapped to genes with counts, as well as a 
heatmap visualization summary of the expression data from the 
processed samples using Clustergrammer. 
 
As shown in Figure 5.1, the dominant cell type involved in the 
inflammatory and metabolic protein signature of the DIASTRAT cohort is 
the macrophage (P=0.0005). Interestingly, CD4+ T cells, which in addition 
to macrophages are a primary driver of the T1DM phenotype, were 







Figure 5.1 Cell types associated with proteins highly expressed in the  
DIASTRAT cohort 
 
Cell types are ranked based on outputs from the All RNA-seq and CHIP-seq 
Sample Search Space (ARCHS4). Data are depicted as a heatmap (top panel) 
and ranked according to significance (lower panel). 
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In addition to examining the proteins most highly expressed in the 
DIASTRAT cohort, examination of those poorly expressed (i.e. those that 
fell below the level of meaningful detection in the Olink proximity assay) 
was also undertaken, to determine what cell types were not involved in 
the inflammatory and metabolic profiles of this cohort. 
 
To this end, all proteins that fell below the level of detection in more than 
60% of the DIASTRAT cohort were identified and the 25 proteins meeting 
this criterion are summarized in table 5.3. Unfortunately, because these 
proteins fell below the detection limits of the assay, an assessment of the 
abundance of each protein cannot be made and therefore, a ranking is 
not possible. 
 
IL-5 IL-13 ARNT 
NRTN IL-24 PRKCQ 
LIF IL-22RA1 JUN 
IL-1 TSLP NF2 
IFN-gamma IL-2 EIF5A 
IL-33 IL-1alpha DGKZ 
IL-20 IL-2RB PI3 
TNF IL-20RA  
ARTN KPNA1  
 
Table 5.3 Proteins below the detection limits of the Olink proximity assays 
 
25 proteins were found to be below the detection limits of the Olink proximity 
assay in 60% or more of the cohort. 
 
 
The 25 proteins not detected in this analysis are most commonly 
associated with gastric epithelial cells (P=0.01), keratinocytes (P=0.01) 
and basal cells (P=0.03) consistent with a non-diabetic phenotype 
(Figure 5.2). Interestingly, T cells and specifically, CD4+ T cells were 
significantly associated with this protein signature (P=0.07 in both 
instances; Figure 5.2). These findings reinforce the notion that T cells are 






Figure 5.2 Cell types associated with proteins poorly expressed in the  
DIASTRAT cohort 
 
Cell types are ranked based on outputs from the All RNA-seq and CHIP-seq 
Sample Search Space (ARCHS4). Data are depicted as a heatmap (top panel) 





5.3.3 The protein signature of the DIASTRAT cohort is predominantly  
associated with cells of the immune system  
 
The association of the 75 protein signature with tissue types was assessed 
using the JENSEN TISSUES database (Chen et al., 2013, Kuleshov et al., 
2016). This database incorporates evidence on the tissue-specific 
expression of genes, proteomics and transcriptomics screens, and 
automatic text mining. The evidence is mapped to common protein 
identifiers and Brenda Tissue Ontology terms, and further supported 
through the assignment of confidence scores.  
 
Consistent with the finding that macrophages drive the inflammatory 
response, the most common tissue type associated with the protein 
signature of the DIASTRAT cohort was cells of the immune system 
(P=0.0002; Figure 5.3). Interestingly, bronchoalveolar lavage was also 
significantly associated with this phenotype (P=0.002) consistent with the 
observation that alveolar macrophages played a dominant role in the 








Figure 5.3 Tissue-specific expression of proteins highly expressed in the  
DIASTRAT cohort 
 
Tissue types expressing proteins highly expressed in the DIASTRAT cohort are 
ranked based on outputs from the JENSENS TISSUE database. Data are 




5.3.4 The protein signature of the DIASTRAT cohort is consistent with 
Coronary Artery Disease. 
 
The association of the 75 protein signature with disease phenotypes was 
assessed. Following imputation of the gene list into Enrichr, the 
association with disease phenotypes was assessed using the JENSEN 
DISEASES database (Chen et al., 2013, Kuleshov et al., 2016). This 
database integrates evidence on disease-gene associations from 
automatic text mining, manually curated literature, cancer mutation 
data, and genome-wide association studies. The evidence is further 
validated by assigning confidence scores that facilitate comparison of 
the different types and sources of evidence. 
 
The protein signature of the DIASTRAT cohort was most significantly 
associated with Coronary Artery Disease (CAD; P=0.01) consistent with 
the findings that CAD is a major complication of T2DM. Interestingly, the 
protein signature was also significantly associated with a host of other 
inflammatory conditions including lung disease and arthritis (Figure 5.4). 
Hyperglycaemia was ranked 3rd in this analysis (P=0.01) consistent with 
the reported HbA1c values for the cohort. Diabetic retinopathy was 
ranked 14th in this analysis (P=0.1) and with T2DM ranked 52nd (P=0.3). This 
may reflect (1) the lack of a defined protein signature for T2DM or (2) the 
fact that secondary complications of hyperglycaemia are driving the 







Figure 5.4 Disease phenotypes associated with proteins highly expressed in 
the DIASTRAT cohort 
 
Diseases are ranked based on data obtained from the Jensen lab DISEASES 
database. Data are depicted as a heatmap (top panel) and ranked 




5.3.5 Effect of prescribing practices on protein expression 
 
Based on rankings outlined in Table 5.1, the 20 proteins with most 
significant differential expression between control subjects and those in 
the DIASTRAT cohort were graphed according to prescription of 
exogenous insulin (INS) or sulphonylurea (SU). As with Chapter 4, this 
resulted in 5 subgroupings: (1) All participants; (2) SU+/INS+; (3) SU-/INS+; 
(4) SU+/INS-; and (5) SU-/INS-. All 20 proteins were associated with the 
immune response in some capacity, consistent with observations 
outlined in Figure 5.1 – 5.4. Significant differences in protein expression 
between the 5 subgroupings are discussed below according to the 
dominant function of the proteins.  
 
Relative protein expression of Gal-4, CD84, Il4-RA, CCL4 and CLEC4A 
(seen in Figure 5.5), which are known to have effects on cell adhesion 
and cellular communication. There were no significant differences in the 
expression of CD84 between any of the subgroupings (Figure 5.5B). In all 
other instances, the expression of the protein differed significantly 
(P<0.05-0.0001) between the entire cohort values (All participants) and 
subgroupings of those on SU and/or INS (Figure 5.5A, C-E). This however, 
may potentially be explained by the differences in group size and the 
spread observed throughout the entire cohort versus the smaller groups 
of participants receiving SU and/or INS. Importantly, SU or INS prescription 
alone or in combination, did not appear to significantly influence the 










Genetic variants associated with a T2DM phenotype 

























Genome-wide association studies (GWAS), linkage analysis, candidate 
gene approaches and sequencing have allowed for the identification of 
common, low-frequency and rare variants that are characteristic of 
T2DM (Stancakova and Laakso, 2016, Fuchsberger et al., 2016). As a 
result over 80 variants for T2DM have been identified. These variants are 
common, but yield a small effect with a minor allele frequency >5%, and 
therefore account only for around 10 % of heritability of T2DM 
(Stancakova and Laakso, 2016, Fuchsberger et al., 2016), the focus of 
most studies does tend to be on common variation with larger gene 
effects. This is a result of the fact that studies have greater power to 
detect these size effects. Whilst the minor allele frequency does impact 
the size of gene effect it is not the only factor. How much the variant 
disrupts the protein for example, also plays a role. The cause of the 
remaining heritability is thought to be due to the large effects of low 
frequency and rare variants, interactions between genes, genes and 
environmental factors or even epigenetic factors (Stancakova and 
Laakso, 2016, Fuchsberger et al., 2016).  
 
The current study is interested in identifying genetic driver of glycaemic 
control, particularly in those treated with sulphonylurea (SU). Prior work 
has unsurprisingly shown that members of the KATP channel, namely ATP 
binding site cassette, subfamily C, member 8 (ABCC8) that encodes for 
the sulphonylurea receptor 1 (SUR1) in pancreatic β-cells (Kapoor, 2010, 
Haghverdizadeh et al., 2014) and the inwardly rectifying potassium 
channel, subfamily J, member 11 (KCNJ11) gene (Qin et al., 2013)., 
which encodes for Kir6.2, play an essential role in response to SU (Klen et 
al., 2014). Variants identified in each of these genes that have been 
associated with an increased risk of T2DM. With ABCC8 those include 
S1369A polymorphism (Hansen et al., 1998, Fatehi et al., 2012), which also 
impacts the efficacy of the SU gliclazide (Feng et al., 2008), R1273R 
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polymorphism (Rissanen et al., 2000), the -3c → t (rs1799854) (Hart et al., 
1999). Some of the variants in KCNJ11 that are associated with a risk of 
T2DM include rs5219 (Abdelhamid et al., 2014), which can impact the 
insulin secretion pathway also (Haghvirdizadeh et al., 2015), rs5215 
(Chavali et al., 2011) and rs5210 (Koo et al., 2007) which may also 
improve the efficacy of gliclazide (Haghvirdizadeh et al., 2015). The E23K 
polymorphism has been widely studied in this gene and shown in some 
populations to be linked to risk of T2DM (Hani et al., 1998, van Dam et al., 
2005, Florez et al., 2007, Abdelhamid et al., 2014).  
 
Variants in hepatocyte nuclear factor-1α (HNF-1α) transcription factor 
(Hansen et al., 1997, McDonald et al., 2012) have also been implicated 
in causing increased risk to T2DM and affecting insulin secretion, 
examples include I27L and A98V (rs1920792) polymorphisms (Holmkvist et 
al., 2006). Lastly, the potassium voltage-gated channel, KQT-like 
subfamily, member 1 (KCNQ1) gene encodes for the pore-forming 
subunit of a voltage gated potassium channel (KvLQT1) of the 
pancreatic β-cell (Schroner et al., 2011, Travers et al., 2013). Prior work 
has shown that not only are common variants of this gene associated 
with risk of T2DM, but also impaired insulin secretion and response to SU 
(Unoki et al., 2008, Schroner et al., 2011, van Vliet-Ostaptchouk et al., 
2012). Examples include rs163184 (T>G) polymorphism(Schroner et al., 
2011), rs2283228 and rs2237895 (Unoki et al., 2008). 
 
In Chapter 3, the mechanistic impact of altering expression of these 
genes on SU response was explored. However understanding more 
about the single nucleotide polymorphisms (SNPs) in these genes in the 
DIASTRAT cohort is potentially key to understanding more about the 
response to treatment among this cohort. To this end the aims of this 
analysis were two fold. First was to determine the prevalence of SNPs 
associated with genes of interest within the DIASTRAT cohort. Second was 





6.2 Materials and Methods 
 
6.2.1 Chemicals 
Reagents of analytical grade and deionized water were used. All other 
chemicals used are listed in Chapter 2, Section 2.1. 
 
6.2.2 Participant Recruitment 
Participants were recruited onto the Stratified Medicine, optimizing 
treatment for Diabetes (DIASTRAT) study as described in Chapter 2, 
Section 2.2.15. 
 
6.2.3 Processing Blood samples 
Blood samples taken from consented participants was processed using 
the method described in Chapter 2, Section 2.2.16. 
  
6.2.4 DNA Extraction and quantification 
DNA extraction from whole blood was performed as described in 
Chapter 2, Section 2.2.16, and quantified using Qubit Fluorometric 
Quantitation (ThermoFisher Scientific Inc.). The Qubit allows for 
quantitation of dsDNA using fluorescence-based quantitation assays. 
 
6.2.5 SNP genotyping using the Affymetrix UK Biobank array 
SNP genotyping was performed by Cambridge Genomics Services 
(Cambridge, UK), for analysis on the Affymetrix UK Biobank array. Details 
of sample preparation for this array are found in Chapter 2, Section 
2.2.21 
 
6.2.6 Variant Calling 
In bound SNPs were called using Axiom’s Genotype Console software 
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(Affymetrix, UK) as described in Chapter 2, Section 2.2.21. Samples failing 




Differences between genotypes were calculated using a two-sample t-
test for proportions following conversion of percentages to proportions 





6.3.1 Identifying prevalent variants within the DIASTRAT cohort 
 
This included SNPs associated with ABCC8, KCNJ11, KCNQ1, HNF1α and 
TCF7L2. Due to time constraints, and thus in an attempt to finish this 
project DNA was isolated from only 254 DIASTRAT participants and 19 
age and gender-matched non-diabetic control participants, and 
sequenced on the UK Biobank Array (Affymetrix, UK) which contains 
~850k unique targets. Variant calling identified 31 unique SNPs 
associated with the ABCC8 gene, 101 SNPs associated with KCNJ11, 66 
SNPs associated with KCNQ1, 38 SNPs with HNF1α and 44 SNPs associated 
with TCF7L2. SNP attributes are summarized in Tables 6.1 – 6.5 below, 
which detail the call rate, Minor Allele Frequency (MAF) score and 
Hardy-Weinberg P value. MAF scores revealed that the vast majority of 
identified SNPs were common variants (MAF>0.05). A significant 
difference in the call rate between control and DIASTRAT populations 





























Table 6.1 Attributes of SNPs associated with ABCC8 
 
31 unique SNPs associated with ABCC8 were identified. SNP call rate is given as a percentage of total participants. MAF, Minor Allele 
Frequency; H.W. P value, Hardy-Weinberg P Value. 
dbSNP	RS	ID A	allele B	allele Control DIASTRAT Control DIASTRAT Control DIASTRAT
rs10961940 A G 100.00 98.81 0.1842 0.1314 0.5876 0.4884
rs17743658 A G 100.00 99.70 0.2895 0.2529 0.6491 0.4587
rs3738591 C G 100.00 100.00 0.0263 0.0448 0.9062 0.6029
rs4741478 T G 100.00 100.00 0.0263 0.0492 0.9062 0.1784
rs649224 A G 100.00 100.00 0.0789 0.0807 0.7087 0.7827
rs9458011 T C 100.00 100.00 0.0263 0.0656 0.9062 0.4519
rs8098346 T G 100.00 100.00 0.3421 0.4568 0.2123 0.2539
rs75780075 A G 100.00 100.00 0.0263 0.0194 0.9062 0.8427
rs73017157 A G 100.00 100.00 0.0000 0.0164 1.0000 0.8560
rs11647027 A C 100.00 99.70 0.1053 0.0630 0.0545 0.3734
rs59409558 A C 100.00 98.21 0.0000 0.0106 1.0000 0.9086
rs11942387 A G 100.00 99.70 0.3947 0.3819 0.3182 0.1391
rs62295555 T C 100.00 100.00 0.1053 0.1000 0.6081 0.5250
rs12548842 T C 100.00 100.00 0.2895 0.3745 0.1163 0.4845
rs79345026 T C 100.00 99.70 0.1842 0.1451 0.3250 0.6131
rs10961999 T C 100.00 100.00 0.1579 0.1687 0.4138 0.3365
rs111736238 T G 100.00 100.00 0.0263 0.0269 0.9062 0.7566
rs114570814 A G 100.00 98.21 0.0263 0.0154 0.9062 0.8514
rs116734533 T C 100.00 93.42 0.0000 0.0232 1.0000 0.7821
rs78306404 T C 100.00 99.41 0.0263 0.0015 0.9062 0.9845
rs111577081 T C 100.00 99.40 0.0526 0.0692 0.8087 0.4169
rs117279260 T C 100.00 100.00 0.0000 0.0388 1.0000 0.6775
rs117407497 A G 100.00 99.70 0.0263 0.0286 0.9062 0.7215
rs2666826 T C 100.00 100.00 0.2105 0.2687 0.2451 0.5581
rs2297775 T C 100.00 100.00 0.1842 0.2882 0.3250 0.5711
rs10153859 A G 100.00 99.70 0.0000 0.0270 1.0000 0.4236
rs17597643 A G 100.00 99.11 0.0263 0.0331 0.9062 0.6963
rs58584712 A G 100.00 100.00 0.2368 0.2000 0.1761 0.3753
rs78504459 T C 100.00 99.70 0.0526 0.0240 0.8087 0.7868
rs150028933 - A 100.00 100.00 0.0000 0.0194 1.0000 0.4222






























Table 6.2 Attributes of SNPs associated with KCNJ11 
 
101 unique SNPs associated with KCNJ11 were identified. SNP call rate is given as a percentage of total participants. MAF, Minor Allele 
Frequency; H.W. P value, Hardy-Weinberg P value. 
dbSNP	RS	ID A	allele B	allele Control DIASTRAT Control DIASTRAT Control DIASTRAT
rs1030986 T C 100 100 0.0000 0.0075 1.0000 0.9315
rs16875779 A G 100 100 0.1316 0.1747 0.5090 0.4333
rs17062197 A G 100 100 0.2105 0.1254 0.2451 0.3358
rs2517646 T C 100 99.7 0.3421 0.2977 0.8196 0.2734
rs2607614 T C 100 100 0.0000 0.0254 1.0000 0.7718
rs33949518 T C 100 99.405 0.1316 0.1742 0.5090 0.4336
rs34505188 A G 100 99.4 0.0526 0.0678 0.8087 0.4241
rs35978505 T C 100 100 0.0789 0.0239 0.7087 0.7871
rs369738 T G 100 98.8 0.0000 0.0545 1.0000 0.3253
rs3815082 A G 100 98.51 0.2895 0.2559 0.5090 0.8515
rs2849089 T C 100 100 0.0000 0.0000 1.0000 1.0000
rs4479449 A G 100 100 0.0526 0.0940 0.0000 0.2627
rs454748 A G 100 99.7 0.5000 0.3924 0.4913 0.2435
rs683687 A G 100 100 0.0526 0.0761 0.8087 0.6767
rs683866 T G 100 99.7 0.2368 0.4099 0.9335 0.5936
rs6919617 A G 100 100 0.1053 0.0821 0.6081 0.5434
rs7431770 A G 100 99.105 0.0000 0.0828 1.0000 0.6365
rs757260 T C 100 100 0.1316 0.1358 0.5090 0.5447
rs920829 T C 100 99.4 0.1053 0.1182 0.6081 0.5161
rs9261151 A G 100 100 0.0526 0.0358 0.8087 0.6752
rs9261216 A G 100 99.7 0.1053 0.0809 0.6081 0.5118
rs9261302 A G 100 100 0.1053 0.0821 0.6081 0.5434
rs9261471 T C 100 100 0.2895 0.2329 0.5090 0.7592
rs9268135 A G 100 99.405 0.2895 0.2553 0.5090 0.3965
rs9366752 T C 100 100 0.1842 0.1792 0.5876 0.7184
rs9811423 C G 100 100 0.3947 0.4030 0.9698 0.3430
rs1693703 T C 100 98.805 0.1579 0.2781 0.3638 0.6514






























Table 6.2 Attributes of SNPs associated with KCNJ11 (continued) 
 
101 unique SNPs associated with KCNJ11 were identified. SNP call rate is given as a percentage of total participants. MAF, Minor Allele 
Frequency; H.W. P value, Hardy-Weinberg P value. 
dbSNP	RS	ID A	allele B	allele Control DIASTRAT Control DIASTRAT Control DIASTRAT
rs76592289 A G 100 100 0.0000 0.0463 1.0000 0.4392
rs76557252 T G 100 100 0.0789 0.0045 0.7087 0.9626
rs506757 T G 100 99.7 0.2632 0.3232 0.7087 0.3082
rs62166939 A C 100 97.915 0.1842 0.2115 0.5876 0.4693
rs78082945 T C 100 100 0.0263 0.0328 0.9062 0.7121
rs62272114 A G 100 99.7 0.0000 0.0255 1.0000 0.7714
rs112288451 T C 100 97.905 0.0000 0.0153 1.0000 0.8605
rs74806059 T C 100 100 0.0000 0.0179 1.0000 0.8316
rs79876945 A G 100 100 0.0526 0.0299 0.8087 0.7343
rs114687906 A C 94.74 99.105 0.0000 0.0196 1.0000 0.8241
rs115477611 T C 100 100 0.0526 0.0180 0.8087 0.8150
rs78771971 T C 100 100 0.0000 0.0030 1.0000 0.9781
rs78854530 A G 100 100 0.0000 0.0090 1.0000 0.9159
rs62503295 T C 94.74 100 0.0556 0.0731 0.8029 0.6219
rs114756881 T C 94.74 94.62 0.0000 0.0475 1.0000 0.5907
rs4498896 T C 100 100 0.3947 0.3701 0.3182 0.2276
rs79035182 T G 100 100 0.0000 0.0194 1.0000 0.8249
rs74898314 A G 100 100 0.0000 0.0209 1.0000 0.4352
rs28445507 A C 100 99.7 0.2895 0.2291 0.5090 0.6970
rs55851518 A G 100 100 0.0789 0.0537 0.7087 0.4286
rs79263726 A C 100 100 0.0000 0.0224 1.0000 0.8026
rs10898365 T G 100 100 0.2105 0.2672 0.8275 0.4778
rs66546253 A G 100 99.4 0.3158 0.2451 0.0254 0.3526
rs783307 T C 100 100 0.0789 0.1553 0.7087 0.7106
rs17734780 T C 100 100 0.0000 0.0120 1.0000 0.8847
rs10432095 A C 100 100 0.1316 0.1522 0.5090 0.5252
rs75107770 A G 100 100 0.0263 0.0224 0.9062 0.8026
rs13061963 T G 100 100 0.1053 0.0537 0.0545 0.5286
rs60400172 T G 100 100 0.0526 0.0671 0.0000 0.0000
rs76451747 A C 100 100 0.0000 0.0060 1.0000 0.9378


























Table 6.2 Attributes of SNPs associated with KCNJ11 (continued) 
 
101 unique SNPs associated with KCNJ11 were identified. SNP call rate is given as a percentage of total participants. MAF, Minor Allele 
Frequency; H.W. P value, Hardy-Weinberg P value. 
dbSNP	RS	ID A	allele B	allele Control DIASTRAT Control DIASTRAT Control DIASTRAT
rs13183249 A G 100 100 0.2368 0.2374 0.9335 0.3232
rs72725509 T C 100 100 0.0000 0.0060 1.0000 0.9471
rs80184435 A G 100 98.505 0.0263 0.0257 0.9062 0.7786
rs62404592 A C 100 97.915 0.0000 0.0121 1.0000 0.8840
rs117910348 A C 100 100 0.0000 0.0134 1.0000 0.8872
rs79853069 A G 100 99.105 0.1842 0.0858 0.3250 0.6422
rs71521249 A G 100 100 0.0000 0.0074 1.0000 0.9406
rs114234140 A G 100 100 0.0263 0.0179 0.9062 0.8231
rs114249268 A G 100 92.815 0.0000 0.0633 1.0000 0.0023
rs112623189 A G 100 100 0.1053 0.0388 0.6081 0.6530
rs115010323 T C 100 99.7 0.0000 0.0105 1.0000 0.9000
rs116250326 T C 100 99.7 0.0263 0.0045 0.9062 0.9532
rs77111308 T C 100 100 0.0263 0.0582 0.9062 0.4949
rs77823977 T C 100 100 0.0000 0.0179 1.0000 0.8404
rs78374474 T C 100 100 0.0789 0.0179 0.7087 0.4899
rs192657690 T C 100 100 0.0000 0.0075 1.0000 0.9315
rs116983235 T C 100 100 0.0000 0.0030 1.0000 0.9781
rs10846754 A G 100 100 0.1316 0.1956 0.5090 0.6429
rs576184 A C 100 100 0.3684 0.3851 0.1195 0.8357
rs16951460 A G 100 97.305 0.0000 0.0327 1.0000 0.4338
rs3748592 A G 100 100 0.0526 0.0686 0.8087 0.4332
rs2096376 T C 100 100 0.1842 0.2880 0.3250 0.1887
rs32555 A G 100 99.4 0.1579 0.1771 0.4138 0.3994
rs9261089 T C 100 99.7 0.0526 0.0360 0.8087 0.6746
rs28400886 A G 100 100 0.0263 0.0493 0.9062 0.5988
rs4959042 T C 100 100 0.0000 0.0060 1.0000 0.9471
rs34704616 A G 100 100 0.0000 0.0030 1.0000 0.9781
rs1573298 C G 100 99.405 0.2895 0.2567 0.5090 0.7659
rs397596 T C 100 100 0.0000 0.0000 1.0000 1.0000









Table 6.2 Attributes of SNPs associated with KCNJ11 (final) 
 
101 unique SNPs associated with KCNJ11 were identified. SNP call rate is given as a percentage of total participants. MAF, Minor Allele 





dbSNP	RS	ID A	allele B	allele Control DIASTRAT Control DIASTRAT Control DIASTRAT
rs13268757 A G 100 100 0.1316 0.1567 0.1779 0.9487
rs114814001 T C 100 100 0.0000 0.0254 1.0000 0.7718
rs79765628 T C 100 100 0.0263 0.0254 0.9062 0.7638
rs117389196 T C 100 99.7 0.0000 0.0194 1.0000 0.8425
rs141834826 A G 100 99.7 0.0000 0.0000 1.0000 1.0000
rs201447432 T C 100 99.1 0.0000 0.0137 1.0000 0.8589
rs146548891 T G 100 99.7 0.0000 0.0030 1.0000 0.9781
rs142720326 A G 100 100 0.0000 0.0030 1.0000 0.9781
rs201960928 A G 100 99.7 0.0000 0.0105 1.0000 0.8907
rs139889337 A G 100 99.7 0.0000 0.0090 1.0000 0.9249
rs113993403 T C 100 100 0.0000 0.0089 1.0000 0.9250






























Table 6.3 Attributes of SNPs associated with KCNQ1 
 
68 unique SNPs associated with KCNQ1 were identified. SNP call rate is given as a percentage of total participants. MAF, Minor Allele 
Frequency; H.W. P value, Hardy-Weinberg P value. 
dbSNP	RS	ID A	allele B	allele Control DIASTRAT Control DIASTRAT Control DIASTRAT
rs16841998 T C 84.21 89.26 0.1250 0.0882 0.5677 0.3247
rs17461843 T C 100 97.32 0.0000 0.0460 1.0000 0.6039
rs17571372 T C 100 100.00 0.0263 0.0538 0.9062 0.1909
T G 100 99.70 0.0000 0.0000 1.0000 1.0000
rs3006968 A G 100 99.70 0.5000 0.4730 0.8185 0.3712
rs6039591 A G 100 100.00 0.0000 0.0239 1.0000 0.7871
rs6883010 A G 100 100.00 0.3158 0.4164 0.3421 0.4232
rs6133707 A G 100 99.70 0.2368 0.2185 0.1761 0.8125
rs77707280 A G 100 99.70 0.0526 0.0568 0.8087 0.4589
rs807936 T C 100 100.00 0.3158 0.3984 0.3421 0.4444
rs114348392 T G 94.74 99.70 0.0278 0.0150 0.9035 0.8714
rs9356928 A G 100 99.40 0.4211 0.4653 0.7288 0.6553
rs9460973 A T 100 99.70 0.0000 0.0449 1.0000 0.6087
rs58554303 T C 100 99.70 0.0263 0.0269 0.9062 0.7645
rs920628 A G 100 100.00 0.0263 0.0388 0.9062 0.3248
rs16873732 T C 100 100.00 0.0263 0.0388 0.9062 0.3248
rs1041791 T C 100 99.70 0.2105 0.1870 0.2451 0.5258
rs61741363 A G 100 100.00 0.0000 0.0000 1.0000 1.0000
rs113319303 A G 100 99.70 0.0000 0.0435 1.0000 0.3893
rs116581086 A G 100 100.00 0.0000 0.0045 1.0000 0.9626
rs74745471 A G 100 100.00 0.0263 0.0567 0.9062 0.5118
rs61936141 T C 100 99.70 0.0000 0.0180 1.0000 0.8312
rs79090092 A G 100 100.00 0.0263 0.0389 0.9062 0.6288
rs10905750 A C 100 100.00 0.0000 0.0239 1.0000 0.7871
rs231847 A G 100 100.00 0.3158 0.4075 0.3421 0.0792
rs129072 T C 100 99.70 0.0789 0.1737 0.7087 0.6597
rs75898263 T C 100 100.00 0.0000 0.0000 1.0000 1.0000





























Table 6.3 Attributes of SNPs associated with KCNQ1 (continued) 
 
68 unique SNPs associated with KCNQ1 were identified. SNP call rate is given as a percentage of total participants. MAF, Minor Allele 
Frequency; H.W. P value, Hardy-Weinberg P value. 
dbSNP	RS	ID A	allele B	allele Control DIASTRAT Control DIASTRAT Control DIASTRAT
rs75875515 A G 100 99.40 0.0000 0.0211 1.0000 0.8001
rs7156987 T C 100 98.22 0.0000 0.0183 1.0000 0.8476
rs55767542 T C 100 99.40 0.0000 0.0210 1.0000 0.8086
rs35162844 A G 100 99.70 0.0789 0.0389 0.7087 0.3243
rs73063633 T G 100 99.70 0.0263 0.0240 0.9062 0.7868
rs116045044 T G 100 99.11 0.0263 0.0407 0.9062 0.6517
rs77692939 A G 100 97.91 0.0000 0.0076 1.0000 0.9306
rs72811968 T C 100 100.00 0.0000 0.0164 1.0000 0.8649
rs76238538 T C 100 100.00 0.0000 0.0269 1.0000 0.7649
rs79931282 A G 100 99.41 0.0526 0.0330 0.8087 0.7113
rs9467059 A G 100 99.11 0.0000 0.0512 1.0000 0.5524
rs188539852 T C 100 100.00 0.0263 0.0119 0.9062 0.9028
rs115704940 T C 100 100.00 0.0263 0.0299 0.9062 0.4514
rs116858972 T C 100 100.00 0.0263 0.0194 0.9062 0.8249
rs117103115 A G 100 96.12 0.0000 0.0311 1.0000 0.7210
rs77936291 A G 100 100.00 0.0263 0.0284 0.9062 0.7277
rs79947987 T C 100 99.70 0.0000 0.0030 1.0000 0.9781
rs78468689 A G 100 100.00 0.0263 0.0373 0.9062 0.6675
rs80140016 T G 100 99.70 0.0526 0.0389 0.8087 0.6524
rs75894327 A G 100 100.00 0.0000 0.0358 1.0000 0.6901
rs114351051 T C 100 94.65 0.0000 0.0627 1.0000 0.4832
rs115005266 T C 100 99.41 0.0263 0.0225 0.9062 0.8020
rs112214748 A G 100 100.00 0.1316 0.0269 0.5090 0.7489
rs7119884 A G 100 100.00 0.0263 0.0343 0.9062 0.7144
rs6057010 A G 100 100.00 0.0526 0.0642 0.8087 0.4512
rs4690087 A G 100 100.00 0.1316 0.0732 0.5090 0.3671
rs11754464 T C 100 99.70 0.0000 0.0000 1.0000 1.0000


























Table 6.3 Attributes of SNPs associated with KCNQ1 (final) 
 
68 unique SNPs associated with KCNQ1 were identified. SNP call rate is given as a percentage of total participants. MAF, Minor Allele 
Frequency; H.W. P value, Hardy-Weinberg P value. 
  
dbSNP	RS	ID A	allele B	allele Control DIASTRAT Control DIASTRAT Control DIASTRAT
rs35185125 A C 100 100.00 0.0263 0.0060 0.9062 0.9471
rs28381355 A G 100 100.00 0.0000 0.0060 1.0000 0.9378
rs183314661 A C 100 100.00 0.0000 0.0239 1.0000 0.7788
rs77320475 A G 100 99.70 0.0789 0.0359 0.7087 0.6816
rs17812699 A G 100 100.00 0.0000 0.0791 1.0000 0.6406
rs199853687 A C 100 100.00 0.0000 0.0000 1.0000 1.0000
rs115491500 T C 100 100.00 0.0000 0.0000 1.0000 1.0000
rs11553182 T C 100 100.00 0.0789 0.0895 0.7087 0.2887
C G 100 100.00 0.0000 0.0015 1.0000 0.9845
rs341047 A G 100 99.41 0.1579 0.1080 0.4138 0.4724
rs150934987 A G 100 100.00 0.0000 0.0000 1.0000 1.0000





























Table 6.4 Attributes of SNPs associated with HNF1α 
 
38 unique SNPs associated with HNF1α were identified. SNP call rate is given as a percentage of total participants. MAF, Minor Allele 
Frequency; H.W. P value, Hardy-Weinberg P value. 
dbSNP	RS	ID A	allele B	allele Control DIASTRAT Control DIASTRAT Control DIASTRAT
rs11755881 A G 100.00 100.00 0.0263 0.1000 0.9062 0.5564
rs1861 A C 100.00 100.00 0.0263 0.0254 0.9062 0.3895
rs28568667 T C 89.47 97.01 0.1471 0.1237 0.4772 0.1781
rs4770748 A G 100.00 100.00 0.0000 0.0702 1.0000 0.7022
rs663824 A G 100.00 100.00 0.4211 0.3567 0.5522 0.6183
rs6905159 A G 100.00 99.40 0.4474 0.4475 0.4564 0.9362
rs888576 T C 100.00 100.00 0.1579 0.0880 0.4138 0.1605
rs13325508 T C 100.00 100.00 0.0263 0.0239 0.9062 0.7959
rs55723035 T C 100.00 100.00 0.0000 0.0149 1.0000 0.8626
rs77356515 T G 100.00 100.00 0.0526 0.0090 0.8087 0.9159
rs75363174 A G 100.00 100.00 0.0526 0.0582 0.8087 0.4421
rs4751674 T C 100.00 99.70 0.3947 0.3039 0.3182 0.2773
rs61433965 A G 100.00 99.70 0.0000 0.0150 1.0000 0.8714
rs58838391 A G 100.00 100.00 0.0000 0.0149 1.0000 0.8626
rs76280424 A G 100.00 100.00 0.0000 0.0000 1.0000 1.0000
rs77794667 T C 100.00 100.00 0.0263 0.0164 0.9062 0.8560
rs59559871 T C 100.00 99.70 0.0000 0.0000 1.0000 1.0000
rs72826927 A G 100.00 100.00 0.0526 0.0687 0.8087 0.6969
rs945094 A T 100.00 100.00 0.0263 0.0254 0.9062 0.7564
rs72751116 A G 100.00 100.00 0.0000 0.0030 1.0000 0.9690
rs59706474 T C 100.00 100.00 0.0263 0.0164 0.9062 0.8649
rs73251982 A G 100.00 98.21 0.0789 0.0291 0.7087 0.4338
rs72489176 A G 100.00 100.00 0.2368 0.2134 0.9335 0.2682
rs77367389 A C 100.00 100.00 0.0263 0.0074 0.9062 0.9406
rs73668591 T C 100.00 99.70 0.0000 0.0090 1.0000 0.9249
rs73669423 T C 100.00 100.00 0.0789 0.0761 0.7087 0.3774
rs62493228 A C 100.00 100.00 0.0789 0.0522 0.7087 0.5461













Table 6.4 Attributes of SNPs associated with HNF1α (final) 
 
38 unique SNPs associated with HNF1α were identified. SNP call rate is given as a percentage of total participants. MAF, Minor Allele 
Frequency; H.W. P value, Hardy-Weinberg P value. 
 
 
dbSNP	RS	ID A	allele B	allele Control DIASTRAT Control DIASTRAT Control DIASTRAT
rs80312260 A G 100.00 100.00 0.0526 0.0179 0.8087 0.8404
rs2244608 A G 100.00 100.00 0.3158 0.2806 0.0442 0.3364
rs11616995 A G 100.00 100.00 0.0000 0.0164 1.0000 0.8560
rs11647932 T C 100.00 99.70 0.2105 0.1079 0.2451 0.4511
rs8102561 T C 100.00 100.00 0.2105 0.1627 0.8275 0.6045
rs340141 T C 100.00 99.70 0.3158 0.3306 0.9110 0.6290
rs150333766 T C 100.00 100.00 0.0000 0.0045 1.0000 0.9626
rs189023122 T C 100.00 100.00 0.0000 0.0000 1.0000 1.0000
rs150428096 T C 100.00 99.10 0.0000 0.0061 1.0000 0.9372





























Table 6.5 Attributes of SNPs associated with TCF7L2 
 
44 unique SNPs associated with TCF7L2 were identified. SNP call rate is given as a percentage of total participants. MAF, Minor Allele 
Frequency; H.W. P value, Hardy-Weinberg P value. 
dbSNP	RS	ID A	allele B	allele Control DIASTRAT Control DIASTRAT Control DIASTRAT
rs12894204 A G 100.00 100.00 0.1842 0.2015 0.3250 0.1198
rs17605420 A G 100.00 100.00 0.0263 0.0194 0.9062 0.8163
rs17763253 T C 100.00 100.00 0.0526 0.0492 0.8087 0.2809
rs6728493 A C 100.00 100.00 0.3158 0.2761 0.9110 0.3339
rs9906935 A G 100.00 99.70 0.3947 0.2949 0.3564 0.5542
rs7089262 T C 100.00 99.70 0.0000 0.0389 1.0000 0.6679
rs76677854 T C 100.00 99.70 0.0789 0.0434 0.7087 0.6162
rs145079521 A C 100.00 99.70 0.0526 0.0330 0.8087 0.7038
rs78082945 T C 100.00 100.00 0.0263 0.0328 0.9062 0.7121
rs62272114 A G 100.00 99.70 0.0000 0.0255 1.0000 0.7714
rs77385406 A G 100.00 100.00 0.1053 0.0298 0.6081 0.7427
rs61732118 A G 100.00 100.00 0.0000 0.0000 1.0000 1.0000
rs61875109 A C 100.00 99.70 0.4211 0.2201 0.5522 0.6466
rs116369954 T C 100.00 99.40 0.0000 0.0465 1.0000 0.3649
rs79805154 A G 100.00 99.70 0.0526 0.0704 0.8087 0.7404
rs77064952 A G 100.00 99.41 0.0000 0.0075 1.0000 0.9314
rs10059523 A G 100.00 100.00 0.0263 0.0298 0.9062 0.7517
rs78183526 T C 100.00 100.00 0.0000 0.0015 1.0000 0.9845
rs587667473 A C 100.00 99.70 0.2632 0.1825 0.1195 0.0162
rs73179006 T G 100.00 100.00 0.0526 0.0388 0.8087 0.6684
rs113262704 T G 100.00 99.70 0.0526 0.0298 0.8087 0.7809
rs61989114 A G 100.00 100.00 0.0000 0.0075 1.0000 0.9315
rs55656505 T C 100.00 100.00 0.0000 0.0433 1.0000 0.5489
rs4783943 A G 100.00 100.00 0.2368 0.2491 0.1761 0.5079
rs3026084 A G 100.00 98.81 0.0000 0.0242 1.0000 0.7945
rs189314829 A G 100.00 99.40 0.0000 0.0270 1.0000 0.7641
rs75107770 A G 100.00 100.00 0.0263 0.0224 0.9062 0.8026
rs73223028 T C 100.00 100.00 0.0526 0.0119 0.8087 0.8938












Table 6.5 Attributes of SNPs associated with TCF7L2 (final) 
 
44 unique SNPs associated with TCF7L2 were identified. SNP call rate is given as a percentage of total participants. MAF, Minor Allele 
Frequency; H.W. P value, Hardy-Weinberg P value. 
dbSNP	RS	ID A	allele B	allele Control DIASTRAT Control DIASTRAT Control DIASTRAT
rs117041486 A G 100.00 100.00 0.0526 0.0104 0.8087 0.9094
rs79565172 A G 100.00 99.41 0.0263 0.0090 0.9062 0.9247
rs117582734 T C 100.00 100.00 0.0789 0.0552 0.7087 0.5163
rs12243326 T C 100.00 100.00 0.3158 0.3582 0.9110 0.6068
rs4889830 A G 100.00 100.00 0.4737 0.4791 0.4977 0.6780
rs3787493 A G 100.00 99.70 0.4474 0.4684 0.8547 0.3243
rs4713505 T G 100.00 100.00 0.3684 0.2015 0.0110 0.6215
rs2070600 T C 100.00 99.70 0.1842 0.0689 0.3250 0.4181
rs3131300 A G 100.00 99.70 0.2632 0.2559 0.7087 0.1733
rs73471190 T C 100.00 99.41 0.0000 0.0030 1.0000 0.9780
rs148924158 A G 100.00 100.00 0.0000 0.0000 1.0000 1.0000
rs143828311 T C 100.00 100.00 0.0263 0.0104 0.9062 0.9094
rs201967398 A G 100.00 100.00 0.0000 0.0000 1.0000 1.0000
rs143652701 T C 100.00 100.00 0.0000 0.0000 1.0000 1.0000
rs142236510 T C 100.00 100.00 0.0000 0.0239 1.0000 0.7959
SNP	call	rate	(%) MAF H.W.	P	value
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6.3.2 Variation in genotype between DIASTRAT and control cohorts. 
 
Next, genotyping was performed using the Axiom Genotype Console 
programme. Overall, the genotypes of control and DIASTRAT cohorts 
were largely comparable as shown in Tables 6.6 – 6.10. No significant 
difference in the prevalence of any SNP associated with ABCC8 was 
observed between the control and DIASTRAT cohorts (Table 6.6). 
Consistently, differences were not observed in the prevalence of SNPs 
associated with KCNQ1 (Table 6.8) and HNF1α (Table 6.9). However, 




As is shown below in Table 6.7, the AB genotype of rs7841649 was more 
commonly observed in the non-diabetic control cohort compared to the 
diabetic cohort (15.79% control versus 2.39% DIASTRAT, P=0.01, 95% CI -
0.06, 0.33 OR 7.6) . This is similar to the AB genotype of rs78374474 (15.79% 
control versus 2.99% DIASTRAT, P=0.03, 95% CI -0.07, 0.32, OR 6.08). 
Conversely, the BB genotype of this SNP was more common among the 
diabetic cohort (84.21% control versus 96.71% DIASTRAT, P=0.04, 95% CI -
0.32, 0.067, OR 0.181). The AB genotype of rs76557252 was also more 
dominant in the non-diabetic control cohort (15.79% control versus 0.89% 
DIASTRAT, P=0.0002, 95% CI -0.04, 0.34, OR 20.77), whilst the BB genotype 
for this SNP was more commonly observed in the diabetic cohort (84.21% 
control versus 99.11% DIASTRAT, P=0.0002, 95% CI -0.343, 0.043, OR 0.048). 
Clustering of genotypes between the control and DIASTRAT cohorts are 
shown graphically for rs78374474 and rs76557252 in Figure 6.1 and 6.2 
respectively. Despite significant P values and ORs the instability of the CIs 
mean that these SNPs are unlikely to have significant pathogenic effect. 
Furthermore, data from the T2D Knowledge portal does not identify any 





As is shown in Table 6.10, the AB genotype of rs4713505 was more 
commonly observed in the non-diabetic control cohort than in the 
diabetic cohort (73.68% control versus 30.75% DIASTRAT, P=0.0004, 95% CI 
0.196, 0.664, OR 6.3); however, the opposite was seen in the BB genotype 
of the same SNP (26.32% control versus 64.48% DIASTRAT, P=0.002, 95% CI 
-0.617, -0.148, OR 0.197). Clustering of these genotypes is presented 
graphically in Figure 6.3. This SNP is associated with a wide range of 
phenotypes including, T2DM, height, waist-hip ratio, fasting insulin, 
coronary artery disease, HDL cholesterol and fasting glucose, according 
























Table 6.6 SNPs associated with ABCC8 
31 unique SNPs associated with ABCC8 were identified, and genotyped. Following a two-sample t-test for proportions, significant 
















rs10961940 A G 68.42 74.33 0.780 -0.304 0.184 0.748 26.32 22.99 0.962 -0.198 0.268 1.197 5.26 2.38 0.992 -0.101 0.159 2.278
rs17743658 A G 10.53 7.46 0.973 -0.140 0.200 1.460 36.84 35.53 1.000 -0.225 0.253 1.059 52.63 57.14 0.887 -0.305 0.216 0.833
rs3738591 C G 94.74 91.04 0.874 -0.097 0.173 1.771 5.26 8.96 0.872 -0.173 0.097 0.565 0.00 0.00 1.000 0.000 0.000 0.000
rs4741478 T G 94.74 91.06 0.877 -0.097 0.173 1.768 5.26 8.05 0.874 -0.158 0.106 0.635 0.00 1.19 1.000 -0.037 0.013 0.000
rs649224 A G 0.00 0.60 1.000 -0.027 0.011 0.000 15.79 14.94 1.000 -0.170 0.186 1.068 84.21 89.29 0.793 -0.248 0.145 0.640
rs9458011 T C 0.00 0.00 1.000 0.000 0.000 0.000 5.26 13.13 0.294 -0.214 0.060 0.368 94.74 84.52 0.187 -0.037 0.239 3.296
rs8098346 T G 5.26 19.70 0.210 -0.284 -0.004 0.226 57.89 51.96 0.792 -0.199 0.318 1.271 36.84 34.52 1.000 -0.225 0.269 1.106
rs75780075 A G 94.74 96.13 1.000 -0.130 0.103 0.725 5.26 3.87 1.000 -0.103 0.130 1.378 0.00 0.00 1.000 0.000 0.000 0.000
rs73017157 A G 0.00 0.00 1.000 0.000 0.000 0.000 0.00 3.28 1.000 -0.081 0.018 0.000 100.00 96.43 0.524 -0.016 0.086 0.000
rs11647027 A C 84.21 88.34 0.880 -0.237 0.157 0.704 10.53 10.16 1.000 -0.143 0.149 1.040 5.26 0.00 0.635 -0.076 0.181 0.000
rs59409558 A C 100.00 96.12 0.385 -0.013 0.092 0.000 0.00 2.09 1.000 -0.056 0.017 0.000 0.00 0.00 1.000 0.000 0.000 0.000
rs11942387 A G 21.05 12.85 0.575 -0.136 0.297 1.808 36.84 50.43 0.349 -0.389 0.118 0.573 42.11 35.71 0.761 -0.195 0.321 1.309
rs62295555 T C 0.00 0.60 1.000 -0.027 0.011 0.000 21.05 18.80 1.000 -0.190 0.233 1.152 78.95 79.76 1.000 -0.209 0.190 0.951
rs12548842 T C 15.79 15.81 1.000 -0.170 0.171 0.998 26.32 43.27 0.182 -0.405 0.066 0.468 57.89 33.33 0.063 -0.013 0.502 2.750
rs79345026 T C 0.00 1.49 1.000 -0.047 0.015 0.000 36.84 25.96 0.480 -0.143 0.360 1.664 63.16 69.05 0.789 -0.310 0.195 0.768
rs10961999 T C 0.00 4.17 0.285 -0.097 0.010 0.000 31.58 25.38 0.759 -0.180 0.308 1.357 68.42 72.62 0.901 -0.285 0.204 0.817
rs111736238 T G 94.74 94.63 1.000 -0.104 0.109 1.022 5.26 5.37 1.000 -0.109 0.104 0.978 0.00 0.00 1.000 0.000 0.000 0.000
rs114570814 A G 94.74 95.21 1.000 -0.115 0.104 0.905 5.26 2.99 0.880 -0.103 0.145 1.802 0.00 0.00 1.000 0.000 0.000 0.000
rs116734533 T C 100.00 89.23 0.266 0.040 0.172 0.000 0.00 4.19 0.279 -0.097 0.010 0.000 0.00 0.00 1.000 0.000 0.000 0.000
rs78306404 T C 0.00 0.00 1.000 0.000 0.000 0.000 5.26 0.30 0.678 -0.080 0.178 18.500 94.74 98.81 0.810 -0.170 0.089 0.217
rs111577081 T C 0.00 0.00 1.000 0.000 0.000 0.000 10.53 13.74 0.959 -0.205 0.140 0.739 89.47 88.10 1.000 -0.144 0.169 1.149
rs117279260 T C 0.00 0.00 1.000 0.000 0.000 0.000 0.00 7.75 0.424 -0.140 -0.017 0.000 100.00 89.29 0.269 0.040 0.172 0.000
rs117407497 A G 94.74 94.02 1.000 -0.105 0.117 1.146 5.26 5.69 1.000 -0.109 0.104 0.922 0.00 0.00 1.000 0.000 0.000 0.000
rs2666826 T C 57.89 53.13 0.869 -0.211 0.306 1.213 42.11 40.00 1.000 -0.230 0.269 1.091 0.00 4.76 0.148 -0.102 0.007 0.000
rs2297775 T C 63.16 51.63 0.449 -0.138 0.370 1.606 36.84 39.11 1.000 -0.268 0.225 0.908 0.00 5.95 0.566 -0.116 -0.002 0.000
rs10153859 A G 0.00 0.30 1.000 -0.016 0.008 0.000 0.00 4.78 0.145 -0.102 0.007 0.000 100.00 95.24 0.148 -0.007 0.102 0.000
rs17597643 A G 94.74 92.53 1.000 -0.105 0.150 1.453 5.26 6.57 1.000 -0.134 0.105 0.790 0.00 0.00 1.000 0.000 0.000 0.000
rs58584712 A G 0.00 5.67 0.593 -0.111 0.001 0.000 47.37 28.67 0.179 -0.073 0.446 2.239 52.63 70.24 0.211 -0.434 0.085 0.471
rs78504459 T C 89.47 94.92 0.715 -0.223 0.115 0.454 10.53 4.78 0.684 -0.111 0.227 2.346 0.00 0.00 1.000 0.000 0.000 0.000
rs150028933 - A 100.00 96.72 0.686 -0.018 0.081 0.000 0.00 2.69 1.000 -0.075 0.020 0.000 0.00 1.19 1.000 -0.037 0.013 0.000
rs200349598 A C 100.00 99.70 1.000 -0.008 0.016 0.000 0.00 0.30 1.000 -0.016 0.008 0.000 0.00 0.00 1.000 0.000 0.000 0.000
%	AA %	AB %	BB
Minor	
allele	(A) 95%	CI 95%	CI 95%	CI
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Table 6.7 SNPs associated with KCNJ11 
101 unique SNPs associated with KCNJ11 were identified, and genotyped. Following a two-sample t-test for proportions, significant 



















rs1030986 T C 0.00 0.00 1.00 0.00 0.00 0.00 0.00 1.49 1.00 -0.05 0.02 0.00 100.00 98.51 1.00 -0.015 0.047 0.000
rs16875779 A G 0.00 4.48 0.73 -0.10 0.01 0.00 26.32 25.98 1.00 -0.21 0.21 1.02 73.68 69.54 0.90 -0.194 0.274 1.226
rs17062197 A G 0.00 1.20 1.00 -0.04 0.01 0.00 42.11 22.68 0.10 -0.06 0.45 2.48 57.89 76.12 0.14 -0.437 0.076 0.431
rs2517646 T C 42.11 51.35 0.59 -0.35 0.17 0.69 47.37 37.31 0.53 -0.16 0.36 1.51 10.53 11.04 1.00 -0.153 0.143 0.948
rs2607614 T C 0.00 0.00 1.00 0.00 0.00 0.00 0.00 5.08 0.66 -0.11 0.00 0.00 100.00 94.92 0.66 -0.004 0.107 0.000
rs33949518 T C 0.00 4.18 0.77 -0.10 0.01 0.00 26.32 26.27 1.00 -0.21 0.21 1.00 73.68 68.95 0.86 -0.186 0.282 1.261
rs34505188 A G 0.00 0.90 1.00 -0.03 0.01 0.00 10.53 11.65 1.00 -0.17 0.14 0.89 89.47 86.85 1.00 -0.144 0.193 1.287
rs35978505 T C 84.21 95.22 0.13 -0.30 0.08 0.27 15.79 4.78 0.13 -0.08 0.30 3.74 0.00 0.00 1.00 0.000 0.000 0.000
rs369738 T G 100.00 88.95 0.26 0.04 0.18 0.00 0.00 8.96 0.35 -0.15 -0.03 0.00 0.00 0.89 1.00 -0.027 0.011 0.000
rs3815082 A G 47.37 54.92 0.69 -0.33 0.19 0.74 47.37 36.73 0.50 -0.15 0.37 1.55 5.26 6.87 1.00 -0.134 0.105 0.753
rs2849089 T C 100.00 100.00 1.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 1.00 0.000 0.000 0.000
rs4479449 A G 94.74 81.19 0.24 0.00 0.28 4.17 0.00 18.81 0.08 -0.27 -0.11 0.00 5.26 0.00 0.09 -0.076 0.181 0.000
rs454748 A G 21.05 16.71 0.87 -0.17 0.26 1.33 57.89 44.80 0.39 -0.13 0.39 1.69 21.05 38.19 0.21 -0.392 0.050 0.432
rs683687 A G 0.00 0.89 1.00 -0.03 0.01 0.00 10.53 13.43 0.99 -0.20 0.14 0.76 89.47 85.68 0.91 -0.136 0.209 1.421
rs683866 T G 57.89 33.74 0.06 -0.02 0.50 2.70 36.84 50.15 0.38 -0.39 0.12 0.58 5.26 15.81 0.36 -0.243 0.033 0.296
rs6919617 A G 78.95 84.17 0.78 -0.27 0.16 0.71 21.05 15.23 0.73 -0.16 0.27 1.48 0.00 0.60 1.00 -0.027 0.011 0.000
rs7431770 A G 0.00 0.60 1.00 -0.03 0.01 0.00 0.00 15.23 0.13 -0.23 -0.08 0.00 100.00 83.28 0.11 0.091 0.239 0.000
rs757260 T C 0.00 1.19 1.00 -0.04 0.01 0.00 26.32 24.78 1.00 -0.21 0.24 1.08 73.68 74.03 1.00 -0.212 0.205 0.982
rs920829 T C 0.00 0.30 1.00 -0.02 0.01 0.00 21.05 22.96 1.00 -0.23 0.19 0.89 78.95 76.14 1.00 -0.189 0.249 1.175
rs9261151 A G 0.00 0.00 1.00 0.00 0.00 0.00 10.53 7.17 0.93 -0.14 0.20 1.52 89.47 92.83 0.93 -0.204 0.135 0.656
rs9261216 A G 78.95 84.17 0.78 -0.27 0.16 0.71 21.05 14.93 0.70 -0.16 0.28 1.52 0.00 0.60 1.00 -0.027 0.011 0.000
rs9261302 A G 0.00 0.60 1.00 -0.03 0.01 0.00 21.05 15.23 0.73 -0.16 0.27 1.48 78.95 84.17 0.78 -0.270 0.164 0.705
rs9261471 T C 47.37 59.09 0.45 -0.38 0.14 0.62 47.37 35.24 0.42 -0.14 0.38 1.65 5.26 5.67 1.00 -0.109 0.104 0.924
rs9268135 A G 47.37 55.82 0.63 -0.35 0.18 0.71 47.37 36.42 0.48 -0.15 0.37 1.57 5.26 7.16 1.00 -0.142 0.105 0.721
rs9366752 T C 5.26 2.99 1.00 -0.10 0.14 1.80 26.32 29.87 0.95 -0.27 0.20 0.84 68.42 67.15 1.00 -0.217 0.239 1.060
rs9811423 C G 36.84 37.30 1.00 -0.24 0.22 0.98 47.37 44.79 1.00 -0.23 0.28 1.11 15.79 17.90 1.00 -0.209 0.171 0.860
rs1693703 T C 73.68 51.03 0.10 -0.01 0.46 2.69 21.05 40.61 0.15 -0.42 0.03 0.39 5.26 7.17 1.00 -0.142 0.105 0.720
rs7841649 T C 0.00 0.00 1.00 0.00 0.00 0.00 15.79 2.39 0.01 -0.06 0.33 7.66 84.21 96.42 0.06 -0.316 0.071 0.198
rs76592289 A G 0.00 0.30 1.00 -0.02 0.01 0.00 0.00 8.65 0.37 -0.15 -0.02 0.00 100.00 91.05 0.35 0.027 0.154 0.000
rs76557252 T G 0.00 0.00 1.00 0.00 0.00 0.00 15.79 0.89 0.00 -0.04 0.34 20.77 84.21 99.11 0.00 -0.343 0.043 0.048
rs506757 T G 52.63 43.59 0.60 -0.17 0.35 1.44 42.11 47.75 0.81 -0.31 0.20 0.80 5.26 8.35 0.97 -0.164 0.104 0.609









Table 6.7 SNPs associated with KCNJ11 (continued) 
101 unique SNPs associated with KCNJ11 were identified, and genotyped. Following a two-sample t-test for proportions, significant 

















rs78082945 T C 94.74 93.43 1.00 -0.11 0.13 1.26 5.26 6.57 1.00 -0.13 0.11 0.79 0.00 0.00 1.00 0.000 0.000 0.000
rs62272114 A G 0.00 0.00 1.00 0.00 0.00 0.00 0.00 5.08 0.66 -0.11 0.00 0.00 100.00 94.63 0.62 -0.001 0.111 0.000
rs112288451 T C 100.00 94.92 0.66 0.00 0.11 0.00 0.00 2.99 0.97 -0.08 0.02 0.00 0.00 0.00 1.00 0.000 0.000 0.000
rs74806059 T C 0.00 0.00 1.00 0.00 0.00 0.00 0.00 3.59 0.86 -0.09 0.02 0.00 100.00 96.41 0.86 -0.016 0.086 0.000
rs79876945 A G 0.00 0.00 1.00 0.00 0.00 0.00 10.53 5.97 0.76 -0.12 0.22 1.85 89.47 94.03 0.76 -0.215 0.123 0.540
rs114687906 A C 0.00 0.00 1.00 0.00 0.00 0.00 0.00 3.88 0.81 -0.09 0.01 0.00 94.74 95.22 1.00 -0.115 0.104 0.903
rs115477611 T C 0.00 0.00 1.00 0.00 0.00 0.00 10.53 3.59 0.38 -0.10 0.24 3.16 89.47 96.41 0.98 -0.238 0.098 0.317
rs78771971 T C 100.00 99.40 1.00 -0.01 0.03 0.00 0.00 0.60 1.00 -0.03 0.01 0.00 0.00 0.00 1.00 0.000 0.000 0.000
rs78854530 A G 0.00 0.00 1.00 0.00 0.00 0.00 0.00 1.79 1.00 -0.06 0.02 0.00 100.00 98.21 1.00 -0.017 0.056 0.000
rs62503295 T C 84.21 85.68 1.00 -0.20 0.17 0.89 10.53 14.03 0.93 -0.21 0.14 0.72 0.00 0.30 1.00 -0.016 0.008 0.000
rs114756881 T C 94.74 85.66 0.44 -0.05 0.23 3.01 0.00 8.96 0.35 -0.15 -0.03 0.00 0.00 0.00 1.00 0.000 0.000 0.000
rs4498896 T C 21.05 14.34 0.65 -0.15 0.29 1.59 36.84 45.36 0.63 -0.34 0.17 0.70 42.11 40.31 1.00 -0.230 0.269 1.077
rs79035182 T G 0.00 0.00 1.00 0.00 0.00 0.00 0.00 3.88 0.86 -0.09 0.01 0.00 100.00 96.12 0.80 -0.013 0.092 0.000
rs74898314 A G 0.00 0.30 1.00 -0.02 0.01 0.00 0.00 3.58 0.81 -0.09 0.02 0.00 100.00 96.12 0.80 -0.013 0.092 0.000
rs28445507 A C 5.26 4.48 1.00 -0.10 0.12 1.18 47.37 36.71 0.50 -0.15 0.37 1.55 47.37 58.51 0.48 -0.374 0.148 0.638
rs55851518 A G 0.00 0.30 1.00 -0.02 0.01 0.00 15.79 10.14 0.70 -0.14 0.25 1.66 84.21 89.56 0.73 -0.248 0.145 0.622
rs79263726 A C 100.00 95.52 0.73 -0.01 0.10 0.00 0.00 4.48 0.73 -0.10 0.01 0.00 0.00 0.00 1.00 0.000 0.000 0.000
rs10898365 T G 5.26 8.65 0.93 -0.17 0.10 0.59 31.58 36.13 0.88 -0.29 0.20 0.82 63.16 55.21 0.66 -0.173 0.334 1.391
rs66546253 A G 21.05 12.86 0.51 -0.14 0.30 1.81 21.05 22.96 1.00 -0.23 0.19 0.89 57.89 63.58 0.80 -0.313 0.203 0.788
rs783307 T C 84.21 71.33 0.35 -0.07 0.33 2.14 15.79 26.28 0.46 -0.31 0.10 0.53 0.00 2.39 1.00 -0.066 0.019 0.000
rs17734780 T C 0.00 0.00 1.00 0.00 0.00 0.00 0.00 2.39 1.00 -0.07 0.02 0.00 100.00 97.61 1.00 -0.019 0.066 0.000
rs10432095 A C 73.68 71.05 1.00 -0.21 0.26 1.14 26.32 27.46 1.00 -0.23 0.21 0.94 0.00 1.49 1.00 -0.047 0.015 0.000
rs75107770 A G 0.00 0.00 1.00 0.00 0.00 0.00 5.26 4.48 1.00 -0.10 0.12 1.19 94.74 95.52 1.00 -0.122 0.103 0.844
rs13061963 T G 5.26 0.00 0.09 -0.08 0.18 0.00 10.53 10.75 1.00 -0.15 0.14 0.98 84.21 89.25 0.77 -0.248 0.145 0.642
rs60400172 T G 5.26 4.77 1.00 -0.10 0.11 1.11 0.00 3.88 0.81 -0.09 0.01 0.00 94.74 91.35 0.93 -0.100 0.168 1.705
rs76451747 A C 0.00 0.00 1.00 0.00 0.00 0.00 0.00 1.20 1.00 -0.04 0.01 0.00 100.00 98.80 1.00 -0.013 0.037 0.000
rs12520495 A G 47.37 45.96 1.00 -0.23 0.26 1.06 36.84 45.97 0.60 -0.35 0.16 0.69 15.79 8.07 0.46 -0.116 0.275 2.137
rs13183249 A G 5.26 3.89 1.00 -0.10 0.13 1.37 36.84 39.70 1.00 -0.28 0.22 0.89 57.89 56.41 1.00 -0.230 0.262 1.062
rs72725509 T C 0.00 0.00 1.00 0.00 0.00 0.00 0.00 1.19 1.00 -0.04 0.01 0.00 100.00 98.81 1.00 -0.013 0.037 0.000
rs80184435 A G 0.00 0.00 1.00 0.00 0.00 0.00 5.26 5.07 1.00 -0.10 0.11 1.04 94.74 93.43 1.00 -0.105 0.134 1.265
rs62404592 A C 0.00 0.00 1.00 0.00 0.00 0.00 0.00 2.39 1.00 -0.07 0.02 0.00 100.00 95.52 0.73 -0.010 0.097 0.000
rs117910348 A C 0.00 0.00 1.00 0.00 0.00 0.00 0.00 2.68 1.00 -0.08 0.02 0.00 100.00 97.32 1.00 -0.020 0.075 0.000









Table 6.7 SNPs associated with KCNJ11 (continued) 
101 unique SNPs associated with KCNJ11 were identified, and genotyped. Following a two-sample t-test for proportions, significant 

























rs71521249 A G 100.00 98.51 1.00 -0.02 0.05 0.00 0.00 1.49 1.00 -0.05 0.02 0.00 0.00 0.00 1.00 0.000 0.000 0.000
rs114234140 A G 0.00 0.00 1.00 0.00 0.00 0.00 5.26 3.59 1.00 -0.10 0.14 1.49 94.74 96.41 0.49 -0.137 0.103 0.670
rs114249268 A G 0.00 4.49 1.00 -0.10 0.01 0.00 0.00 2.38 1.00 -0.07 0.02 0.00 100.00 85.95 0.16 0.071 0.213 0.000
rs112623189 A G 0.00 0.00 1.00 0.00 0.00 0.00 21.05 7.76 0.12 -0.08 0.35 3.17 78.95 92.24 0.12 -0.346 0.083 0.316
rs115010323 T C 0.00 0.00 1.00 0.00 0.00 0.00 0.00 2.09 1.00 -0.06 0.02 0.00 100.00 97.61 1.00 -0.019 0.066 0.000
rs116250326 T C 0.00 0.00 1.00 0.00 0.00 0.00 5.26 0.90 0.55 -0.08 0.17 6.13 94.74 98.80 0.67 -0.170 0.089 0.218
rs77111308 T C 0.00 0.00 1.00 0.00 0.00 0.00 5.26 11.64 0.64 -0.20 0.07 0.42 94.74 88.36 0.64 -0.071 0.202 2.372
rs77823977 T C 100.00 96.42 0.86 -0.02 0.09 0.00 0.00 3.58 0.86 -0.09 0.02 0.00 0.00 0.00 1.00 0.000 0.000 0.000
rs78374474 T C 0.00 0.30 1.00 -0.02 0.01 0.00 15.79 2.99 0.03 -0.07 0.32 6.08 84.21 96.71 0.04 -0.320 0.067 0.181
rs192657690 T C 0.00 0.00 1.00 0.00 0.00 0.00 0.00 1.49 1.00 -0.05 0.02 0.00 100.00 98.51 1.00 -0.015 0.047 0.000
rs116983235 T C 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.60 1.00 -0.03 0.01 0.00 100.00 99.40 1.00 -0.011 0.027 0.000
rs10846754 A G 0.00 3.58 0.86 -0.09 0.02 0.00 26.32 31.95 0.80 -0.29 0.18 0.76 73.68 64.47 0.57 -0.144 0.326 1.543
rs576184 A C 5.26 15.22 0.39 -0.24 0.04 0.31 63.16 46.56 0.25 -0.09 0.42 1.97 31.58 38.21 0.74 -0.312 0.180 0.746
rs16951460 A G 100.00 92.23 0.42 0.02 0.14 0.00 0.00 3.88 0.80 -0.09 0.01 0.00 0.00 1.20 1.00 -0.037 0.013 0.000
rs3748592 A G 0.00 0.00 1.00 0.00 0.00 0.00 10.53 13.72 0.96 -0.21 0.14 0.74 89.47 86.28 0.96 -0.140 0.205 1.352
rs2096376 T C 63.16 52.53 0.51 -0.15 0.36 1.55 36.84 37.33 1.00 -0.24 0.22 0.98 0.00 10.14 0.29 -0.168 -0.037 0.000
rs32555 A G 68.42 68.36 1.00 -0.22 0.22 1.00 31.58 26.87 0.86 -0.20 0.29 1.26 0.00 4.17 0.77 -0.097 0.010 0.000
rs9261089 T C 89.47 92.53 0.97 -0.20 0.14 0.69 10.53 7.17 0.93 -0.14 0.20 1.52 0.00 0.00 1.00 0.000 0.000 0.000
rs28400886 A G 0.00 0.30 1.00 -0.02 0.01 0.00 5.26 9.26 0.86 -0.18 0.09 0.54 94.74 90.44 0.83 -0.093 0.177 1.902
rs4959042 T C 100.00 98.81 1.00 -0.01 0.04 0.00 0.00 1.19 1.00 -0.04 0.01 0.00 0.00 0.00 1.00 0.000 0.000 0.000





















Table 6.7 SNPs associated with KCNJ11 (final) 
101 unique SNPs associated with KCNJ11 were identified, and genotyped. Following a two-sample t-test for proportions, significant 
















rs1573298 C G 5.26 6.87 1.00 -0.13 0.11 0.75 47.37 37.33 0.53 -0.16 0.36 1.51 47.37 55.21 0.69 -0.338 0.183 0.730
rs397596 T C 100.00 100.00 1.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 1.00 0.000 0.000 0.000
rs139080520 A G 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 100.00 100.00 1.00 0.000 0.000 0.000
rs13268757 A G 5.26 2.39 0.99 -0.10 0.16 2.27 15.79 26.57 0.44 -0.31 0.10 0.52 78.95 71.04 0.64 -0.139 0.301 1.528
rs114814001 T C 0.00 0.00 1.00 0.00 0.00 0.00 0.00 5.08 0.66 -0.11 0.00 0.00 100.00 94.92 0.66 -0.004 0.107 0.000
rs79765628 T C 0.00 0.00 1.00 0.00 0.00 0.00 5.26 5.08 1.00 -0.10 0.11 1.04 94.74 94.92 1.00 -0.107 0.104 0.963
rs117389196 T C 0.00 0.00 1.00 0.00 0.00 0.00 0.00 3.87 0.81 -0.09 0.01 0.00 100.00 95.83 0.77 -0.010 0.097 0.000
rs141834826 A G 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 100.00 99.70 1.00 -0.008 0.016 0.000
rs201447432 T C 0.00 0.00 1.00 0.00 0.00 0.00 0.00 2.69 1.00 -0.08 0.02 0.00 100.00 96.41 0.86 -0.016 0.086 0.000
rs146548891 T G 100.00 99.11 1.00 -0.01 0.03 0.00 0.00 0.60 1.00 -0.03 0.01 0.00 0.00 0.00 1.00 0.000 0.000 0.000
rs142720326 A G 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.60 1.00 -0.03 0.01 0.00 100.00 99.40 1.00 -0.011 0.027 0.000
rs201960928 A G 0.00 0.00 1.00 0.00 0.00 0.00 0.00 2.10 1.00 -0.06 0.02 0.00 100.00 97.60 1.00 -0.019 0.066 0.000
rs139889337 A G 0.00 0.00 1.00 0.00 0.00 0.00 0.00 1.79 1.00 -0.06 0.02 0.00 100.00 97.91 1.00 -0.017 0.056 0.000
rs113993403 T C 0.00 0.00 1.00 0.00 0.00 0.00 0.00 1.79 1.00 -0.06 0.02 0.00 100.00 98.21 1.00 -0.017 0.056 0.000






Figure 6.1 Clustering analysis for KCNJ11- rs78374474  
Clustering of genotypes between the control (top panel) and DIASTRAT 
(bottom panel) cohorts shown graphically for rs78374474  
 
 
Figure 6.2 Clustering analysis for KCNJ11- rs76557252 
 
Clustering of genotypes between the control (top panel) and DIASTRAT 










Table 6.8 SNPs associated with KCNQ1 
68 unique SNPs associated with KCNQ1 were identified, and genotyped. Following a two-sample t-test for proportions, significant 

















rs16841998 T C 63.16 73.44 0.514 -0.356 0.147 0.620 21.05 15.83 0.804 -0.164 0.270 1.418 0.00 0.00 1.000 0.000 0.000 0.000
rs17461843 T C 100.00 88.36 0.233 0.050 0.186 0.000 0.00 8.95 0.352 -0.154 -0.027 0.000 0.00 0.00 1.000 0.000 0.000 0.000
rs17571372 T C 0.00 0.60 1.000 -0.027 0.011 0.000 5.26 9.56 0.787 -0.177 0.093 0.525 94.74 89.84 0.704 -0.086 0.185 2.035
T G 0.00 0.00 1.000 0.000 0.000 0.000 0.00 0.00 1.000 0.000 0.000 0.000 100.00 99.70 1.000 -0.008 0.016 0.000
rs3006968 A G 26.32 23.29 0.985 -0.202 0.264 1.176 47.37 47.75 1.000 -0.238 0.233 0.985 26.32 28.66 1.000 -0.254 0.206 0.889
rs6039591 A G 100.00 95.22 0.145 -0.007 0.102 0.000 0.00 4.78 0.145 -0.102 0.007 0.000 0.00 0.00 1.000 0.000 0.000 0.000
rs6883010 A G 5.26 18.81 0.059 -0.276 0.003 0.240 52.63 45.66 0.727 -0.191 0.331 1.322 42.11 35.53 0.749 -0.191 0.325 1.320
rs6133707 A G 52.63 60.90 0.646 -0.345 0.177 0.713 47.37 34.02 0.374 -0.125 0.395 1.745 0.00 4.78 0.145 -0.102 0.007 0.000
rs77707280 A G 0.00 0.60 1.000 -0.027 0.011 0.000 10.53 10.14 1.000 -0.143 0.149 1.042 89.47 88.96 1.000 -0.143 0.153 1.055
rs807936 T C 42.11 37.92 0.908 -0.215 0.301 1.191 52.63 44.47 0.670 -0.180 0.342 1.387 5.26 17.61 0.092 -0.264 0.015 0.260
rs114348392 T G 0.00 0.00 1.000 0.000 0.000 0.000 5.26 2.98 1.000 -0.103 0.145 1.807 89.47 96.72 0.535 -0.242 0.094 0.289
rs9356928 A G 15.79 22.68 0.643 -0.271 0.130 0.639 52.63 47.17 0.825 -0.207 0.315 1.244 31.58 29.56 1.000 -0.216 0.257 1.100
rs9460973 A T 0.00 0.00 1.000 0.000 0.000 0.000 0.00 8.95 0.352 -0.154 -0.027 0.000 100.00 90.75 0.336 0.030 0.159 0.000
rs58554303 T C 94.74 94.33 1.000 -0.104 0.109 1.082 5.26 5.37 1.000 -0.109 0.104 0.979 0.00 0.00 1.000 0.000 0.000 0.000
rs920628 A G 94.74 92.84 1.000 -0.105 0.142 1.389 5.26 6.57 1.000 -0.134 0.105 0.790 0.00 0.60 1.000 -0.027 0.011 0.000
rs16873732 T C 94.74 92.84 1.000 -0.105 0.142 1.389 5.26 6.57 1.000 -0.134 0.105 0.790 0.00 0.60 1.000 -0.027 0.011 0.000
rs1041791 T C 57.89 65.08 0.710 -0.329 0.187 0.738 42.11 31.93 0.530 -0.155 0.360 1.550 0.00 2.68 1.000 -0.075 0.020 0.000
rs61741363 A G 100.00 100.00 1.000 0.000 0.000 0.000 0.00 0.00 1.000 0.000 0.000 0.000 0.00 0.00 1.000 0.000 0.000 0.000
rs113319303 A G 0.00 2.69 1.000 -0.075 0.020 0.000 0.00 3.28 0.686 -0.081 0.018 0.000 100.00 93.73 0.537 0.005 0.121 0.000
rs116581086 A G 0.00 0.00 1.000 0.000 0.000 0.000 0.00 0.89 1.000 -0.027 0.011 0.000 100.00 99.11 1.000 -0.011 0.027 0.000
rs74745471 A G 0.00 0.00 1.000 0.000 0.000 0.000 5.26 11.34 0.554 -0.198 0.074 0.434 94.74 88.66 0.554 -0.074 0.198 2.303
rs61936141 T C 100.00 96.11 0.145 -0.013 0.092 0.000 0.00 3.59 0.686 -0.086 0.016 0.000 0.00 0.00 1.000 0.000 0.000 0.000
rs79090092 A G 0.00 0.30 1.000 -0.016 0.008 0.000 5.26 7.17 1.000 -0.142 0.105 0.719 94.74 92.53 1.000 -0.105 0.150 1.453
rs10905750 A C 0.00 0.00 1.000 0.000 0.000 0.000 0.00 4.78 0.145 -0.102 0.007 0.000 100.00 95.22 0.145 -0.007 0.102 0.000
rs231847 A G 5.26 12.54 0.421 -0.210 0.063 0.387 52.63 56.42 0.935 -0.298 0.224 0.858 42.11 31.03 0.480 -0.147 0.367 1.616
rs129072 T C 0.00 3.58 0.519 -0.086 0.016 0.000 15.79 27.46 0.318 -0.319 0.084 0.495 84.21 68.66 0.151 -0.045 0.359 2.435

















Table 6.8 SNPs associated with KCNQ1 (continued) 
68 unique SNPs associated with KCNQ1 were identified, and genotyped. Following a two-sample t-test for proportions, significant 


















rs111871569 A G 0.00 0.30 1.000 -0.016 0.008 0.000 10.53 6.86 0.907 -0.131 0.208 1.597 89.47 92.24 1.000 -0.195 0.142 0.715
rs75875515 A G 0.00 0.00 1.000 0.000 0.000 0.000 0.00 4.18 0.145 -0.097 0.010 0.000 100.00 95.22 0.145 -0.007 0.102 0.000
rs7156987 T C 0.00 0.00 1.000 0.000 0.000 0.000 0.00 3.58 0.686 -0.086 0.016 0.000 100.00 94.64 0.145 -0.001 0.111 0.000
rs55767542 T C 0.00 0.00 1.000 0.000 0.000 0.000 0.00 4.18 0.145 -0.097 0.010 0.000 100.00 95.22 0.145 -0.007 0.102 0.000
rs35162844 A G 0.00 0.60 1.000 -0.027 0.011 0.000 15.79 6.57 0.453 -0.104 0.286 2.667 84.21 92.54 0.519 -0.278 0.112 0.430
rs73063633 T G 94.74 94.92 1.000 -0.107 0.104 0.962 5.26 4.78 1.000 -0.104 0.115 1.108 0.00 0.00 1.000 0.000 0.000 0.000
rs116045044 T G 94.74 91.05 0.874 -0.097 0.173 1.769 5.26 8.06 1.000 -0.158 0.106 0.634 0.00 0.00 1.000 0.000 0.000 0.000
rs77692939 A G 100.00 96.41 0.145 -0.016 0.086 0.000 0.00 1.49 1.000 -0.047 0.015 0.000 0.00 0.00 1.000 0.000 0.000 0.000
rs72811968 T C 0.00 0.00 1.000 0.000 0.000 0.000 0.00 3.28 0.145 -0.081 0.018 0.000 100.00 96.72 0.686 -0.018 0.081 0.000
rs76238538 T C 100.00 94.63 0.145 -0.001 0.111 0.000 0.00 5.37 0.072 -0.111 0.001 0.000 0.00 0.00 1.000 0.000 0.000 0.000
rs79931282 A G 89.47 92.84 0.940 -0.204 0.135 0.656 10.53 6.57 0.875 -0.131 0.208 1.674 0.00 0.00 1.000 0.000 0.000 0.000
rs9467059 A G 100.00 88.95 0.255 0.043 0.177 0.000 0.00 10.15 0.292 -0.168 -0.037 0.000 0.00 0.00 1.000 0.000 0.000 0.000
rs188539852 T C 0.00 0.00 1.000 0.000 0.000 0.000 5.26 2.38 0.992 -0.101 0.159 2.274 94.74 97.62 0.992 -0.159 0.101 0.440
rs115704940 T C 0.00 0.30 1.000 -0.016 0.008 0.000 5.26 5.37 1.000 -0.109 0.104 0.978 94.74 94.33 1.000 -0.104 0.109 1.083
rs116858972 T C 0.00 0.00 1.000 0.000 0.000 0.000 5.26 3.88 1.000 -0.103 0.130 1.376 94.74 96.12 1.000 -0.130 0.103 0.727
rs117103115 A G 100.00 90.14 0.306 0.034 0.163 0.000 0.00 5.97 0.072 -0.116 -0.002 0.000 0.00 0.00 1.000 0.000 0.000 0.000
rs77936291 A G 94.74 94.32 1.000 -0.104 0.109 1.084 5.26 5.68 1.000 -0.109 0.104 0.922 0.00 0.00 1.000 0.000 0.000 0.000
rs79947987 T C 100.00 99.11 1.000 -0.011 0.027 0.000 0.00 0.60 1.000 -0.027 0.011 0.000 0.00 0.00 1.000 0.000 0.000 0.000
rs78468689 A G 0.00 0.00 1.000 0.000 0.000 0.000 5.26 7.46 1.000 -0.150 0.105 0.689 94.74 92.54 1.000 -0.105 0.150 1.452
rs80140016 T G 0.00 0.00 1.000 0.000 0.000 0.000 10.53 7.76 0.875 -0.142 0.195 1.398 89.47 91.94 1.000 -0.195 0.142 0.745


















Table 6.8 SNPs associated with KCNQ1 (final) 
68 unique SNPs associated with KCNQ1 were identified, and genotyped. Following a two-sample t-test for proportions, significant 

















rs114351051 T C 100.00 84.22 0.124 0.084 0.231 0.000 0.00 9.53 0.321 -0.159 -0.030 0.000 0.00 0.89 1.000 -0.027 0.011 0.000
rs115005266 T C 0.00 0.00 1.000 0.000 0.000 0.000 5.26 4.48 1.000 -0.103 0.122 1.185 94.74 94.93 1.000 -0.107 0.104 0.962
rs112214748 A G 0.00 0.00 1.000 0.000 0.000 0.000 26.32 5.38 0.076 -0.020 0.436 6.283 73.68 94.62 0.076 -0.436 0.020 0.159
rs7119884 A G 94.74 93.14 1.000 -0.105 0.134 1.325 5.26 6.86 1.000 -0.134 0.105 0.755 0.00 0.00 1.000 0.000 0.000 0.000
rs6057010 A G 89.47 87.15 1.000 -0.144 0.193 1.253 10.53 12.85 1.000 -0.193 0.144 0.798 0.00 0.00 1.000 0.000 0.000 0.000
rs4690087 A G 0.00 5.39 0.071 -0.111 0.001 0.000 26.32 3.87 0.054 -0.004 0.452 8.869 73.68 90.74 0.166 -0.398 0.061 0.286
rs11754464 T C 0.00 0.00 1.000 0.000 0.000 0.000 0.00 0.00 1.000 0.000 0.000 0.000 100.00 99.70 1.000 -0.008 0.016 0.000
rs707938 A G 42.11 41.78 1.000 -0.230 0.238 1.014 47.37 46.29 1.000 -0.233 0.251 1.044 10.53 11.33 1.000 -0.161 0.143 0.920
rs35185125 A C 0.00 0.00 1.000 0.000 0.000 0.000 5.26 1.19 0.810 -0.089 0.170 4.597 94.74 98.81 0.810 -0.170 0.089 0.218
rs28381355 A G 0.00 0.00 1.000 0.000 0.000 0.000 0.00 1.20 1.000 -0.037 0.013 0.000 100.00 98.80 1.000 -0.013 0.037 0.000
rs183314661 A C 0.00 0.00 1.000 0.000 0.000 0.000 0.00 4.78 0.145 -0.102 0.007 0.000 100.00 95.22 0.145 -0.007 0.102 0.000
rs77320475 A G 0.00 0.00 1.000 0.000 0.000 0.000 15.79 7.16 0.496 -0.108 0.282 2.430 84.21 92.54 0.519 -0.278 0.112 0.430
rs17812699 A G 0.00 0.30 1.000 -0.016 0.008 0.000 0.00 15.23 0.135 -0.226 -0.081 0.000 100.00 84.47 0.129 0.081 0.226 0.000
rs199853687 A C 100.00 100.00 1.000 0.000 0.000 0.000 0.00 0.00 1.000 0.000 0.000 0.000 0.00 0.00 1.000 0.000 0.000 0.000
rs115491500 T C 0.00 0.00 1.000 0.000 0.000 0.000 0.00 0.00 1.000 0.000 0.000 0.000 100.00 100.00 1.000 0.000 0.000 0.000
rs11553182 T C 0.00 0.00 1.000 0.000 0.000 0.000 15.79 17.90 1.000 -0.209 0.171 0.860 84.21 82.10 1.000 -0.171 0.209 1.163
C G 100.00 99.70 1.000 -0.008 0.016 0.000 0.00 0.30 1.000 -0.016 0.008 0.000 0.00 0.00 1.000 0.000 0.000 0.000
rs341047 A G 0.00 0.60 1.000 -0.027 0.011 0.000 31.58 20.31 0.441 -0.132 0.354 1.811 68.42 78.50 0.509 -0.343 0.144 0.594
rs150934987 A G 0.00 0.00 1.000 0.000 0.000 0.000 0.00 0.00 1.000 0.000 0.000 0.000 100.00 100.00 1.000 0.000 0.000 0.000
















Table 6.9 SNPs associated with HNF1α 
38 unique SNPs associated with HNF1α were identified, and genotyped. Following a two-sample t-test for proportions, significant 


















rs11755881 A G 0.00 1.49 1.000 -0.047 0.015 0.000 5.26 17.02 0.113 -0.255 0.022 0.271 94.74 81.49 0.066 -0.007 0.272 4.089
rs1861 A C 0.00 0.30 1.000 -0.016 0.008 0.000 5.26 4.47 1.000 -0.103 0.122 1.186 94.74 95.23 1.000 -0.115 0.104 0.902
rs28568667 T C 63.16 73.11 0.533 -0.353 0.151 0.630 26.32 23.90 1.000 -0.205 0.251 1.137 0.00 0.00 1.000 0.000 0.000 0.000
rs4770748 A G 0.00 0.30 1.000 -0.016 0.008 0.000 0.00 13.44 0.177 -0.204 -0.064 0.000 100.00 86.26 0.169 0.067 0.208 0.000
rs663824 A G 36.84 42.39 0.813 -0.310 0.197 0.793 42.11 43.88 1.000 -0.262 0.230 0.930 21.05 13.73 0.640 -0.144 0.289 1.675
rs6905159 A G 15.79 25.66 0.424 -0.299 0.103 0.543 57.89 49.55 0.639 -0.176 0.342 1.400 26.32 24.19 1.000 -0.205 0.251 1.119
rs888576 T C 0.00 0.60 1.000 -0.027 0.011 0.000 31.58 16.40 0.258 -0.092 0.393 2.353 68.42 83.00 0.282 -0.389 0.096 0.444
rs13325508 T C 94.74 95.23 1.000 -0.115 0.104 0.902 5.26 4.77 1.000 -0.104 0.115 1.108 0.00 0.00 1.000 0.000 0.000 0.000
rs55723035 T C 0.00 0.00 1.000 0.000 0.000 0.000 0.00 2.99 0.887 -0.081 0.018 0.000 100.00 97.01 0.880 -0.018 0.081 0.000
rs77356515 T G 0.00 0.00 1.000 0.000 0.000 0.000 10.53 1.79 0.404 -0.082 0.253 6.444 89.47 98.21 0.404 -0.253 0.082 0.155
rs75363174 A G 0.00 0.30 1.000 -0.016 0.008 0.000 10.53 11.04 1.000 -0.153 0.143 0.948 89.47 88.66 1.000 -0.143 0.161 1.087
rs4751674 T C 21.05 11.64 0.491 -0.123 0.308 2.023 36.84 37.31 1.000 -0.236 0.225 0.980 42.11 50.75 0.621 -0.345 0.172 0.706
rs61433965 A G 100.00 96.72 0.081 -0.018 0.081 0.000 0.00 2.98 0.887 -0.081 0.018 0.000 0.00 0.00 1.000 0.000 0.000 0.000
rs58838391 A G 0.00 0.00 1.000 0.000 0.000 0.000 0.00 2.99 0.887 -0.081 0.018 0.000 100.00 97.01 0.880 -0.018 0.081 0.000
rs76280424 A G 0.00 0.00 1.000 0.000 0.000 0.000 0.00 0.00 1.000 0.000 0.000 0.000 100.00 100.00 1.000 0.000 0.000 0.000
rs77794667 T C 0.00 0.00 1.000 0.000 0.000 0.000 5.26 3.28 1.000 -0.103 0.145 1.637 94.74 96.72 1.000 -0.145 0.103 0.611
rs59559871 T C 0.00 0.00 1.000 0.000 0.000 0.000 0.00 0.00 1.000 0.000 0.000 0.000 100.00 99.70 1.000 -0.008 0.016 0.000
rs72826927 A G 0.00 0.30 1.000 -0.016 0.008 0.000 10.53 13.13 1.000 -0.193 0.144 0.778 89.47 86.57 1.000 -0.144 0.201 1.319
rs945094 A T 0.00 0.00 1.000 0.000 0.000 0.000 5.26 5.08 1.000 -0.104 0.107 1.037 94.74 94.92 1.000 -0.107 0.104 0.964
rs72751116 A G 100.00 99.40 1.000 -0.011 0.027 0.000 0.00 0.60 1.000 -0.027 0.011 0.000 0.00 0.00 1.000 0.000 0.000 0.000
rs59706474 T C 0.00 0.00 1.000 0.000 0.000 0.000 5.26 3.28 1.000 -0.103 0.145 1.639 94.74 96.72 1.000 -0.145 0.103 0.610



















Table 6.9 SNPs associated with HNF1α (final) 
38 unique SNPs associated with HNF1α were identified, and genotyped. Following a two-sample t-test for proportions, significant 



















rs72489176 A G 57.89 62.39 0.887 -0.301 0.215 0.829 36.84 32.55 0.898 -0.211 0.294 1.209 5.26 5.07 1.000 -0.104 0.107 1.041
rs77367389 A C 94.74 98.51 0.856 -0.167 0.093 0.272 5.26 1.49 0.856 -0.093 0.167 3.673 0.00 0.00 1.000 0.000 0.000 0.000
rs73668591 T C 0.00 0.00 1.000 0.000 0.000 0.000 0.00 1.79 1.000 -0.056 0.017 0.000 100.00 97.91 1.000 -0.017 0.056 0.000
rs73669423 T C 84.21 84.78 1.000 -0.179 0.170 0.957 15.79 15.22 1.000 -0.170 0.179 1.045 0.00 0.00 1.000 0.000 0.000 0.000
rs62493228 A C 0.00 0.00 1.000 0.000 0.000 0.000 15.79 10.45 0.770 -0.145 0.248 1.607 84.21 89.55 0.770 -0.248 0.145 0.622
rs76569571 T G 0.00 0.00 1.000 0.000 0.000 0.000 0.00 4.47 0.205 -0.097 0.010 0.000 100.00 93.74 0.538 0.005 0.121 0.000
rs80312260 A G 0.00 0.00 1.000 0.000 0.000 0.000 10.53 3.58 0.564 -0.098 0.238 3.167 89.47 96.42 0.564 -0.238 0.098 0.316
rs2244608 A G 36.84 52.25 0.274 -0.409 0.099 0.533 63.16 39.39 0.068 -0.015 0.491 2.638 0.00 8.36 0.385 -0.145 -0.021 0.000
rs11616995 A G 100.00 96.72 0.686 -0.018 0.081 0.000 0.00 3.28 0.686 -0.081 0.018 0.000 0.00 0.00 1.000 0.000 0.000 0.000
rs11647932 T C 0.00 0.89 1.000 -0.027 0.011 0.000 42.11 19.71 0.092 -0.031 0.480 2.962 57.89 79.09 0.114 -0.468 0.043 0.363
rs8102561 T C 63.16 70.16 0.715 -0.322 0.183 0.729 31.58 27.16 0.885 -0.200 0.288 1.238 5.26 2.69 1.000 -0.102 0.153 2.012
rs340141 T C 10.53 10.74 1.000 -0.145 0.143 0.977 42.11 44.46 1.000 -0.278 0.230 0.908 47.37 44.49 0.997 -0.232 0.290 1.123
rs150333766 T C 0.00 0.00 1.000 0.000 0.000 0.000 0.00 0.89 1.000 -0.027 0.011 0.000 100.00 99.11 1.000 -0.011 0.027 0.000
rs189023122 T C 0.00 0.00 1.000 0.000 0.000 0.000 0.00 0.00 1.000 0.000 0.000 0.000 100.00 100.00 1.000 0.000 0.000 0.000
rs150428096 T C 0.00 0.00 1.000 0.000 0.000 0.000 0.00 1.20 1.000 -0.037 0.013 0.000 100.00 97.90 1.000 -0.017 0.056 0.000
















Table 6.10 SNPs associated with TCF7L2 
44 unique SNPs associated with TCF7L2 were identified, and genotyped. Following a two-sample t-test for proportions, significant 


















rs12894204 A G 0.00 3.57 0.524 -0.086 0.016 0.000 36.84 33.15 0.940 -0.215 0.290 1.176 63.16 63.27 1.000 -0.229 0.225 0.995
rs17605420 A G 94.74 96.11 1.000 -0.130 0.103 0.729 5.26 3.89 1.000 -0.103 0.130 1.374 0.00 0.00 1.000 0.000 0.000 0.000
rs17763253 T C 0.00 1.80 1.000 -0.056 0.017 0.000 10.53 6.25 0.840 -0.127 0.212 1.764 89.47 91.95 1.000 -0.195 0.142 0.744
rs6728493 A C 47.37 51.94 0.883 -0.307 0.215 0.833 42.11 40.90 1.000 -0.230 0.253 1.051 10.53 7.16 0.940 -0.135 0.204 1.526
rs9906935 A G 31.58 50.75 0.142 -0.438 0.054 0.448 57.89 39.10 0.174 -0.069 0.447 2.141 10.53 9.85 1.000 -0.143 0.156 1.077
rs7089262 T C 0.00 0.00 1.000 0.000 0.000 0.000 0.00 7.76 0.423 -0.140 -0.017 0.000 100.00 91.94 0.404 0.017 0.140 0.000
rs76677854 T C 84.21 91.04 0.640 -0.263 0.129 0.525 15.79 8.66 0.615 -0.125 0.267 1.978 0.00 0.00 1.000 0.000 0.000 0.000
rs145079521 A C 89.47 93.13 0.908 -0.208 0.131 0.627 10.53 6.57 0.875 -0.131 0.208 1.673 0.00 0.00 1.000 0.000 0.000 0.000
rs78082945 T C 94.74 93.43 1.000 -0.105 0.134 1.267 5.26 6.57 1.000 -0.134 0.105 0.791 0.00 0.00 1.000 0.000 0.000 0.000
rs62272114 A G 0.00 0.00 1.000 0.000 0.000 0.000 0.00 5.08 0.102 -0.107 0.004 0.000 100.00 94.63 0.072 -0.001 0.111 0.000
rs77385406 A G 0.00 0.00 1.000 0.000 0.000 0.000 21.05 5.97 0.192 -0.062 0.365 4.203 78.95 94.03 0.174 -0.365 0.062 0.238
rs61732118 A G 0.00 0.00 1.000 0.000 0.000 0.000 0.00 0.00 1.000 0.000 0.000 0.000 100.00 100.00 1.000 0.000 0.000 0.000
rs61875109 A C 21.05 5.37 0.174 -0.058 0.369 4.698 42.11 33.14 0.600 -0.167 0.348 1.467 36.84 61.19 0.061 -0.495 0.012 0.370
rs116369954 T C 100.00 90.45 0.321 0.030 0.159 0.000 0.00 8.65 0.368 -0.149 -0.024 0.000 0.00 0.30 1.000 -0.016 0.008 0.000
rs79805154 A G 89.47 85.96 0.926 -0.136 0.209 1.388 10.53 13.44 0.991 -0.201 0.144 0.758 0.00 0.30 1.000 -0.016 0.008 0.000
rs77064952 A G 0.00 0.00 1.000 0.000 0.000 0.000 0.00 1.49 1.000 -0.047 0.015 0.000 100.00 97.91 1.000 -0.017 0.056 0.000
rs10059523 A G 0.00 0.00 1.000 0.000 0.000 0.000 5.26 5.96 1.000 -0.117 0.105 0.876 94.74 94.04 1.000 -0.105 0.117 1.141
rs78183526 T C 0.00 0.00 1.000 0.000 0.000 0.000 0.00 0.30 1.000 -0.016 0.008 0.000 100.00 99.70 1.000 -0.008 0.016 0.000
rs587667473 A C 47.37 63.29 0.269 -0.421 0.100 0.522 52.63 36.41 0.258 -0.096 0.425 1.941 0.00 0.00 1.000 0.000 0.000 0.000
rs73179006 T G 0.00 0.00 1.000 0.000 0.000 0.000 10.53 7.76 1.000 -0.142 0.195 1.399 89.47 92.24 1.000 -0.195 0.142 0.715
rs113262704 T G 0.00 0.00 1.000 0.000 0.000 0.000 10.53 5.95 0.808 -0.123 0.215 1.859 89.47 93.75 0.840 -0.212 0.127 0.567

















Table 6.10 SNPs associated with TCF7L2 (final) 
44 unique SNPs associated with TCF7L2 were identified, and genotyped. Following a two portions t-test significantly different 
















rs55656505 T C 100.00 91.64 0.385 0.021 0.145 0.000 0.00 8.06 0.404 -0.140 -0.017 0.000 0.00 0.30 1.000 -0.016 0.008 0.000
rs4783943 A G 0.00 6.56 0.512 -0.126 -0.008 0.000 47.37 36.71 0.509 -0.153 0.368 1.551 52.63 56.73 0.915 -0.302 0.220 0.848
rs3026084 A G 100.00 94.04 0.565 0.002 0.116 0.000 0.00 4.77 0.147 -0.102 0.007 0.000 0.00 0.00 1.000 0.000 0.000 0.000
rs189314829 A G 0.00 0.00 1.000 0.000 0.000 0.000 0.00 5.37 0.072 -0.111 0.001 0.000 100.00 94.03 0.072 0.002 0.116 0.000
rs75107770 A G 0.00 0.00 1.000 0.000 0.000 0.000 5.26 4.48 1.000 -0.103 0.122 1.185 94.74 95.52 1.000 -0.122 0.103 0.844
rs73223028 T C 0.00 0.00 1.000 0.000 0.000 0.000 10.53 2.39 0.455 -0.086 0.249 4.809 89.47 97.61 0.455 -0.249 0.086 0.208
rs116929578 A G 94.74 90.14 0.745 -0.089 0.181 1.970 5.26 8.96 0.872 -0.173 0.097 0.564 0.00 0.30 1.000 -0.016 0.008 0.000
rs117041486 A G 0.00 0.00 1.000 0.000 0.000 0.000 10.53 2.09 0.455 -0.082 0.253 5.515 89.47 97.91 0.455 -0.253 0.082 0.181
rs79565172 A G 94.74 97.62 0.992 -0.159 0.101 0.439 5.26 1.79 0.902 -0.097 0.163 3.049 0.00 0.00 1.000 0.000 0.000 0.000
rs117582734 T C 0.00 0.00 1.000 0.000 0.000 0.000 15.79 11.05 0.824 -0.149 0.244 1.509 84.21 88.95 0.824 -0.244 0.149 0.662
rs12243326 T C 47.37 39.71 0.684 -0.185 0.337 1.367 42.11 48.94 0.734 -0.326 0.192 0.759 10.53 11.35 1.000 -0.161 0.143 0.919
rs4889830 A G 31.58 25.66 0.779 -0.184 0.304 1.337 42.11 51.65 0.568 -0.353 0.164 0.681 26.32 22.69 0.939 -0.198 0.268 1.217
rs3787493 A G 21.05 24.17 0.976 -0.249 0.189 0.836 47.37 45.07 1.000 -0.233 0.282 1.097 31.58 30.45 1.000 -0.217 0.242 1.054
rs4713505 T G 0.00 4.77 0.524 -0.102 0.007 0.000 73.68 30.75 0.000 0.196 0.664 6.306 26.32 64.48 0.002 -0.617 -0.148 0.197
rs2070600 T C 0.00 0.00 1.000 0.000 0.000 0.000 36.84 13.73 0.072 -0.019 0.480 3.664 63.16 85.97 0.076 -0.476 0.023 0.280
rs3131300 A G 52.63 56.72 0.524 -0.302 0.220 0.848 42.11 34.94 0.711 -0.187 0.329 1.354 5.26 8.05 1.000 -0.158 0.106 0.635
rs73471190 T C 0.00 0.00 1.000 0.000 0.000 0.000 0.00 0.60 1.000 -0.027 0.011 0.000 100.00 98.81 1.000 -0.013 0.037 0.000
rs148924158 A G 100.00 100.00 1.000 0.000 0.000 0.000 0.00 0.00 1.000 0.000 0.000 0.000 0.00 0.00 1.000 0.000 0.000 0.000
rs143828311 T C 0.00 0.00 1.000 0.000 0.000 0.000 5.26 2.09 0.948 -0.097 0.163 2.604 94.74 97.91 0.948 -0.163 0.097 0.384
rs201967398 A G 0.00 0.00 1.000 0.000 0.000 0.000 0.00 0.00 1.000 0.000 0.000 0.000 100.00 100.00 1.000 0.000 0.000 0.000
rs143652701 T C 0.00 0.00 1.000 0.000 0.000 0.000 0.00 0.00 1.000 0.000 0.000 0.000 100.00 100.00 1.000 0.000 0.000 0.000









Figure 6.3 Clustering analysis for TCF7L2- rs4713505 
 
Clustering of genotypes between the control (top panel) and DIASTRAT 
































Table 6.11 Difference in prevalence of SNPs in a control and diabetic cohort 
 
A summary of SNPs that are significantly different between the non-diabetic control and the diabetic DIASTRAT cohort 
dbSNP	RS	ID A	allele B	allele Control DIASTRAT Control DIASTRAT Control DIASTRAT Control DIASTRAT p-value Control DIASTRAT p-value Control DIASTRAT p-value
rs7841649 T C 100 98.81 0.0789 0.0121 0.7087 0.8933 0.00 0.00 1.00 15.79 2.39 0.01 84.21 96.42 0.06
rs76557252 T G 100 100 0.0789 0.0045 0.7087 0.9626 0.00 0.00 1.00 15.79 0.89 0.00 84.21 99.11 0.00
rs78374474 T C 100 100 0.0789 0.0179 0.7087 0.4899 0.00 0.30 1.00 15.79 2.99 0.03 84.21 96.71 0.04
TCF7L2 rs4713505 T G 100.00 100.00 0.3684 0.2015 0.0110 0.6215 0.00 4.77 0.524 73.68 30.75 0.000 26.32 64.48 0.002
Gene
KCNJ11
SNP	call	rate	(%) MAF H.W.	P	value %	AA %	AB %	BB
 164 
6.3.3 Association of variants with glycaemic control 
 
A major aim of the current study was to identify genetic markers of 
glycaemic control, and in particular, markers of glycaemic control in 
response to sulphonylurea treatment. The DIASTRAT cohort was therefore 
subdivided into those receiving sulphonylureas and those who were not. 
Subgroupings were further divided into lowest (Q1) and highest (Q4) 
quartiles according to HbA1c. In the group receiving sulphonylureas, this 
resulted in 21 individuals in Q1 and a further 17 individuals in Q4. In the 
non-sulphonylurea group, the numbers were 46 in Q1 and 32 in Q4.  
 
Consistent with the analysis above, SNP call rates did not differ 
significantly between Q1 and Q4 in the sulphonylurea group (Tables 6.12 
– 6.16). MAF scores again suggested that the vast majority of variants 


































Table 6.12 Attributes of SNPs associated with ABCC8 for participants in the lowest (Q1) and highest (Q4) quartiles for HbA1c among 
those receiving sulphonylurea therapy. 
 
31 unique SNPs associated with ABCC8 were identified. SNP call rate is given as a percentage of total participants. MAF, Minor Allele 
Frequency; H.W. P value, Hardy-Weinberg P Value. 
dbSNP	RS	ID A	allele B	allele Q1 Q4 Q1 Q4 Q1 Q4
rs10961940 A G 95.24 100.00 0.1250 0.1176 0.1599 0.5825
rs17743658 A G 95.24 100.00 0.2500 0.3824 0.0369 0.1272
rs3738591 C G 100.00 100.00 0.0476 0.0000 0.8188 1.0000
rs4741478 T G 100.00 100.00 0.0952 0.0588 0.0404 0.7966
rs649224 A G 100.00 100.00 0.0714 0.0588 0.7245 0.7966
rs9458011 T C 100.00 100.00 0.0952 0.0882 0.6295 0.6899
rs8098346 T G 100.00 100.00 0.4286 0.3235 0.3085 0.1762
rs75780075 A G 100.00 100.00 0.0714 0.0588 0.7245 0.7966
rs73017157 A G 100.00 100.00 0.0476 0.0000 0.8188 1.0000
rs11647027 A C 100.00 100.00 0.0476 0.0000 0.8188 1.0000
rs59409558 A C 95.24 100.00 0.0250 0.0000 0.9087 1.0000
rs11942387 A G 100.00 100.00 0.3095 0.3824 0.0400 0.1272
rs62295555 T C 100.00 100.00 0.0714 0.2059 0.7245 0.2851
rs12548842 T C 100.00 100.00 0.4048 0.3529 0.1578 0.3487
rs79345026 T C 100.00 100.00 0.1667 0.2059 0.5127 0.2851
rs10961999 T C 100.00 100.00 0.2381 0.2059 0.0295 0.6785
rs111736238 T G 100.00 100.00 0.0000 0.0294 1.0000 0.9006
rs114570814 A G 100.00 100.00 0.0000 0.0000 1.0000 1.0000
rs116734533 T C 100.00 100.00 0.0000 0.0000 1.0000 1.0000
rs78306404 T C 95.24 100.00 0.0000 0.0000 1.0000 1.0000
rs111577081 T C 100.00 100.00 0.0238 0.0588 0.9110 0.7966
rs117279260 T C 100.00 100.00 0.0000 0.0294 1.0000 0.9006
rs117407497 A G 100.00 100.00 0.0000 0.0000 1.0000 1.0000
rs2666826 T C 100.00 100.00 0.2143 0.3235 0.9631 0.3877
rs2297775 T C 100.00 100.00 0.3095 0.2059 0.3130 0.2851
rs10153859 A G 100.00 100.00 0.0238 0.0294 0.9110 0.9006
rs17597643 A G 100.00 100.00 0.0238 0.0294 0.9110 0.9006
rs58584712 A G 100.00 100.00 0.1905 0.1765 0.0015 0.4322
rs78504459 T C 100.00 100.00 0.0238 0.0000 0.9110 1.0000
rs150028933 - A 100.00 100.00 0.0714 0.0000 0.0033 1.0000



















Table 6.13 Attributes of SNPs associated with KCNJ11 for participants in the lowest (Q1) and highest (Q4) quartiles for HbA1c among 
those receiving sulphonylurea therapy. 
 
101 unique SNPs associated with KCNJ11 were identified. SNP call rate is given as a percentage of total participants. MAF, Minor Allele 
Frequency; H.W. P value, Hardy-Weinberg P value. 
dbSNP	RS	ID A	allele B	allele Q1 Q4 Q1 Q4 Q1 Q4
rs1030986 T C 100 100 0.0238 0.0000 0.9110 1.0000
rs16875779 A G 100 100 0.1667 0.1765 0.3594 0.4322
rs17062197 A G 100 100 0.1429 0.1471 0.4450 0.4772
rs2517646 T C 100 100 0.2619 0.3235 0.0783 0.3877
rs2607614 T C 100 100 0.0238 0.0000 0.9110 1.0000
rs33949518 T C 95.24 100 0.2250 0.2941 0.9872 0.5363
rs34505188 A G 100 100 0.0714 0.0294 0.7245 0.9006
rs35978505 T C 100 100 0.0000 0.0588 1.0000 0.7966
rs369738 T G 100 100 0.0476 0.0000 0.8188 1.0000
rs3815082 A G 100 100 0.3571 0.2353 0.2091 0.2046
rs2849089 T C 95.24 100 0.0000 0.0000 1.0000 1.0000
rs4479449 A G 100 100 0.0714 0.1471 0.7245 0.4772
rs454748 A G 100 100 0.2619 0.5000 0.5276 0.4669
rs683687 A G 100 100 0.0714 0.1176 0.0033 0.5825
rs683866 T G 100 100 0.4286 0.4706 0.0980 0.8188
rs6919617 A G 100 100 0.0476 0.0882 0.8188 0.6899
rs7431770 A G 100 100 0.0476 0.1176 0.8188 0.5825
rs757260 T C 100 100 0.1905 0.1176 0.2809 0.5825
rs920829 T C 100 100 0.1190 0.1765 0.5357 0.3770
rs9261151 A G 100 100 0.0238 0.0294 0.9110 0.9006
rs9261216 A G 100 100 0.0476 0.0882 0.8188 0.6899
rs9261302 A G 100 100 0.0476 0.0882 0.8188 0.6899
rs9261471 T C 100 100 0.3095 0.2059 0.3130 0.2851
rs9268135 A G 95.24 94.12 0.3000 0.2500 0.2013 1.0000
rs9366752 T C 100 100 0.1667 0.1471 0.0260 0.4772
rs9811423 C G 100 100 0.4524 0.3824 0.7932 0.1198
rs1693703 T C 100 100 0.1905 0.2941 0.0797 0.5363



















Table 6.13 Attributes of SNPs associated with KCNJ11 for participants in the lowest (Q1) and highest (Q4) quartiles for HbA1c among 
those receiving sulphonylurea therapy (continued) 
 
101 unique SNPs associated with KCNJ11 were identified. SNP call rate is given as a percentage of total participants. MAF, Minor Allele 
Frequency; H.W. P value, Hardy-Weinberg P value. 
dbSNP	RS	ID A	allele B	allele Q1 Q4 Q1 Q4 Q1 Q4
rs76592289 A G 100 100 0.0714 0.0294 0.7245 0.9006
rs76557252 T G 100 100 0.0000 0.0000 1.0000 1.0000
rs506757 T G 100 100 0.3810 0.4412 0.0581 0.0962
rs62166939 A C 95.24 100 0.2250 0.1765 0.1942 0.3770
rs78082945 T C 100 100 0.0476 0.0588 0.8188 0.7966
rs62272114 A G 100 100 0.0238 0.0000 0.9110 1.0000
rs112288451 T C 100 100 0.0000 0.0294 1.0000 0.9006
rs74806059 T C 100 100 0.0000 0.0000 1.0000 1.0000
rs79876945 A G 100 100 0.0476 0.0588 0.8188 0.7966
rs114687906 A C 100 100 0.0714 0.0000 0.7245 1.0000
rs115477611 T C 100 100 0.0000 0.0000 1.0000 1.0000
rs78771971 T C 100 100 0.0000 0.0000 1.0000 1.0000
rs78854530 A G 100 100 0.0000 0.0294 1.0000 0.9006
rs62503295 T C 100 100 0.0714 0.0294 0.7245 0.9006
rs114756881 T C 95.24 82.35 0.0750 0.1429 0.7169 0.5329
rs4498896 T C 100 100 0.4048 0.3529 0.1920 0.2352
rs79035182 T G 100 100 0.0000 0.0294 1.0000 0.9006
rs74898314 A G 100 100 0.0238 0.0000 0.9110 1.0000
rs28445507 A C 100 100 0.2143 0.2647 0.2114 0.3135
rs55851518 A G 100 100 0.0714 0.0588 0.7245 0.7966
rs79263726 A C 100 100 0.0000 0.0294 1.0000 0.9006
rs10898365 T G 100 100 0.2619 0.2353 0.5276 0.9368
rs66546253 A G 100 94.12 0.1429 0.2188 0.3085 0.0710
rs783307 T C 100 100 0.1190 0.1176 0.5357 0.5825
rs17734780 T C 100 100 0.0000 0.0000 1.0000 1.0000
rs10432095 A C 100 100 0.1190 0.0882 0.5357 0.6899
rs75107770 A G 100 100 0.0000 0.0882 1.0000 0.6899



















Table 6.13 Attributes of SNPs associated with KCNJ11 for participants in the lowest (Q1) and highest (Q4) quartiles for HbA1c among 
those receiving sulphonylurea therapy (continued) 
 
101 unique SNPs associated with KCNJ11 were identified. SNP call rate is given as a percentage of total participants. MAF, Minor Allele 
Frequency; H.W. P value, Hardy-Weinberg P value. 
dbSNP	RS	ID A	allele B	allele Q1 Q4 Q1 Q4 Q1 Q4
rs60400172 T G 100 100 0.0714 0.0882 0.0033 0.0089
rs76451747 A C 100 100 0.0000 0.0000 1.0000 1.0000
rs12520495 A G 100 100 0.3095 0.2353 0.9903 0.2046
rs13183249 A G 100 100 0.1905 0.2941 0.0797 0.0858
rs72725509 T C 100 100 0.0000 0.0294 1.0000 0.9006
rs80184435 A G 100 100 0.0238 0.0588 0.9110 0.7966
rs62404592 A C 100 94.12 0.0238 0.0000 0.9110 1.0000
rs117910348 A C 100 100 0.0000 0.0294 1.0000 0.9006
rs79853069 A G 95.24 100 0.0750 0.0882 0.7169 0.6899
rs71521249 A G 100 100 0.0238 0.0000 0.9110 1.0000
rs114234140 A G 100 100 0.0000 0.0000 1.0000 1.0000
rs114249268 A G 100 100 0.0476 0.0588 0.8188 0.0000
rs112623189 A G 100 100 0.0238 0.0882 0.9110 0.6899
rs115010323 T C 100 100 0.0000 0.0294 1.0000 0.9006
rs116250326 T C 100 100 0.0000 0.0000 1.0000 1.0000
rs77111308 T C 100 100 0.0000 0.0588 1.0000 0.7966
rs77823977 T C 100 100 0.0476 0.0000 0.8188 1.0000
rs78374474 T C 100 100 0.0238 0.0000 0.9110 1.0000
rs192657690 T C 100 100 0.0238 0.0000 0.9110 1.0000
rs116983235 T C 100 100 0.0238 0.0000 0.9110 1.0000
rs10846754 A G 100 100 0.1429 0.2353 0.3085 0.2046
rs576184 A C 100 100 0.4048 0.4706 0.6123 0.8188
rs16951460 A G 100 100 0.0238 0.0000 0.9110 1.0000
rs3748592 A G 100 100 0.0714 0.0588 0.7245 0.7966
rs2096376 T C 100 100 0.4762 0.2353 0.2787 0.1535
rs32555 A G 100 100 0.1905 0.1471 0.7362 0.4772






Table 6.13 Attributes of SNPs associated with KCNJ11 for participants in the lowest (Q1) and highest (Q4) quartiles for HbA1c among 
those receiving sulphonylurea therapy (final) 
 
101 unique SNPs associated with KCNJ11 were identified. SNP call rate is given as a percentage of total participants. MAF, Minor Allele 
Frequency; H.W. P value, Hardy-Weinberg P value. 
dbSNP	RS	ID A	allele B	allele Q1 Q4 Q1 Q4 Q1 Q4
rs28400886 A G 100 100 0.0476 0.0000 0.8188 1.0000
rs4959042 T C 100 100 0.0000 0.0000 1.0000 1.0000
rs34704616 A G 100 100 0.0000 0.0000 1.0000 1.0000
rs1573298 C G 100 100 0.3333 0.2353 0.1017 0.2046
rs397596 T C 100 100 0.0000 0.0000 1.0000 1.0000
rs139080520 A G 100 100 0.0000 0.0000 1.0000 1.0000
rs13268757 A G 100 100 0.1429 0.2647 0.4450 0.3135
rs114814001 T C 100 100 0.0476 0.0294 0.8188 0.9006
rs79765628 T C 100 100 0.0000 0.0000 1.0000 1.0000
rs117389196 T C 100 100 0.0476 0.0000 0.8188 1.0000
rs141834826 A G 100 100 0.0000 0.0000 1.0000 1.0000
rs201447432 T C 100 100 0.0238 0.0000 0.9110 1.0000
rs146548891 T G 100 100 0.0000 0.0000 1.0000 1.0000
rs142720326 A G 100 100 0.0238 0.0000 0.9110 1.0000
rs201960928 A G 100 100 0.0000 0.0000 1.0000 1.0000
rs139889337 A G 100 100 0.0238 0.0000 0.9110 1.0000
rs113993403 T C 100 100 0.0238 0.0294 0.9110 0.9006



















Table 6.14 Attributes of SNPs associated with KCNQ1 for participants in the lowest (Q1) and highest (Q4) quartiles for HbA1c among 
those receiving sulphonylurea therapy. 
 
68 unique SNPs associated with KCNQ1 were identified. SNP call rate is given as a percentage of total participants. MAF, Minor Allele 
Frequency; H.W. P value, Hardy-Weinberg P value. 
dbSNP	RS	ID A	allele B	allele Q1 Q4 Q1 Q4 Q1 Q4
rs16841998 T C 90.48 88.24 0.0263 0.1667 0.9062 0.4386
rs17461843 T C 95.24 100.00 0.1000 0.0000 0.6193 1.0000
rs17571372 T C 100 100.00 0.0714 0.0588 0.0033 0.7966
T G 100 100.00 0.0000 0.0000 1.0000 1.0000
rs3006968 A G 100 100.00 0.5000 0.4412 0.5127 0.4965
rs6039591 A G 100 100.00 0.0000 0.0588 1.0000 0.7966
rs6883010 A G 100 100.00 0.4524 0.4118 0.7932 0.9062
rs6133707 A G 100 100.00 0.2619 0.1471 0.6190 0.4772
rs77707280 A G 100 100.00 0.0952 0.0294 0.0404 0.9006
rs807936 T C 100 100.00 0.4762 0.4118 0.2787 0.0595
rs114348392 T G 100 100.00 0.0238 0.0000 0.9110 1.0000
rs9356928 A G 100 100.00 0.4048 0.4412 0.1578 0.7613
rs9460973 A T 100 100.00 0.0238 0.0588 0.9110 0.7966
rs58554303 T C 100 100.00 0.0476 0.0294 0.8188 0.9006
rs920628 A G 100 100.00 0.0476 0.0882 0.8188 0.0089
rs16873732 T C 100 100.00 0.0476 0.0882 0.8188 0.0089
rs1041791 T C 100 100.00 0.1429 0.1765 0.4450 0.3770
rs61741363 A G 100 100.00 0.0000 0.0000 1.0000 1.0000
rs113319303 A G 100 100.00 0.0238 0.0588 0.9110 0.7966
rs116581086 A G 100 100.00 0.0238 0.0000 0.9110 1.0000
rs74745471 A G 100 100.00 0.0476 0.0294 0.8188 0.9006
rs61936141 T C 100 100.00 0.0000 0.0294 1.0000 0.9006
rs79090092 A G 100 100.00 0.0238 0.0294 0.9110 0.9006
rs10905750 A C 100 100.00 0.0238 0.0294 0.9110 0.9006
rs231847 A G 100 100.00 0.4048 0.3824 0.6899 0.1272
rs129072 T C 95.24 100.00 0.1000 0.1765 0.0469 0.3770
rs75898263 T C 100 100.00 0.0000 0.0000 1.0000 1.0000



















Table 6.14 Attributes of SNPs associated with KCNQ1 for participants in the lowest (Q1) and highest (Q4) quartiles for HbA1c among 
those receiving sulphonylurea therapy (continued) 
 
68 unique SNPs associated with KCNQ1 were identified. SNP call rate is given as a percentage of total participants. MAF, Minor Allele 
Frequency; H.W. P value, Hardy-Weinberg P value. 
dbSNP	RS	ID A	allele B	allele Q1 Q4 Q1 Q4 Q1 Q4
rs75875515 A G 100 100.00 0.0000 0.0000 1.0000 1.0000
rs7156987 T C 95.24 100.00 0.0000 0.0588 1.0000 0.7966
rs55767542 T C 100 100.00 0.0238 0.0000 0.9110 1.0000
rs35162844 A G 100 100.00 0.0476 0.0000 0.8188 1.0000
rs73063633 T G 100 100.00 0.0476 0.0294 0.8188 0.9006
rs116045044 T G 100 100.00 0.0714 0.0588 0.7245 0.7966
rs77692939 A G 95.24 100.00 0.0000 0.0294 1.0000 0.9006
rs72811968 T C 100 100.00 0.0238 0.0588 0.9110 0.7966
rs76238538 T C 100 100.00 0.0238 0.0882 0.9110 0.6899
rs79931282 A G 100 100.00 0.0476 0.0000 0.8188 1.0000
rs9467059 A G 100 100.00 0.0238 0.0588 0.9110 0.7966
rs188539852 T C 100 100.00 0.0000 0.0000 1.0000 1.0000
rs115704940 T C 100 100.00 0.0238 0.0000 0.9110 1.0000
rs116858972 T C 100 100.00 0.0238 0.0588 0.9110 0.7966
rs117103115 A G 90.48 94.12 0.0526 0.0625 0.8087 0.7897
rs77936291 A G 100 100.00 0.0238 0.0294 0.9110 0.9006
rs79947987 T C 100 100.00 0.0000 0.0000 1.0000 1.0000
rs78468689 A G 100 100.00 0.0714 0.0000 0.7245 1.0000
rs80140016 T G 100 100.00 0.0476 0.0588 0.8188 0.7966
rs75894327 A G 100 100.00 0.0238 0.0588 0.9110 0.7966
rs114351051 T C 100 94.12 0.0952 0.0938 0.6295 0.6790
rs115005266 T C 100 100.00 0.0476 0.0588 0.8188 0.7966
rs112214748 A G 100 100.00 0.0714 0.0000 0.7245 1.0000
rs7119884 A G 100 100.00 0.0476 0.0294 0.8188 0.9006
rs6057010 A G 100 100.00 0.0476 0.0588 0.8188 0.7966
rs4690087 A G 100 100.00 0.0238 0.0294 0.9110 0.9006
rs11754464 T C 100 100.00 0.0000 0.0000 1.0000 1.0000



















Table 6.14 Attributes of SNPs associated with KCNQ1 for participants in the lowest (Q1) and highest (Q4) quartiles for HbA1c among 
those receiving sulphonylurea therapy (final) 
 
68 unique SNPs associated with KCNQ1 were identified. SNP call rate is given as a percentage of total participants. MAF, Minor Allele 
Frequency; H.W. P value, Hardy-Weinberg P value. 
dbSNP	RS	ID A	allele B	allele Q1 Q4 Q1 Q4 Q1 Q4
rs35185125 A C 100 100.00 0.0000 0.0000 1.0000 1.0000
rs28381355 A G 100 100.00 0.0000 0.0000 1.0000 1.0000
rs183314661 A C 100 100.00 0.0238 0.0294 0.9110 0.9006
rs77320475 A G 100 100.00 0.0000 0.0882 1.0000 0.6899
rs17812699 A G 100 100.00 0.1429 0.0588 0.4450 0.7966
rs199853687 A C 100 100.00 0.0000 0.0000 1.0000 1.0000
rs115491500 T C 100 100.00 0.0000 0.0000 1.0000 1.0000
rs11553182 T C 95.24 100.00 0.1000 0.0294 0.6193 0.9006
C G 100 100.00 0.0000 0.0000 1.0000 1.0000
rs341047 A G 100 100.00 0.0952 0.0588 0.6295 0.7966
rs150934987 A G 100 100.00 0.0000 0.0000 1.0000 1.0000



















Table 6.15 Attributes of SNPs associated with HNF1α for participants in the lowest (Q1) and highest (Q4) quartiles for HbA1c among 
those receiving sulphonylurea therapy. 
 
38 unique SNPs associated with HNF1α were identified. SNP call rate is given as a percentage of total participants. MAF, Minor Allele 
Frequency; H.W. P value, Hardy-Weinberg P value. 
 
dbSNP	RS	ID A	allele B	allele Q1 Q4 Q1 Q4 Q1 Q4
rs11755881 A G 100.00 100.00 0.0714 0.0588 0.7245 0.7966
rs1861 A C 100.00 100.00 0.0238 0.0294 0.9110 0.9006
rs28568667 T C 90.48 88.24 0.0789 0.1333 0.7087 0.5513
rs4770748 A G 100.00 100.00 0.0476 0.0294 0.8188 0.9006
rs663824 A G 100.00 100.00 0.3333 0.3824 0.5127 0.0107
rs6905159 A G 100.00 100.00 0.4762 0.3824 0.1232 0.1272
rs888576 T C 100.00 100.00 0.1667 0.1176 0.3594 0.5825
rs13325508 T C 100.00 100.00 0.0000 0.0294 1.0000 0.9006
rs55723035 T C 100.00 100.00 0.0000 0.0588 1.0000 0.7966
rs77356515 T G 100.00 100.00 0.0000 0.0294 1.0000 0.9006
rs75363174 A G 100.00 100.00 0.0238 0.0882 0.9110 0.6899
rs4751674 T C 100.00 100.00 0.3810 0.3529 0.9649 0.3487
rs61433965 A G 100.00 100.00 0.0714 0.0000 0.7245 1.0000
rs58838391 A G 100.00 100.00 0.0000 0.0000 1.0000 1.0000
rs76280424 A G 100.00 100.00 0.0000 0.0000 1.0000 1.0000
rs77794667 T C 100.00 100.00 0.0238 0.0000 0.9110 1.0000
rs59559871 T C 100.00 100.00 0.0000 0.0000 1.0000 1.0000
rs72826927 A G 100.00 100.00 0.0714 0.0882 0.7245 0.6899
rs945094 A T 100.00 100.00 0.0238 0.0000 0.9110 1.0000
rs72751116 A G 100.00 100.00 0.0000 0.0000 1.0000 1.0000
rs59706474 T C 100.00 100.00 0.0238 0.0294 0.9110 0.9006
rs73251982 A G 100.00 100.00 0.0000 0.0000 1.0000 1.0000
rs72489176 A G 100.00 100.00 0.1667 0.2353 0.0260 0.1535
rs77367389 A C 95.24 100.00 0.0250 0.0000 0.9087 1.0000
rs73668591 T C 100.00 100.00 0.0000 0.0294 1.0000 0.9006
rs73669423 T C 100.00 100.00 0.0952 0.0588 0.6295 0.7966
rs62493228 A C 100.00 100.00 0.0714 0.0294 0.7245 0.9006


















Table 6.15 Attributes of SNPs associated with HNF1α for participants in the lowest (Q1) and highest (Q4) quartiles for HbA1c among 
those receiving sulphonylurea therapy (final) 
 
38 unique SNPs associated with HNF1α were identified. SNP call rate is given as a percentage of total participants. MAF, Minor Allele 
Frequency; H.W. P value, Hardy-Weinberg P value. 
 
dbSNP	RS	ID A	allele B	allele Q1 Q4 Q1 Q4 Q1 Q4
rs80312260 A G 100.00 100.00 0.0000 0.0294 1.0000 0.9006
rs2244608 A G 100.00 100.00 0.1667 0.4118 0.3594 0.3770
rs11616995 A G 100.00 100.00 0.0476 0.0000 0.8188 1.0000
rs11647932 T C 100.00 100.00 0.0476 0.1471 0.8188 0.4772
rs8102561 T C 100.00 100.00 0.3571 0.1176 0.5190 0.5825
rs340141 T C 100.00 100.00 0.2857 0.4412 0.0668 0.1979
rs150333766 T C 100.00 100.00 0.0000 0.0000 1.0000 1.0000
rs189023122 T C 100.00 100.00 0.0000 0.0000 1.0000 1.0000
rs150428096 T C 100.00 100.00 0.0000 0.0000 1.0000 1.0000



















Table 6.16 Attributes of SNPs associated with TCF7L2 for participants in the lowest (Q1) and highest (Q4) quartiles for HbA1c among 
those receiving sulphonylurea therapy. 
 
44 unique SNPs associated with TCF7L2 were identified. SNP call rate is given as a percentage of total participants. MAF, Minor Allele 
Frequency; H.W. P value, Hardy-Weinberg P value. 
dbSNP	RS	ID A	allele B	allele Q1 Q4 Q1 Q4 Q1 Q4
rs12894204 A G 100.00 100.00 0.1190 0.2059 0.5357 0.6785
rs17605420 A G 95.24 100.00 0.0250 0.0000 0.9087 1.0000
rs17763253 T C 100.00 100.00 0.0714 0.0294 0.7245 0.9006
rs6728493 A C 100.00 100.00 0.3095 0.2059 0.0400 0.6785
rs9906935 A G 100.00 100.00 0.2619 0.2941 0.5276 0.5363
rs7089262 T C 100.00 100.00 0.0714 0.0588 0.7245 0.7966
rs76677854 T C 100.00 100.00 0.0714 0.0294 0.7245 0.9006
rs145079521 A C 100.00 100.00 0.0476 0.0000 0.8188 1.0000
rs78082945 T C 100.00 100.00 0.0476 0.0588 0.8188 0.7966
rs62272114 A G 100.00 100.00 0.0238 0.0000 0.9110 1.0000
rs77385406 A G 100.00 100.00 0.0000 0.0882 1.0000 0.6899
rs61732118 A G 100.00 100.00 0.0000 0.0000 1.0000 1.0000
rs61875109 A C 100.00 100.00 0.2619 0.2647 0.0783 0.8117
rs116369954 T C 100.00 100.00 0.0952 0.0588 0.6295 0.7966
rs79805154 A G 100.00 100.00 0.0714 0.0588 0.7245 0.7966
rs77064952 A G 100.00 100.00 0.0000 0.0000 1.0000 1.0000
rs10059523 A G 100.00 100.00 0.0714 0.0294 0.7245 0.9006
rs78183526 T C 100.00 100.00 0.0000 0.0000 1.0000 1.0000
rs587667473 A C 95.24 100.00 0.1750 0.1471 0.3428 0.4772
rs73179006 T G 100.00 100.00 0.0714 0.0294 0.7245 0.9006
rs113262704 T G 100.00 100.00 0.0952 0.0588 0.6295 0.7966
rs61989114 A G 100.00 100.00 0.0000 0.0294 1.0000 0.9006
rs55656505 T C 100.00 100.00 0.0476 0.0588 0.8188 0.7966
rs4783943 A G 100.00 100.00 0.3333 0.2941 0.5127 0.0858
rs3026084 A G 100.00 100.00 0.0476 0.0294 0.8188 0.9006
rs189314829 A G 100.00 100.00 0.0476 0.0588 0.8188 0.7966
rs75107770 A G 100.00 100.00 0.0000 0.0882 1.0000 0.6899



















Table 6.16 Attributes of SNPs associated with TCF7L2 for participants in the lowest (Q1) and highest (Q4) quartiles for HbA1c among 
those receiving sulphonylurea therapy (final) 
 
44 unique SNPs associated with TCF7L2 were identified. SNP call rate is given as a percentage of total participants. MAF, Minor Allele 
Frequency; H.W. P value, Hardy-Weinberg P value. 
dbSNP	RS	ID A	allele B	allele Q1 Q4 Q1 Q4 Q1 Q4
rs116929578 A G 95.24 94.12 0.0500 0.0938 0.8139 0.6790
rs117041486 A G 100.00 100.00 0.0000 0.0294 1.0000 0.9006
rs79565172 A G 100.00 100.00 0.0000 0.0000 1.0000 1.0000
rs117582734 T C 100.00 100.00 0.0714 0.0294 0.7245 0.9006
rs12243326 T C 100.00 100.00 0.2857 0.5000 0.7600 0.8084
rs4889830 A G 100.00 100.00 0.4048 0.5000 0.6899 0.0896
rs3787493 A G 100.00 100.00 0.4762 0.3824 0.2787 0.5971
rs4713505 T G 100.00 100.00 0.2857 0.2647 0.7600 0.8117
rs2070600 T C 100.00 100.00 0.0952 0.1176 0.6295 0.5825
rs3131300 A G 100.00 100.00 0.2381 0.2941 0.3302 0.0740
rs73471190 T C 100.00 100.00 0.0000 0.0294 1.0000 0.9006
rs148924158 A G 100.00 100.00 0.0000 0.0000 1.0000 1.0000
rs143828311 T C 100.00 100.00 0.0000 0.0000 1.0000 1.0000
rs201967398 A G 100.00 100.00 0.0000 0.0000 1.0000 1.0000
rs143652701 T C 100.00 100.00 0.0000 0.0000 1.0000 1.0000
rs142236510 T C 100.00 100.00 0.0000 0.0588 1.0000 0.7966
SNP	call	rate	(%) MAF H.W.	P	value
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Within the sulphonylurea group, the AB genotype of rs17743658 
associated with ABCC8 was observed at a significantly higher rate in Q4 
(19.05% Q1 versus 64.71% Q4, P=0.011, 95% CI -0.792, -0.121, OR 0.0128; 
Table 6.17). However, this trend was not observed in the non-
sulphonylurea group (39.15% Q1 versus 50.0% Q4, P=0.471) suggesting 
that this variant may have utility in prediction of good glycaemic control 
in those receiving sulphonylurea therapy. However, this clearly requires 
further validation. According to data available from the T2D Knowledge 
portal this SNP is significantly associated with height and although not 
significant, the direction of effect in relation to HbA1c was positive (i.e. 
associated with higher HbA1c).  
 
Within the sulphonylurea group, the AB genotype of rs506757 associated 
with KCNJ11 was observed at a significantly higher rate in Q1 (66.67% Q1 
versus 29.41% Q4, P=0.050, 95% CI 0.023, 0.722, OR 4.80; Table 6.18). This 
was not replicated in the non-sulphonylurea group (52.13% Q1 versus 
37.50% Q4, P=0.239). Data from the T2D knowledge portal suggest an 
association of rs506757 with systolic blood pressure. Staying with SNPs 
associated with KCNJ11, the AB genotype of rs13183249 was more 
prevalent in Q4 (19.05% Q1 versus 58.82% Q4, P=0.029, 95% CI -0.739, - 
0.057, OR 0.165, Table 6.18). The AB genotype of rs13183249 was not 
observed in the non-sulphonylurea group where only the AB genotype 
was observed.  
 
The AB genotype of rs663824, which is associated with HNF1α was more 
commonly observed in Q4 of the sulphonylurea group (38.10% Q1 versus 
76.47% Q4, P=0.042, 95% CI -0.726, -0.041, OR 0.189 Table 6.20), this SNP is 
associated with BMI, triglycerides and bipolar disorder according to data 
from the T2D knowledge portal. The AA genotype of rs2244608 was more 
common in Q1 of the sulphonylurea group (66.67% Q1 versus 29.41% Q4, 
P=0.050, 95% CI 0.023, 0.722, OR 4.80; Table 6.20), this SNP is also 
significantly associated with a number of phenotype’s according to the 
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T2D Knowledge portal including T2DM, HDL, LDL, Cholesterol, coronary 
artery disease, corrected insulin response, proinsulin, fasting insulin, two 
hour glucose, eGFR-cys, insulin at 30 min OGTT and the disposition index. 
Finally, within the sulphonylurea group, the AA genotype of rs8102561 
was observed more frequently in Q4 (38.10% Q1 versus 76.47% Q4, 
P=0.042, 95% CI -0.726, -0.041, OR 0.189, Table 6.20), and after consulting 
the T2D knowledge portal was shown to be significantly associated with 
HOMA IR and modified Stumvoll insulin sensitivity index. There was no 
significant difference in the prevalence of any of these variants in the 
non-sulphonylurea group, again suggesting that these variants may 
have utility in the prediction of good glycaemic control for individuals 
receiving sulphonylureas.  
 
Significant differences in the genotypes of those in Q1 and Q4 were not 
observed for any variant associated with either KCNQ1 (Table 6.19), or 
TCF7L2 (Table 6.21), However, all other significant differences are 





Table 6.17 SNPs associated with ABCC8 
 
31 unique SNPs associated with ABCC8 were identified, and genotyped. Following a two-sample t-test for proportions, significant 







allele	(B) Q1 Q4 p-value Odds	Ratio Q1 Q4 p-value Odds	Ratio Q1 Q4 p-value Odds	Ratio
rs10961940 A G 76.19 76.47 1.000 -0.277 0.272 0.985 14.29 23.53 0.760 -0.397 0.212 0.542 4.76 0.00 1.000 -0.091 0.186 0.000
rs17743658 A G 14.29 5.88 0.746 -0.156 0.324 2.667 19.05 64.71 0.011 -0.792 -0.121 0.128 61.90 29.41 0.076 -0.028 0.678 3.900
rs3738591 C G 90.48 100.00 0.512 -0.274 0.084 0.000 9.52 0.00 0.512 -0.084 0.274 0.000 0.00 0.00 1.000 0.000 0.000 0.000
rs4741478 T G 85.71 88.24 1.000 -0.265 0.214 0.800 9.52 11.76 1.000 -0.243 0.198 0.789 4.76 0.00 1.000 -0.091 0.186 0.000
rs649224 A G 0.00 0.00 1.000 0.000 0.000 0.000 14.29 11.76 1.000 -0.214 0.265 1.250 85.71 88.24 1.000 -0.265 0.214 0.800
rs9458011 T C 0.00 0.00 1.000 0.000 0.000 0.000 19.05 17.65 1.000 -0.247 0.275 1.098 80.95 82.35 1.000 -0.275 0.247 0.911
rs8098346 T G 38.10 17.65 0.282 -0.124 0.533 2.872 38.10 29.41 0.826 -0.266 0.440 1.477 23.81 52.94 0.119 -0.644 0.061 0.278
rs75780075 A G 85.71 88.24 1.000 -0.265 0.214 0.800 14.29 11.76 1.000 -0.214 0.265 1.250 0.00 0.00 1.000 0.000 0.000 0.000
rs73017157 A G 0.00 0.00 1.000 0.000 0.000 0.000 9.52 0.00 0.512 -0.084 0.274 0.000 90.48 100.00 0.542 -0.274 0.084 0.000
rs11647027 A C 90.48 100.00 0.512 -0.274 0.084 0.000 9.52 0.00 0.512 -0.084 0.274 0.000 0.00 0.00 1.000 0.000 0.000 0.000
rs59409558 A C 90.48 100.00 0.512 -0.274 0.084 0.000 4.76 0.00 1.000 -0.091 0.186 0.000 0.00 0.00 1.000 0.000 0.000 0.000
rs11942387 A G 0.00 5.88 0.922 -0.224 0.106 0.000 61.90 64.71 1.000 -0.364 0.308 0.886 38.10 29.41 0.826 -0.266 0.440 1.477
rs62295555 T C 0.00 0.00 1.000 0.000 0.000 0.000 14.29 41.18 0.128 -0.600 0.062 0.238 85.71 58.82 0.128 -0.062 0.600 4.200
rs12548842 T C 23.81 17.65 0.949 -0.249 0.372 1.458 33.33 35.29 1.000 -0.343 0.304 0.917 42.86 47.06 1.000 -0.402 0.318 0.844
rs79345026 T C 4.76 0.00 1.000 -0.091 0.186 0.000 23.81 41.18 0.426 -0.523 0.176 0.446 71.43 58.82 0.638 -0.231 0.483 1.750
rs10961999 T C 14.29 5.88 0.746 -0.156 0.324 2.667 19.05 29.41 0.719 -0.431 0.224 0.565 66.67 64.71 1.000 -0.304 0.343 1.091
rs111736238 T G 100.00 94.12 0.922 -0.106 0.224 0.000 0.00 5.88 0.922 -0.224 0.106 0.000 0.00 0.00 1.000 0.000 0.000 0.000
rs114570814 A G 100.00 100.00 1.000 0.000 0.000 0.000 0.00 0.00 1.000 0.000 0.000 0.000 0.00 0.00 1.000 0.000 0.000 0.000
rs116734533 T C 100.00 100.00 1.000 0.000 0.000 0.000 0.00 0.00 1.000 0.000 0.000 0.000 0.00 0.00 1.000 0.000 0.000 0.000
rs78306404 T C 0.00 0.00 1.000 0.000 0.000 0.000 0.00 0.00 1.000 0.000 0.000 0.000 95.24 100.00 1.000 -0.186 0.091 0.000
rs111577081 T C 0.00 0.00 1.000 0.000 0.000 0.000 4.76 11.76 0.854 -0.301 0.161 0.375 95.24 88.24 0.854 -0.161 0.301 2.667
rs117279260 T C 0.00 0.00 1.000 0.000 0.000 0.000 0.00 5.88 0.922 -0.224 0.106 0.000 100.00 94.12 0.922 -0.106 0.224 0.000
rs117407497 A G 100.00 100.00 1.000 0.000 0.000 0.000 0.00 0.00 1.000 0.000 0.000 0.000 0.00 0.00 1.000 0.000 0.000 0.000
rs2666826 T C 61.90 41.18 0.335 -0.159 0.573 2.321 33.33 52.94 0.368 -0.561 0.169 0.444 4.76 5.88 1.000 -0.167 0.144 0.800
rs2297775 T C 52.38 58.82 0.945 -0.434 0.306 0.770 33.33 41.18 0.873 -0.440 0.284 0.714 14.29 0.00 0.240 -0.060 0.346 0.000
rs10153859 A G 0.00 0.00 1.000 0.000 0.000 0.000 4.76 5.88 1.000 -0.167 0.144 0.800 95.24 94.12 1.000 -0.144 0.167 1.250
rs17597643 A G 95.24 94.12 1.000 -0.144 0.167 1.250 4.76 5.88 1.000 -0.167 0.144 0.800 0.00 0.00 1.000 0.000 0.000 0.000
rs58584712 A G 14.29 5.88 0.746 -0.156 0.324 2.667 9.52 23.53 0.473 -0.431 0.151 0.342 76.19 70.59 0.985 -0.280 0.392 1.333
rs78504459 T C 95.24 100.00 1.000 -0.186 0.091 0.000 4.76 0.00 1.000 -0.091 0.186 0.000 0.00 0.00 1.000 0.000 0.000 0.000
rs150028933 - A 90.48 100.00 0.512 -0.274 0.084 0.000 4.76 0.00 1.000 -0.091 0.186 0.000 4.76 0.00 1.000 -0.091 0.186 0.000







Table 6.18 SNPs associated with KCNJ11 
 
101 unique SNPs associated with KCNJ11 were identified, and genotyped. Following a two-sample t-test for proportions, significant 









allele	(B) Q1 Q4 p-value Odds	Ratio Q1 Q4 p-value Odds	Ratio Q1 Q4 p-value Odds	Ratio
rs1030986 T C 0.00 0.00 1.000 0.000 0.000 0.000 4.76 0.00 1.000 -0.091 0.186 0.000 95.24 100.00 0.158 -0.186 0.091 0.000
rs16875779 A G 0.00 5.88 0.573 -0.224 0.106 0.000 33.33 23.53 0.494 -0.240 0.436 1.625 66.67 70.59 0.920 -0.374 0.296 0.833
rs17062197 A G 0.00 0.00 1.000 0.000 0.000 0.000 28.57 29.41 1.000 -0.307 0.290 0.960 71.43 70.59 1.000 -0.290 0.307 1.042
rs2517646 T C 61.90 41.18 0.128 -0.159 0.573 2.321 23.81 52.94 0.130 -0.644 0.061 0.278 14.29 5.88 0.340 -0.156 0.324 2.667
rs2607614 T C 0.00 0.00 1.000 0.000 0.000 0.000 4.76 0.00 1.000 -0.091 0.186 0.000 95.24 100.00 0.158 -0.186 0.091 0.000
rs33949518 T C 4.76 11.76 0.579 -0.301 0.161 0.375 33.33 35.29 1.000 -0.343 0.304 0.917 57.14 52.94 0.908 -0.318 0.402 1.185
rs34505188 A G 0.00 0.00 1.000 0.000 0.000 0.000 14.29 5.88 0.340 -0.156 0.324 2.667 85.71 94.12 0.340 -0.324 0.156 0.375
rs35978505 T C 100.00 88.24 0.229 -0.089 0.324 0.000 0.00 11.76 0.229 -0.324 0.089 0.000 0.00 0.00 1.000 0.000 0.000 0.000
rs369738 T G 90.48 100.00 0.530 -0.274 0.084 0.000 9.52 0.00 0.564 -0.084 0.274 0.000 0.00 0.00 1.000 0.000 0.000 0.000
rs3815082 A G 47.62 52.94 0.834 -0.426 0.319 0.808 33.33 47.06 0.358 -0.502 0.227 0.562 19.05 0.00 0.308 -0.031 0.412 0.000
rs2849089 T C 95.24 100.00 0.158 -0.186 0.091 0.000 0.00 0.00 1.000 0.000 0.000 0.000 0.00 0.00 1.000 0.000 0.000 0.000
rs4479449 A G 85.71 70.59 0.252 -0.165 0.468 2.500 14.29 29.41 0.252 -0.468 0.165 0.400 0.00 0.00 1.000 0.000 0.000 0.000
rs454748 A G 9.52 29.41 0.110 -0.502 0.105 0.253 33.33 41.18 0.667 -0.440 0.284 0.714 57.14 29.41 0.076 -0.079 0.633 3.200
rs683687 A G 4.76 0.00 1.000 -0.091 0.186 0.000 4.76 23.53 0.107 -0.462 0.087 0.163 90.48 76.47 0.261 -0.151 0.431 2.923
rs683866 T G 23.81 23.53 1.000 -0.272 0.277 1.016 66.67 47.06 0.158 -0.169 0.561 2.250 9.52 29.41 0.110 -0.502 0.105 0.253
rs6919617 A G 90.48 82.35 0.531 -0.192 0.355 2.036 9.52 17.65 0.554 -0.355 0.192 0.491 0.00 0.00 1.000 0.000 0.000 0.000
rs7431770 A G 0.00 0.00 1.000 0.000 0.000 0.000 9.52 23.53 0.261 -0.431 0.151 0.342 90.48 76.47 0.261 -0.151 0.431 2.923
rs757260 T C 0.00 0.00 1.000 0.000 0.000 0.000 38.10 23.53 0.251 -0.197 0.488 2.000 61.90 76.47 0.251 -0.488 0.197 0.500
rs920829 T C 0.00 0.00 1.000 0.000 0.000 0.000 23.81 35.29 0.444 -0.459 0.230 0.573 76.19 64.71 0.444 -0.230 0.459 1.745
rs9261151 A G 0.00 0.00 1.000 0.000 0.000 0.000 4.76 5.88 1.000 -0.167 0.144 0.800 95.24 94.12 1.000 -0.144 0.167 1.250
rs9261216 A G 90.48 82.35 0.531 -0.192 0.355 2.036 9.52 17.65 0.554 -0.355 0.192 0.491 0.00 0.00 1.000 0.000 0.000 0.000
rs9261302 A G 0.00 0.00 1.000 0.000 0.000 0.000 9.52 17.65 0.554 -0.355 0.192 0.491 90.48 82.35 0.554 -0.192 0.355 2.036
rs9261471 T C 52.38 58.82 0.758 -0.434 0.306 0.770 33.33 41.18 0.667 -0.440 0.284 0.714 14.29 0.00 0.308 -0.060 0.346 0.000
rs9268135 A G 52.38 52.94 1.000 -0.330 0.319 0.978 28.57 35.29 0.731 -0.419 0.284 0.733 14.29 5.88 0.340 -0.156 0.324 2.667








Table 6.18 SNPs associated with KCNJ11 (continued) 
 
101 unique SNPs associated with KCNJ11 were identified, and genotyped. Following a two-sample t-test for proportions, significant 









allele	(B) Q1 Q4 p-value Odds	Ratio Q1 Q4 p-value Odds	Ratio Q1 Q4 p-value Odds	Ratio
rs9811423 C G 28.57 47.06 0.186 -0.544 0.174 0.450 52.38 29.41 0.067 -0.128 0.587 2.640 19.05 23.53 0.869 -0.352 0.262 0.765
rs1693703 T C 71.43 52.94 0.186 -0.174 0.544 2.222 19.05 35.29 0.234 -0.498 0.173 0.431 9.52 11.76 1.000 -0.243 0.198 0.789
rs7841649 T C 0.00 0.00 1.000 0.000 0.000 0.000 0.00 5.88 0.573 -0.224 0.106 0.000 95.24 94.12 1.000 -0.144 0.167 1.250
rs76592289 A G 0.00 0.00 1.000 0.000 0.000 0.000 14.29 5.88 0.340 -0.156 0.324 2.667 85.71 94.12 0.340 -0.324 0.156 0.375
rs76557252 T G 0.00 0.00 1.000 0.000 0.000 0.000 0.00 0.00 1.000 0.000 0.000 0.000 100.00 100.00 1.000 0.000 0.000 0.000
rs506757 T G 28.57 41.18 0.402 -0.483 0.231 0.571 66.67 29.41 0.050 0.023 0.722 4.800 4.76 29.41 0.104 -0.535 0.042 0.120
rs62166939 A C 0.00 0.00 1.000 0.000 0.000 0.000 42.86 35.29 0.678 -0.288 0.439 1.375 52.38 64.71 0.406 -0.488 0.242 0.600
rs78082945 T C 90.48 88.24 1.000 -0.198 0.243 1.267 9.52 11.76 1.000 -0.243 0.198 0.789 0.00 0.00 1.000 0.000 0.000 0.000
rs62272114 A G 0.00 0.00 1.000 0.000 0.000 0.000 4.76 0.00 1.000 -0.091 0.186 0.000 95.24 100.00 0.158 -0.186 0.091 0.000
rs112288451 T C 100.00 94.12 0.573 -0.106 0.224 0.000 0.00 5.88 0.573 -0.224 0.106 0.000 0.00 0.00 1.000 0.000 0.000 0.000
rs74806059 T C 0.00 0.00 1.000 0.000 0.000 0.000 0.00 0.00 1.000 0.000 0.000 0.000 100.00 100.00 1.000 0.000 0.000 0.000
rs79876945 A G 0.00 0.00 1.000 0.000 0.000 0.000 9.52 11.76 1.000 -0.243 0.198 0.789 90.48 88.24 1.000 -0.198 0.243 1.267
rs114687906 A C 0.00 0.00 1.000 0.000 0.000 0.000 14.29 0.00 0.308 -0.060 0.346 0.000 85.71 100.00 0.308 -0.346 0.060 0.000
rs115477611 T C 0.00 0.00 1.000 0.000 0.000 0.000 0.00 0.00 1.000 0.000 0.000 0.000 100.00 100.00 1.000 0.000 0.000 0.000
rs78771971 T C 100.00 100.00 1.000 0.000 0.000 0.000 0.00 0.00 1.000 0.000 0.000 0.000 0.00 0.00 1.000 0.000 0.000 0.000
rs78854530 A G 0.00 0.00 1.000 0.000 0.000 0.000 0.00 5.88 0.573 -0.224 0.106 0.000 100.00 94.12 0.573 -0.106 0.224 0.000
rs62503295 T C 85.71 94.12 0.340 -0.324 0.156 0.375 14.29 5.88 0.340 -0.156 0.324 2.667 0.00 0.00 1.000 0.000 0.000 0.000
rs114756881 T C 80.95 58.82 0.097 -0.120 0.563 2.975 14.29 23.53 0.521 -0.397 0.212 0.542 0.00 0.00 1.000 0.000 0.000 0.000
rs4498896 T C 9.52 5.88 0.887 -0.168 0.241 1.684 61.90 58.82 0.983 -0.313 0.374 1.137 28.57 35.29 0.731 -0.419 0.284 0.733
rs79035182 T G 0.00 0.00 1.000 0.000 0.000 0.000 0.00 5.88 0.573 -0.224 0.106 0.000 100.00 94.12 0.573 -0.106 0.224 0.000







Table 6.18 SNPs associated with KCNJ11 (continued) 
 
101 unique SNPs associated with KCNJ11 were identified, and genotyped. Following a two-sample t-test for proportions, significant 







allele	(B) Q1 Q4 p-value Odds	Ratio Q1 Q4 p-value Odds	Ratio Q1 Q4 p-value Odds	Ratio
rs28445507 A C 0.00 11.76 0.229 -0.324 0.089 0.000 42.86 29.41 0.331 -0.222 0.491 1.800 57.14 58.82 1.000 -0.349 0.315 0.933
rs55851518 A G 0.00 0.00 1.000 0.000 0.000 0.000 14.29 11.76 1.000 -0.214 0.265 1.250 85.71 88.24 1.000 -0.265 0.214 0.800
rs79263726 A C 100.00 94.12 0.573 -0.106 0.224 0.000 0.00 5.88 0.573 -0.224 0.106 0.000 0.00 0.00 1.000 0.000 0.000 0.000
rs10898365 T G 9.52 5.88 0.890 -0.168 0.241 1.684 33.33 35.29 1.000 -0.343 0.304 0.917 57.14 58.82 1.000 -0.349 0.315 0.933
rs66546253 A G 4.76 11.76 0.579 -0.301 0.161 0.375 19.05 17.65 1.000 -0.247 0.275 1.098 76.19 64.71 0.444 -0.230 0.459 1.745
rs783307 T C 76.19 76.47 1.000 -0.277 0.272 0.985 23.81 23.53 1.000 -0.272 0.277 1.016 0.00 0.00 1.000 0.000 0.000 0.000
rs17734780 T C 0.00 0.00 1.000 0.000 0.000 0.000 0.00 0.00 1.000 0.000 0.000 0.000 100.00 100.00 1.000 0.000 0.000 0.000
rs10432095 A C 76.19 82.35 0.716 -0.372 0.249 0.686 23.81 17.65 0.716 -0.249 0.372 1.458 0.00 0.00 1.000 0.000 0.000 0.000
rs75107770 A G 0.00 0.00 1.000 0.000 0.000 0.000 0.00 17.65 0.093 -0.411 0.058 0.000 100.00 82.35 0.093 -0.058 0.411 0.000
rs13061963 T G 0.00 0.00 1.000 0.000 0.000 0.000 19.05 5.88 0.084 -0.123 0.387 3.765 80.95 94.12 0.084 -0.387 0.123 0.266
rs60400172 T G 4.76 5.88 1.000 -0.167 0.144 0.800 4.76 5.88 1.000 -0.167 0.144 0.800 90.48 88.24 1.000 -0.198 0.243 1.267
rs76451747 A C 0.00 0.00 1.000 0.000 0.000 0.000 0.00 0.00 1.000 0.000 0.000 0.000 100.00 100.00 1.000 0.000 0.000 0.000
rs12520495 A G 47.62 52.94 0.834 -0.426 0.319 0.808 42.86 47.06 0.908 -0.402 0.318 0.844 9.52 0.00 0.564 -0.084 0.274 0.000
rs13183249 A G 9.52 0.00 0.564 -0.084 0.274 0.000 19.05 58.82 0.029 -0.739 -0.057 0.165 71.43 41.18 0.126 -0.054 0.659 3.571
rs72725509 T C 0.00 0.00 1.000 0.000 0.000 0.000 0.00 5.88 0.573 -0.224 0.106 0.000 100.00 94.12 0.573 -0.106 0.224 0.000
rs80184435 A G 0.00 0.00 1.000 0.000 0.000 0.000 4.76 11.76 0.579 -0.301 0.161 0.375 95.24 88.24 0.579 -0.161 0.301 2.667
rs62404592 A C 0.00 0.00 1.000 0.000 0.000 0.000 4.76 0.00 1.000 -0.091 0.186 0.000 95.24 94.12 1.000 -0.144 0.167 1.250
rs117910348 A C 0.00 0.00 1.000 0.000 0.000 0.000 0.00 5.88 0.573 -0.224 0.106 0.000 100.00 94.12 0.573 -0.106 0.224 0.000
rs79853069 A G 80.95 82.35 1.000 -0.275 0.247 0.911 14.29 17.65 0.953 -0.302 0.235 0.778 0.00 0.00 1.000 0.000 0.000 0.000
rs71521249 A G 95.24 100.00 0.158 -0.186 0.091 0.000 4.76 0.00 1.000 -0.091 0.186 0.000 0.00 0.00 1.000 0.000 0.000 0.000
rs114234140 A G 0.00 0.00 1.000 0.000 0.000 0.000 0.00 0.00 1.000 0.000 0.000 0.000 100.00 100.00 1.000 0.000 0.000 0.000
rs114249268 A G 0.00 5.88 0.573 -0.224 0.106 0.000 9.52 0.00 0.564 -0.084 0.274 0.000 90.48 94.12 0.887 -0.241 0.168 0.594
rs112623189 A G 0.00 0.00 1.000 0.000 0.000 0.000 4.76 17.65 0.257 -0.385 0.127 0.233 95.24 82.35 0.257 -0.127 0.385 4.286
rs115010323 T C 0.00 0.00 1.000 0.000 0.000 0.000 0.00 5.88 0.573 -0.224 0.106 0.000 100.00 94.12 0.573 -0.106 0.224 0.000
rs116250326 T C 0.00 0.00 1.000 0.000 0.000 0.000 0.00 0.00 1.000 0.000 0.000 0.000 100.00 100.00 1.000 0.000 0.000 0.000
rs77111308 T C 0.00 0.00 1.000 0.000 0.000 0.000 0.00 11.76 0.229 -0.324 0.089 0.000 100.00 88.24 0.229 -0.089 0.324 0.000
rs77823977 T C 90.48 100.00 0.564 -0.274 0.084 0.000 9.52 0.00 0.564 -0.084 0.274 0.000 0.00 0.00 1.000 0.000 0.000 0.000
rs78374474 T C 0.00 0.00 1.000 0.000 0.000 0.000 4.76 0.00 1.000 -0.091 0.186 0.000 95.24 100.00 0.158 -0.186 0.091 0.000
rs192657690 T C 0.00 0.00 1.000 0.000 0.000 0.000 4.76 0.00 1.000 -0.091 0.186 0.000 95.24 100.00 0.158 -0.186 0.091 0.000







Table 6.18 SNPs associated with KCNJ11 (final) 
 
101 unique SNPs associated with KCNJ11 were identified, and genotyped. Following a two-sample t-test for proportions, significant 









allele	(B) Q1 Q4 p-value Odds	Ratio Q1 Q4 p-value Odds	Ratio Q1 Q4 p-value Odds	Ratio
rs10846754 A G 4.76 0.00 1.000 -0.091 0.186 0.000 19.05 47.06 0.135 -0.624 0.064 0.265 76.19 52.94 0.085 -0.120 0.585 2.844
rs576184 A C 19.05 23.53 0.869 -0.352 0.262 0.765 42.86 47.06 0.908 -0.402 0.318 0.844 38.10 29.41 0.591 -0.266 0.440 1.477
rs16951460 A G 95.24 100.00 0.158 -0.186 0.091 0.000 4.76 0.00 1.000 -0.091 0.186 0.000 0.00 0.00 1.000 0.000 0.000 0.000
rs3748592 A G 0.00 0.00 1.000 0.000 0.000 0.000 14.29 11.76 1.000 -0.214 0.265 1.250 85.71 88.24 1.000 -0.265 0.214 0.800
rs2096376 T C 33.33 64.71 0.115 -0.671 0.043 0.273 38.10 23.53 0.251 -0.197 0.488 2.000 28.57 11.76 0.080 -0.132 0.468 3.000
rs32555 A G 66.67 70.59 0.920 -0.374 0.296 0.833 28.57 29.41 1.000 -0.307 0.290 0.960 4.76 0.00 0.158 -0.091 0.186 0.000
rs9261089 T C 95.24 94.12 1.000 -0.144 0.167 1.250 4.76 5.88 1.000 -0.167 0.144 0.800 0.00 0.00 1.000 0.000 0.000 0.000
rs28400886 A G 0.00 0.00 1.000 0.000 0.000 0.000 9.52 0.00 0.564 -0.084 0.274 0.000 90.48 100.00 0.564 -0.274 0.084 0.000
rs4959042 T C 100.00 100.00 1.000 0.000 0.000 0.000 0.00 0.00 1.000 0.000 0.000 0.000 0.00 0.00 1.000 0.000 0.000 0.000
rs34704616 A G 0.00 0.00 1.000 0.000 0.000 0.000 0.00 0.00 1.000 0.000 0.000 0.000 100.00 100.00 1.000 0.000 0.000 0.000
rs1573298 C G 19.05 0.00 0.257 -0.031 0.412 0.000 28.57 47.06 0.186 -0.544 0.174 0.450 52.38 52.94 1.000 -0.330 0.319 0.978
rs397596 T C 100.00 100.00 1.000 0.000 0.000 0.000 0.00 0.00 1.000 0.000 0.000 0.000 0.00 0.00 1.000 0.000 0.000 0.000
rs139080520 A G 0.00 0.00 1.000 0.000 0.000 0.000 0.00 0.00 1.000 0.000 0.000 0.000 100.00 100.00 1.000 0.000 0.000 0.000
rs13268757 A G 0.00 11.76 0.229 -0.324 0.089 0.000 28.57 29.41 1.000 -0.307 0.290 0.960 71.43 58.82 0.402 -0.231 0.483 1.750
rs114814001 T C 0.00 0.00 1.000 0.000 0.000 0.000 9.52 5.88 0.887 -0.168 0.241 1.684 90.48 94.12 0.887 -0.241 0.168 0.594
rs79765628 T C 0.00 0.00 1.000 0.000 0.000 0.000 0.00 0.00 1.000 0.000 0.000 0.000 100.00 100.00 1.000 0.000 0.000 0.000
rs117389196 T C 0.00 0.00 1.000 0.000 0.000 0.000 9.52 0.00 0.564 -0.084 0.274 0.000 90.48 100.00 0.564 -0.274 0.084 0.000
rs141834826 A G 0.00 0.00 1.000 0.000 0.000 0.000 0.00 0.00 1.000 0.000 0.000 0.000 100.00 100.00 1.000 0.000 0.000 0.000
rs201447432 T C 0.00 0.00 1.000 0.000 0.000 0.000 4.76 0.00 1.000 -0.091 0.186 0.000 95.24 100.00 0.158 -0.186 0.091 0.000
rs146548891 T G 100.00 100.00 1.000 0.000 0.000 0.000 0.00 0.00 1.000 0.000 0.000 0.000 0.00 0.00 1.000 0.000 0.000 0.000
rs142720326 A G 0.00 0.00 1.000 0.000 0.000 0.000 4.76 0.00 1.000 -0.091 0.186 0.000 95.24 100.00 0.158 -0.186 0.091 0.000
rs201960928 A G 0.00 0.00 1.000 0.000 0.000 0.000 0.00 0.00 1.000 0.000 0.000 0.000 100.00 100.00 1.000 0.000 0.000 0.000
rs139889337 A G 0.00 0.00 1.000 0.000 0.000 0.000 4.76 0.00 1.000 -0.091 0.186 0.000 95.24 100.00 0.158 -0.186 0.091 0.000
rs113993403 T C 0.00 0.00 1.000 0.000 0.000 0.000 4.76 5.88 1.000 -0.167 0.144 0.800 95.24 94.12 1.000 -0.144 0.167 1.250








Table 6.19 SNPs associated with KCNQ1 
 
68 unique SNPs associated with KCNQ1 were identified, and genotyped. Following a two-sample t-test for proportions, significant 







allele	(B) Q1 Q4 p-value Odds	Ratio Q1 Q4 p-value Odds	Ratio Q1 Q4 p-value Odds	Ratio
rs16841998 T C 85.71 58.82 0.133 -0.062 0.600 4.200 4.76 29.41 0.104 -0.535 0.042 0.120 0.00 0.00 1.000 0.000 0.000 0.000
rs17461843 T C 76.19 100.00 0.094 -0.473 -0.003 0.000 19.05 0.00 0.170 -0.031 0.412 0.000 0.00 0.00 1.000 0.000 0.000 0.000
rs17571372 T C 4.76 0.00 1.000 -0.091 0.186 0.000 4.76 11.76 0.849 -0.301 0.161 0.375 90.48 88.24 1.000 -0.198 0.243 1.267
T G 0.00 0.00 1.000 0.000 0.000 0.000 0.00 0.00 1.000 0.000 0.000 0.000 100.00 100.00 1.000 0.000 0.000 0.000
rs3006968 A G 28.57 23.53 1.000 -0.279 0.380 1.300 42.86 41.18 1.000 -0.315 0.349 1.071 28.57 35.29 0.927 -0.419 0.284 0.733
rs6039591 A G 100.00 88.24 0.377 -0.089 0.324 0.000 0.00 11.76 0.377 -0.324 0.089 0.000 0.00 0.00 1.000 0.000 0.000 0.000
rs6883010 A G 19.05 17.65 1.000 -0.247 0.275 1.098 52.38 47.06 1.000 -0.319 0.426 1.238 28.57 35.29 0.927 -0.419 0.284 0.733
rs6133707 A G 52.38 70.59 0.431 -0.540 0.175 0.458 42.86 29.41 0.606 -0.222 0.491 1.800 4.76 0.00 1.000 -0.091 0.186 0.000
rs77707280 A G 4.76 0.00 1.000 -0.091 0.186 0.000 9.52 5.88 1.000 -0.168 0.241 1.684 85.71 94.12 0.758 -0.324 0.156 0.375
rs807936 T C 28.57 23.53 1.000 -0.279 0.380 1.300 38.10 70.59 0.095 -0.678 0.028 0.256 33.33 5.88 0.096 -0.009 0.558 8.000
rs114348392 T G 0.00 0.00 1.000 0.000 0.000 0.000 4.76 0.00 1.000 -0.091 0.186 0.000 95.24 100.00 1.000 -0.186 0.091 0.000
rs9356928 A G 23.81 29.41 0.985 -0.392 0.280 0.750 33.33 52.94 0.375 -0.561 0.169 0.444 42.86 17.65 0.190 -0.080 0.584 3.500
rs9460973 A T 0.00 0.00 1.000 0.000 0.000 0.000 4.76 11.76 0.849 -0.301 0.161 0.375 95.24 88.24 0.849 -0.161 0.301 2.667
rs58554303 T C 90.48 94.12 1.000 -0.241 0.168 0.594 9.52 5.88 1.000 -0.168 0.241 1.684 0.00 0.00 1.000 0.000 0.000 0.000
rs920628 A G 90.48 88.24 1.000 -0.198 0.243 1.267 9.52 5.88 1.000 -0.168 0.241 1.684 0.00 5.88 0.915 -0.224 0.106 0.000
rs16873732 T C 90.48 88.24 1.000 -0.198 0.243 1.267 9.52 5.88 1.000 -0.168 0.241 1.684 0.00 5.88 0.915 -0.224 0.106 0.000
rs1041791 T C 71.43 64.71 0.927 -0.284 0.419 1.364 28.57 35.29 0.927 -0.419 0.284 0.733 0.00 0.00 1.000 0.000 0.000 0.000
rs61741363 A G 100.00 100.00 1.000 0.000 0.000 0.000 0.00 0.00 1.000 0.000 0.000 0.000 0.00 0.00 1.000 0.000 0.000 0.000
rs113319303 A G 0.00 0.00 1.000 0.000 0.000 0.000 4.76 11.76 0.849 -0.301 0.161 0.375 95.24 88.24 0.849 -0.161 0.301 2.667
rs116581086 A G 0.00 0.00 1.000 0.000 0.000 0.000 4.76 0.00 1.000 -0.091 0.186 0.000 95.24 100.00 1.000 -0.186 0.091 0.000
rs74745471 A G 0.00 0.00 1.000 0.000 0.000 0.000 9.52 5.88 1.000 -0.168 0.241 1.684 90.48 94.12 1.000 -0.241 0.168 0.594
rs61936141 T C 100.00 94.12 0.915 -0.106 0.224 0.000 0.00 5.88 0.915 -0.224 0.106 0.000 0.00 0.00 1.000 0.000 0.000 0.000
rs79090092 A G 0.00 0.00 1.000 0.000 0.000 0.000 4.76 5.88 1.000 -0.167 0.144 0.800 95.24 94.12 1.000 -0.144 0.167 1.250
rs10905750 A C 0.00 0.00 1.000 0.000 0.000 0.000 4.76 5.88 1.000 -0.167 0.144 0.800 95.24 94.12 1.000 -0.144 0.167 1.250







Table 6.19 SNPs associated with KCNQ1 (continued) 
 
68 unique SNPs associated with KCNQ1 were identified, and genotyped. Following a two-sample t-test for proportions, significant 








allele	(B) Q1 Q4 p-value Odds	Ratio Q1 Q4 p-value Odds	Ratio Q1 Q4 p-value Odds	Ratio
rs129072 T C 4.76 0.00 1.000 -0.091 0.186 0.000 9.52 35.29 0.124 -0.570 0.055 0.193 80.95 64.71 0.447 -0.173 0.498 2.318
rs75898263 T C 0.00 0.00 1.000 0.000 0.000 0.000 0.00 0.00 1.000 0.000 0.000 0.000 100.00 100.00 1.000 0.000 0.000 0.000
rs111871569 A G 0.00 0.00 1.000 0.000 0.000 0.000 9.52 0.00 0.564 -0.084 0.274 0.000 85.71 100.00 0.308 -0.346 0.060 0.000
rs75875515 A G 0.00 0.00 1.000 0.000 0.000 0.000 0.00 0.00 1.000 0.000 0.000 0.000 100.00 100.00 1.000 0.000 0.000 0.000
rs7156987 T C 0.00 0.00 1.000 0.000 0.000 0.000 0.00 11.76 0.377 -0.324 0.089 0.000 95.24 88.24 0.849 -0.161 0.301 2.667
rs55767542 T C 0.00 0.00 1.000 0.000 0.000 0.000 4.76 0.00 1.000 -0.091 0.186 0.000 95.24 100.00 1.000 -0.186 0.091 0.000
rs35162844 A G 0.00 0.00 1.000 0.000 0.000 0.000 9.52 0.00 0.564 -0.084 0.274 0.000 90.48 100.00 0.564 -0.274 0.084 0.000
rs73063633 T G 90.48 94.12 1.000 -0.241 0.168 0.594 9.52 5.88 1.000 -0.168 0.241 1.684 0.00 0.00 1.000 0.000 0.000 0.000
rs116045044 T G 85.71 88.24 1.000 -0.265 0.214 0.800 14.29 11.76 1.000 -0.214 0.265 1.250 0.00 0.00 1.000 0.000 0.000 0.000
rs77692939 A G 95.24 94.12 1.000 -0.144 0.167 1.250 0.00 5.88 0.915 -0.224 0.106 0.000 0.00 0.00 1.000 0.000 0.000 0.000
rs72811968 T C 0.00 0.00 1.000 0.000 0.000 0.000 4.76 11.76 0.849 -0.301 0.161 0.375 95.24 88.24 0.849 -0.161 0.301 2.667
rs76238538 T C 95.24 82.35 0.450 -0.127 0.385 4.286 4.76 17.65 0.450 -0.385 0.127 0.233 0.00 0.00 1.000 0.000 0.000 0.000
rs79931282 A G 90.48 100.00 0.564 -0.274 0.084 0.000 9.52 0.00 0.564 -0.084 0.274 0.000 0.00 0.00 1.000 0.000 0.000 0.000
rs9467059 A G 95.24 88.24 0.849 -0.161 0.301 2.667 4.76 11.76 0.849 -0.301 0.161 0.375 0.00 0.00 1.000 0.000 0.000 0.000
rs188539852 T C 0.00 0.00 1.000 0.000 0.000 0.000 0.00 0.00 1.000 0.000 0.000 0.000 100.00 100.00 1.000 0.000 0.000 0.000
rs115704940 T C 0.00 0.00 1.000 0.000 0.000 0.000 4.76 0.00 1.000 -0.091 0.186 0.000 95.24 100.00 1.000 -0.186 0.091 0.000
rs116858972 T C 0.00 0.00 1.000 0.000 0.000 0.000 4.76 11.76 0.849 -0.301 0.161 0.375 95.24 88.24 0.849 -0.161 0.301 2.667
rs117103115 A G 80.95 82.35 1.000 -0.275 0.247 0.911 9.52 11.76 1.000 -0.243 0.198 0.789 0.00 0.00 1.000 0.000 0.000 0.000
rs77936291 A G 95.24 94.12 1.000 -0.144 0.167 1.250 4.76 5.88 1.000 -0.167 0.144 0.800 0.00 0.00 1.000 0.000 0.000 0.000
rs79947987 T C 100.00 100.00 1.000 0.000 0.000 0.000 0.00 0.00 1.000 0.000 0.000 0.000 0.00 0.00 1.000 0.000 0.000 0.000
rs78468689 A G 0.00 0.00 1.000 0.000 0.000 0.000 14.29 0.00 0.308 -0.060 0.346 0.000 85.71 100.00 0.308 -0.346 0.060 0.000
rs80140016 T G 0.00 0.00 1.000 0.000 0.000 0.000 9.52 11.76 1.000 -0.243 0.198 0.789 90.48 88.24 1.000 -0.198 0.243 1.267
rs75894327 A G 0.00 0.00 1.000 0.000 0.000 0.000 4.76 11.76 0.849 -0.301 0.161 0.375 95.24 88.24 0.849 -0.161 0.301 2.667
rs114351051 T C 80.95 76.47 1.000 -0.262 0.352 1.308 19.05 17.65 1.000 -0.247 0.275 1.098 0.00 0.00 1.000 0.000 0.000 0.000
rs115005266 T C 0.00 0.00 1.000 0.000 0.000 0.000 9.52 11.76 1.000 -0.243 0.198 0.789 90.48 88.24 1.000 -0.198 0.243 1.267










Table 6.19 SNPs associated with KCNQ1 (final) 
 
68 unique SNPs associated with KCNQ1 were identified, and genotyped. Following a two-sample t-test for proportions, significant 









allele	(B) Q1 Q4 p-value Odds	Ratio Q1 Q4 p-value Odds	Ratio Q1 Q4 p-value Odds	Ratio
rs7119884 A G 90.48 94.12 1.000 -0.241 0.168 0.594 9.52 5.88 1.000 -0.168 0.241 1.684 0.00 0.00 1.000 0.000 0.000 0.000
rs6057010 A G 90.48 88.24 1.000 -0.198 0.243 1.267 9.52 11.76 1.000 -0.243 0.198 0.789 0.00 0.00 1.000 0.000 0.000 0.000
rs4690087 A G 0.00 0.00 1.000 0.000 0.000 0.000 4.76 5.88 1.000 -0.167 0.144 0.800 95.24 94.12 1.000 -0.144 0.167 1.250
rs11754464 T C 0.00 0.00 1.000 0.000 0.000 0.000 0.00 0.00 1.000 0.000 0.000 0.000 100.00 100.00 1.000 0.000 0.000 0.000
rs707938 A G 47.62 41.18 0.945 -0.306 0.434 1.299 38.10 47.06 0.821 -0.458 0.279 0.692 14.29 5.88 0.758 -0.156 0.324 2.667
rs35185125 A C 0.00 0.00 1.000 0.000 0.000 0.000 0.00 0.00 1.000 0.000 0.000 0.000 100.00 100.00 1.000 0.000 0.000 0.000
rs28381355 A G 0.00 0.00 1.000 0.000 0.000 0.000 0.00 0.00 1.000 0.000 0.000 0.000 100.00 100.00 1.000 0.000 0.000 0.000
rs183314661 A C 0.00 0.00 1.000 0.000 0.000 0.000 4.76 5.88 1.000 -0.167 0.144 0.800 95.24 94.12 1.000 -0.144 0.167 1.250
rs77320475 A G 0.00 0.00 1.000 0.000 0.000 0.000 0.00 17.65 0.161 -0.411 0.058 0.000 100.00 82.35 0.308 -0.058 0.411 0.000
rs17812699 A G 0.00 0.00 1.000 0.000 0.000 0.000 28.57 11.76 0.388 -0.132 0.468 3.000 71.43 88.24 0.388 -0.468 0.132 0.333
rs199853687 A C 100.00 100.00 1.000 0.000 0.000 0.000 0.00 0.00 1.000 0.000 0.000 0.000 0.00 0.00 1.000 0.000 0.000 0.000
rs115491500 T C 0.00 0.00 1.000 0.000 0.000 0.000 0.00 0.00 1.000 0.000 0.000 0.000 100.00 100.00 1.000 0.000 0.000 0.000
rs11553182 T C 0.00 0.00 1.000 0.000 0.000 0.000 19.05 5.88 0.477 -0.123 0.387 3.765 76.19 94.12 0.388 -0.446 0.088 0.200
C G 100.00 100.00 1.000 0.000 0.000 0.000 0.00 0.00 1.000 0.000 0.000 0.000 0.00 0.00 1.000 0.000 0.000 0.000
rs341047 A G 0.00 0.00 1.000 0.000 0.000 0.000 19.05 11.76 0.869 -0.208 0.353 1.765 80.95 88.24 0.388 -0.353 0.208 0.567
rs150934987 A G 0.00 0.00 1.000 0.000 0.000 0.000 0.00 0.00 1.000 0.000 0.000 0.000 100.00 100.00 0.388 0.000 0.000 0.000









Table 6.20 SNPs associated with HNF1α 
 
38 unique SNPs associated with HNF1α were identified, and genotyped. Following a two-sample t-test for proportions, significant 







allele	(B) Q1 Q4 p-value Odds	Ratio Q1 Q4 p-value Odds	Ratio Q1 Q4 p-value Odds	Ratio
rs11755881 A G 0.00 0.00 1.000 0.000 0.000 0.000 14.29 11.76 1.000 -0.214 0.265 1.250 85.71 88.24 1.000 -0.265 0.214 0.800
rs1861 A C 0.00 0.00 1.000 0.000 0.000 0.000 4.76 5.88 0.746 -0.167 0.144 0.800 95.24 94.12 1.000 -0.144 0.167 1.250
rs28568667 T C 76.19 64.71 0.677 -0.230 0.459 1.745 14.29 23.53 0.757 -0.397 0.212 0.542 0.00 0.00 1.000 0.000 0.000 0.000
rs4770748 A G 0.00 0.00 1.000 0.000 0.000 0.000 9.52 5.88 1.000 -0.168 0.241 1.684 90.48 94.12 1.000 -0.241 0.168 0.594
rs663824 A G 47.62 23.53 0.233 -0.106 0.588 2.955 38.10 76.47 0.042 -0.726 -0.041 0.189 14.29 0.00 0.240 -0.060 0.346 0.000
rs6905159 A G 19.05 29.41 0.716 -0.431 0.224 0.565 66.67 64.71 1.000 -0.304 0.343 1.091 14.29 5.88 0.746 -0.156 0.324 2.667
rs888576 T C 0.00 0.00 1.000 0.000 0.000 0.000 33.33 23.53 0.762 -0.240 0.436 1.625 66.67 76.47 0.762 -0.436 0.240 0.615
rs13325508 T C 100.00 94.12 0.915 -0.106 0.224 0.000 0.00 5.88 0.922 -0.224 0.106 0.000 0.00 0.00 1.000 0.000 0.000 0.000
rs55723035 T C 0.00 0.00 1.000 0.000 0.000 0.000 0.00 11.76 0.377 -0.324 0.089 0.000 100.00 88.24 0.377 -0.089 0.324 0.000
rs77356515 T G 0.00 0.00 1.000 0.000 0.000 0.000 0.00 5.88 0.922 -0.224 0.106 0.000 100.00 94.12 0.915 -0.106 0.224 0.000
rs75363174 A G 0.00 0.00 1.000 0.000 0.000 0.000 4.76 17.65 0.450 -0.385 0.127 0.233 95.24 82.35 0.450 -0.127 0.385 4.286
rs4751674 T C 14.29 17.65 1.000 -0.302 0.235 0.778 47.62 35.29 0.664 -0.242 0.488 1.667 38.10 47.06 0.821 -0.458 0.279 0.692
rs61433965 A G 85.71 100.00 0.308 -0.346 0.060 0.000 14.29 0.00 0.240 -0.060 0.346 0.000 0.00 0.00 1.000 0.000 0.000 0.000
rs58838391 A G 0.00 0.00 1.000 0.000 0.000 0.000 0.00 0.00 1.000 0.000 0.000 0.000 100.00 100.00 1.000 0.000 0.000 0.000
rs76280424 A G 0.00 0.00 1.000 0.000 0.000 0.000 0.00 0.00 1.000 0.000 0.000 0.000 100.00 100.00 1.000 0.000 0.000 0.000
rs77794667 T C 0.00 0.00 1.000 0.000 0.000 0.000 4.76 0.00 1.000 -0.091 0.186 0.000 95.24 100.00 1.000 -0.186 0.091 0.000
rs59559871 T C 0.00 0.00 1.000 0.000 0.000 0.000 0.00 0.00 1.000 0.000 0.000 0.000 100.00 100.00 1.000 0.000 0.000 0.000
rs72826927 A G 0.00 0.00 1.000 0.000 0.000 0.000 14.29 17.65 1.000 -0.302 0.235 0.778 85.71 82.35 1.000 -0.235 0.302 1.286
rs945094 A T 0.00 0.00 1.000 0.000 0.000 0.000 4.76 0.00 1.000 -0.091 0.186 0.000 95.24 100.00 1.000 -0.186 0.091 0.000
rs72751116 A G 100.00 100.00 1.000 0.000 0.000 0.000 0.00 0.00 1.000 0.000 0.000 0.000 0.00 0.00 1.000 0.000 0.000 0.000
rs59706474 T C 0.00 0.00 1.000 0.000 0.000 0.000 4.76 5.88 1.000 -0.167 0.144 0.800 95.24 94.12 1.000 -0.144 0.167 1.250
rs73251982 A G 0.00 0.00 1.000 0.000 0.000 0.000 0.00 0.00 1.000 0.000 0.000 0.000 100.00 100.00 1.000 0.000 0.000 0.000











Table 6.20 SNPs associated with HNF1α (final) 
 
38 unique SNPs associated with HNF1α were identified, and genotyped. Following a two-sample t-test for proportions, significant 








allele	(B) Q1 Q4 p-value Odds	Ratio Q1 Q4 p-value Odds	Ratio Q1 Q4 p-value Odds	Ratio
rs77367389 A C 90.48 100.00 0.564 -0.274 0.084 0.000 4.76 0.00 1.000 -0.091 0.186 0.000 0.00 0.00 1.000 0.000 0.000 0.000
rs73668591 T C 0.00 0.00 1.000 0.000 0.000 0.000 0.00 5.88 0.922 -0.224 0.106 0.000 100.00 94.12 0.915 -0.106 0.224 0.000
rs73669423 T C 80.95 88.24 0.869 -0.353 0.208 0.567 19.05 11.76 0.869 -0.208 0.353 1.765 0.00 0.00 1.000 0.000 0.000 0.000
rs62493228 A C 0.00 0.00 1.000 0.000 0.000 0.000 14.29 5.88 0.746 -0.156 0.324 2.667 85.71 94.12 0.915 -0.324 0.156 0.375
rs76569571 T G 0.00 0.00 1.000 0.000 0.000 0.000 14.29 0.00 0.240 -0.060 0.346 0.000 80.95 100.00 0.170 -0.412 0.031 0.000
rs80312260 A G 0.00 0.00 1.000 0.000 0.000 0.000 0.00 5.88 0.922 -0.224 0.106 0.000 100.00 94.12 0.915 -0.106 0.224 0.000
rs2244608 A G 66.67 29.41 0.050 0.023 0.722 4.800 33.33 58.82 0.214 -0.617 0.107 0.350 0.00 11.76 0.377 -0.324 0.089 0.000
rs11616995 A G 90.48 100.00 0.564 -0.274 0.084 0.000 9.52 0.00 0.512 -0.084 0.274 0.000 0.00 0.00 1.000 0.000 0.000 0.000
rs11647932 T C 0.00 0.00 1.000 0.000 0.000 0.000 9.52 29.41 0.249 -0.502 0.105 0.253 90.48 70.59 0.249 -0.105 0.502 3.958
rs8102561 T C 38.10 76.47 0.042 -0.726 -0.041 0.189 52.38 23.53 0.140 -0.058 0.635 3.575 9.52 0.00 0.512 -0.084 0.274 0.000
rs340141 T C 0.00 23.53 0.069 -0.490 0.020 0.000 57.14 64.71 0.888 -0.439 0.288 0.727 42.86 11.76 0.081 -0.004 0.625 5.625
rs150333766 T C 0.00 0.00 1.000 0.000 0.000 0.000 0.00 0.00 1.000 0.000 0.000 0.000 100.00 100.00 1.000 0.000 0.000 0.000
rs189023122 T C 0.00 0.00 1.000 0.000 0.000 0.000 0.00 0.00 1.000 0.000 0.000 0.000 100.00 100.00 1.000 0.000 0.000 0.000
rs150428096 T C 0.00 0.00 1.000 0.000 0.000 0.000 0.00 0.00 1.000 0.000 0.000 0.000 100.00 100.00 1.000 0.000 0.000 0.000








Table 6.21 SNPs associated with TCF7L2 
 
44 unique SNPs associated with TCF7L2 were identified, and genotyped. Following a two portions t-test significantly different 








allele	(B) Q1 Q4 p-value Odds	Ratio Q1 Q4 p-value Odds	Ratio Q1 Q4 p-value Odds	Ratio
rs12894204 A G 0.00 5.88 0.922 -0.224 0.106 0.000 23.81 29.41 0.985 -0.392 0.280 0.750 76.19 64.71 0.679 -0.230 0.459 1.745
rs17605420 A G 90.48 100.00 0.512 -0.274 0.084 0.000 4.76 0.00 1.000 -0.091 0.186 0.000 0.00 0.00 1.000 0.000 0.000 0.000
rs17763253 T C 0.00 0.00 1.000 0.000 0.000 0.000 14.29 5.88 0.746 -0.156 0.324 2.669 85.71 94.12 0.746 -0.324 0.156 0.375
rs6728493 A C 38.10 64.71 0.175 -0.627 0.095 0.336 61.90 29.41 0.076 -0.028 0.678 3.900 0.00 5.88 0.922 -0.224 0.106 0.000
rs9906935 A G 57.14 52.94 1.000 -0.318 0.402 1.185 33.33 35.29 1.000 -0.343 0.304 0.917 9.52 11.76 1.000 -0.243 0.198 0.789
rs7089262 T C 0.00 0.00 1.000 0.000 0.000 0.000 14.29 11.76 1.000 -0.214 0.265 1.251 85.71 88.24 1.000 -0.265 0.214 0.799
rs76677854 T C 85.71 94.12 0.746 -0.324 0.156 0.375 14.29 5.88 0.746 -0.156 0.324 2.669 0.00 0.00 1.000 0.000 0.000 0.000
rs145079521 A C 90.48 100.00 0.512 -0.274 0.084 0.000 9.52 0.00 0.512 -0.084 0.274 0.000 0.00 0.00 1.000 0.000 0.000 0.000
rs78082945 T C 90.48 88.24 1.000 -0.198 0.243 1.267 9.52 11.76 1.000 -0.243 0.198 0.789 0.00 0.00 1.000 0.000 0.000 0.000
rs62272114 A G 0.00 0.00 1.000 0.000 0.000 0.000 4.76 0.00 1.000 -0.091 0.186 0.000 95.24 100.00 1.000 -0.186 0.091 0.000
rs77385406 A G 0.00 0.00 1.000 0.000 0.000 0.000 0.00 17.65 0.182 -0.411 0.058 0.000 100.00 82.35 0.182 -0.058 0.411 0.000
rs61732118 A G 0.00 0.00 1.000 0.000 0.000 0.000 0.00 0.00 1.000 0.000 0.000 0.000 100.00 100.00 1.000 0.000 0.000 0.000
rs61875109 A C 14.29 5.88 0.746 -0.156 0.324 2.669 23.81 41.18 0.426 -0.523 0.176 0.446 61.90 52.94 0.821 -0.279 0.458 1.444
rs116369954 T C 80.95 88.24 0.865 -0.353 0.208 0.566 19.05 11.76 0.865 -0.208 0.353 1.766 0.00 0.00 1.000 0.000 0.000 0.000
rs79805154 A G 85.71 88.24 1.000 -0.265 0.214 0.799 14.29 11.76 1.000 -0.214 0.265 1.251 0.00 0.00 1.000 0.000 0.000 0.000
rs77064952 A G 0.00 0.00 1.000 0.000 0.000 0.000 0.00 0.00 1.000 0.000 0.000 0.000 100.00 100.00 1.000 0.000 0.000 0.000
rs10059523 A G 0.00 0.00 1.000 0.000 0.000 0.000 14.29 5.88 0.746 -0.156 0.324 2.669 85.71 94.12 0.746 -0.324 0.156 0.375
rs78183526 T C 0.00 0.00 1.000 0.000 0.000 0.000 0.00 0.00 1.000 0.000 0.000 0.000 100.00 100.00 1.000 0.000 0.000 0.000
rs587667473 A C 61.90 70.59 0.826 -0.440 0.266 0.677 33.33 29.41 1.000 -0.296 0.374 1.200 0.00 0.00 1.000 0.000 0.000 0.000
rs73179006 T G 0.00 0.00 1.000 0.000 0.000 0.000 14.29 5.88 0.746 -0.156 0.324 2.669 85.71 94.12 0.746 -0.324 0.156 0.375
rs113262704 T G 0.00 0.00 1.000 0.000 0.000 0.000 19.05 11.76 0.865 -0.208 0.353 1.766 80.95 88.24 0.865 -0.353 0.208 0.566
rs61989114 A G 0.00 0.00 1.000 0.000 0.000 0.000 0.00 5.88 0.922 -0.224 0.106 0.000 100.00 94.12 0.922 -0.106 0.224 0.000
rs55656505 T C 90.48 88.24 1.000 -0.198 0.243 1.267 9.52 11.76 1.000 -0.243 0.198 0.789 0.00 0.00 1.000 0.000 0.000 0.000









Table 6.21 SNPs associated with TCF7L2 (final) 
 
44 unique SNPs associated with TCF7L2 were identified, and genotyped. Following a two portions t-test significantly different 






allele	(B) Q1 Q4 p-value Odds	Ratio Q1 Q4 p-value Odds	Ratio Q1 Q4 p-value Odds	Ratio
rs3026084 A G 90.48 94.12 1.000 -0.241 0.168 0.594 9.52 5.88 1.000 -0.168 0.241 1.684 0.00 0.00 1.000 0.000 0.000 0.000
rs189314829 A G 0.00 0.00 1.000 0.000 0.000 0.000 9.52 11.76 1.000 -0.243 0.198 0.789 90.48 88.24 1.000 -0.198 0.243 1.267
rs75107770 A G 0.00 0.00 1.000 0.000 0.000 0.000 0.00 17.65 0.182 -0.411 0.058 0.000 100.00 82.35 0.182 -0.058 0.411 0.000
rs73223028 T C 0.00 0.00 1.000 0.000 0.000 0.000 0.00 5.88 0.922 -0.224 0.106 0.000 100.00 94.12 0.922 -0.106 0.224 0.000
rs116929578 A G 85.71 76.47 0.760 -0.212 0.397 1.846 9.52 17.65 0.803 -0.355 0.192 0.491 0.00 0.00 1.000 0.000 0.000 0.000
rs117041486 A G 0.00 0.00 1.000 0.000 0.000 0.000 0.00 5.88 0.922 -0.224 0.106 0.000 100.00 94.12 0.922 -0.106 0.224 0.000
rs79565172 A G 100.00 100.00 1.000 0.000 0.000 0.000 0.00 0.00 1.000 0.000 0.000 0.000 0.00 0.00 1.000 0.000 0.000 0.000
rs117582734 T C 0.00 0.00 1.000 0.000 0.000 0.000 14.29 5.88 0.746 -0.156 0.324 2.669 85.71 94.12 0.746 -0.324 0.156 0.375
rs12243326 T C 52.38 23.53 0.116 -0.058 0.635 3.575 38.10 52.94 0.554 -0.517 0.220 0.547 9.52 23.53 0.473 -0.431 0.151 0.342
rs4889830 A G 33.33 35.29 1.000 -0.343 0.304 0.917 52.38 29.41 0.256 -0.128 0.587 2.640 14.29 35.29 0.259 -0.535 0.115 0.306
rs3787493 A G 33.33 41.18 0.873 -0.440 0.284 0.714 38.10 41.18 1.000 -0.374 0.313 0.879 28.57 17.65 0.679 -0.209 0.427 1.866
rs4713505 T G 9.52 5.88 1.000 -0.168 0.241 1.684 38.10 41.18 1.000 -0.374 0.313 0.879 52.38 52.94 1.000 -0.330 0.319 0.978
rs2070600 T C 0.00 0.00 1.000 0.000 0.000 0.000 19.05 23.53 1.000 -0.352 0.262 0.765 80.95 76.47 1.000 -0.262 0.352 1.308
rs3131300 A G 61.90 58.82 1.000 -0.313 0.374 1.137 28.57 23.53 1.000 -0.279 0.380 1.300 9.52 17.65 0.803 -0.355 0.192 0.491
rs73471190 T C 0.00 0.00 1.000 0.000 0.000 0.000 0.00 5.88 0.922 -0.224 0.106 0.000 100.00 94.12 0.922 -0.106 0.224 0.000
rs148924158 A G 100.00 100.00 1.000 0.000 0.000 0.000 0.00 0.00 1.000 0.000 0.000 0.000 0.00 0.00 1.000 0.000 0.000 0.000
rs143828311 T C 0.00 0.00 1.000 0.000 0.000 0.000 0.00 0.00 1.000 0.000 0.000 0.000 100.00 100.00 1.000 0.000 0.000 0.000
rs201967398 A G 0.00 0.00 1.000 0.000 0.000 0.000 0.00 0.00 1.000 0.000 0.000 0.000 100.00 100.00 1.000 0.000 0.000 0.000
rs143652701 T C 0.00 0.00 1.000 0.000 0.000 0.000 0.00 0.00 1.000 0.000 0.000 0.000 100.00 100.00 1.000 0.000 0.000 0.000

















Table 6.22 Difference in prevalence of SNPs in SU+ diabetic cohort 
 
A summary of SNPs that are significantly different between those receiving sulphonylureas after being divided into lowest (Q1) and 
highest (Q4) quartiles according to HbA1c. 
%	BB
dbSNP	RS	ID A	allele B	allele Q1 Q4 Q1 Q4 Q1 Q4 Q1 Q4 p-value Q1 Q4 p-value Q1 Q4 p-value
ABCC8 rs17743658 A G 95.24 100.00 0.2500 0.3824 0.0369 0.1272 14.29 5.88 0.746 19.05 64.71 0.011 61.90 29.41 0.076
KCNJ11 rs506757 T G 100 100 0.3810 0.4412 0.0581 0.0962 28.57 41.18 0.402 66.67 29.41 0.050 4.76 29.41 0.104
rs13183249 A G 100 100 0.1905 0.2941 0.0797 0.0858 9.52 0.00 0.564 19.05 58.82 0.029 71.43 41.18 0.126
HNF1a rs663824 A G 100.00 100.00 0.3333 0.3824 0.5127 0.0107 47.62 23.53 0.233 38.10 76.47 0.042 14.29 0.00 0.240
rs2244608 A G 100.00 100.00 0.1667 0.4118 0.3594 0.3770 66.67 29.41 0.050 33.33 58.82 0.214 0.00 11.76 0.377
rs8102561 T C 100.00 100.00 0.3571 0.1176 0.5190 0.5825 38.10 76.47 0.042 52.38 23.53 0.140 9.52 0.00 0.512





An important first point to make is that the results seen here are 
preliminary and should be treated with caution, while SNPs present have 
been associated with certain phenotypes in the literature, the work 
presented here is not robust enough to definitively state that this is the 
case in this cohort. Multiple tests have been performed on this data, and 
as always multiple testing itself can skew results seen, perhaps producing 
false positive associations. The results are also not wholly representative 
of the cohort as not all participants were sequenced due to a need to 
complete the project on time and within budget. More work is needed 
however, more detail of which is given later in this section. 
 
In the current study, three SNPs were significantly associated with a T2DM 
phenotype. Several variants in KCNJ11 displayed significant differences 
in genotype between those with T2DM and control. rs78374474, 
associated with KCNJ11, is located on chromosome 8 at position 
24469242. It lies in the gene RP11-624C23 (Type 2 Diabetes Knowledge 
Portal, 2017). The nucleotide at this position in the reference sequence is 
C, and the variant allele is T. Data available on the T2D knowledge portal 
suggests that while this variant is not significantly associated with a T2DM 
phenotype, there is a positive direction of effect that suggests a higher 
probability of having the disease. In our cohort, the prevalence of BB 
genotype of rs78374474 was significantly higher in those with T2DM 
compared with our control cohort. 
 
Another variant associated with KCNJ11, rs76557252 is located on 
chromosome 13 at position 97201682, it lies within the gene HS6ST3 (Type 
2 Diabetes Knowledge Portal, 2017). The nucleotide at this position in the 
reference sequence is G, and the variant allele is T. The data available 
for the SNP on the T2D knowledge portal is inconclusive for this variant, as 
the association with a T2DM phenotype is not significant and datasets 
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that show both a positive and negative direction of effect for probability 
of having the disease. The direction of effect may well depend on 
genotype. In this study, the AB genotype was less commonly observed in 
those with T2DM, while the BB genotype was significantly more 
prevalence in the T2DM cohort. 
 
rs4713505 is associated with TCF7L2, and is located on chromosome 6 at 
position 32105001, it lies closest to the gene FKBPL (Type 2 Diabetes 
Knowledge Portal, 2017). The nucleotide at this position in the reference 
sequence is G, and the variant allele is T. In this study, the BB genotype 
was observed in the T2DM population at almost double the rate of the 
control cohort. Variation in TCF7L2 is among the strongest risk factors for 
development of T2DM (Peng et al., 2013). Evidence from the T2D 
knowledge portal has suggests rs4713505 is associated with numerous 
traits; of particular interest for comparison with results here is its 
association with T2DM phenotype.  
 
The use of genetic variants to predict risk of developing a disease is 
useful particularly in populations that are known to be at risk (i.e. in the 
case of T2DM, the obese or prediabetic populations). However, a 
challenge that is common in T2DM is that while clinical features can 
predict disease well it is clear that predicting in other areas isn’t as good, 
like predicting response to treatment. For those with an established 
diagnosis of T2DM, the potential use of genotyping to stratify drug 
treatment may have even greater utility and may help prevent adverse 
events and progression to many of the complications associated with 
long-term hyperglycaemia. This study has highlighted variants that also 
may be predictive of glycaemic control in the T2DM population, and 
those that appear to be associated with good glycaemic control in 
response to sulphonylurea treatment. For example, rs17743658 is 
associated with ABCC8, located on chromosome 18 at position 48476450 
and lies within the gene ME2 (Type 2 Diabetes Knowledge Portal, 2017) 
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(a gene that is important for insulin secretion from pancreatic β-cells 
(Hasan et al., 2015)). The nucleotide at this position in the reference 
sequence is G, and the variant allele is A. In the current study the AB 
genotype was observed in those ranked in Q4 for HbA1c at almost twice 
the rate of those ranked in Q1. This suggests that the presence of this 
genotype may be associated with poor glycaemic control. Importantly, 
this was only observed in those on sulphonylureas. In the non-
sulphonylurea groups, the difference between Q1 and Q4 was not 
significant. 
 
rs13183249 is associated with KCNJ11 and is located on chromosome 5 
at position 5807951, it lies closest to the gene ICE1 (Type 2 Diabetes 
Knowledge Portal, 2017). The nucleotide at this position in the reference 
sequence is G, and the variant allele is A. Another variant associated 
with the KCNJ11 gene in this study, rs663824, is located on chromosome 1 
at position 43649508, It lies in the gene CFAP57 (cilia and flagella 
associated protein 57) (Type 2 Diabetes Knowledge Portal, 2017) and it 
significantly associated with aggressive prostate cancer (Chen, 2014). 
The nucleotide at this position in the reference sequence is A, and the 
variant allele is G. Little is known about these variants in relation to T2DM 
risk or glycaemic control. Prevalence of the AB genotype of each of 
these variants had differing association with glycaemic control in the 
current study. rs13183249 was more prevalent in Q1, whilst rs663824 was 
more prevalent in Q4, reflective of the fact that variants can be both 
protective and detrimental when it comes to glycaemic control.  Again, 
it is important to note, that these observations were exclusive to those on 
sulphonylureas in this study. Participants receiving other anti-diabetic 
drugs did not show differential expression of any genotype associated 
with these SNPs. rs506757 is associated with KCNJ11, and is located on 
chromosome 13 at position 97303709, it lies in the gene HS6ST3 (Type 2 
Diabetes Knowledge Portal, 2017), a gene that has been linked to the 
progression of T2DM (Li et al., 2016). The nucleotide at this position in the 
 195 
reference sequence is T, and the variant allele is G. There is a positive 
direction of effect for its association with a T2DM phenotype, and HbA1c 
according to data from the T2D Knowledge portal.  
 
The variant rs2244608 is located on chromosome 12 at position 
121416988; it lies in the gene HNF1α itself (Type 2 Diabetes Knowledge 
Portal, 2017). The nucleotide at this position in the reference sequence is 
A, and the variant allele is G. This particular polymorphism has been 
cited for its association with C-reactive protein (Reiner et al., 2008), and 
data from the T2D Knowledge portal suggest a significant association 
with a T2DM phenotype and a negative direction of effect for its 
association with HbA1c. Consistent with this, an association between the 
AB genotype and good glycaemic control was observed here. Finally, 
rs8102561 associated in this study with the HNF1α gene, is a variant 
located on chromosome 19 at position 55488150, it lies in the gene NLRP2 
(Type 2 Diabetes Knowledge Portal, 2017), which inhibits the NF-kappa B 
signaling pathway and regulates Caspase-1 (Bruey et al., 2004, Fontalba 
et al., 2007). The nucleotide at this position in the reference sequence is 
T, and the variant allele is C. From data available on the T2D knowledge 
portal, there is no significant association with a T2DM phenotype and 
data sets have both a positive and negative direction of effect for 
probability of having the disease. However, in the current study, the AB 
genotype was again found to be significantly associated with poor 
glycaemic control, only in those receiving sulphonylureas. 
 
This work is a preliminary analysis and further refining is needed. DNA from 
the remainder of the cohort needs to be sequenced. The current 
analysis is also limited by population size. Recruitment is ongoing to 
increase the number of control participants to a minimum of 200, which 
will have to be sequenced also. Reanalysis of the data at this stage will 
validate the findings of this study. Furthermore, the findings require 
validation in secondary cohorts of individuals with T2DM and controls 
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and collaborations are being established with centers throughout the UK 
to allow this to happen. The computational team at the NI Centre for 
Stratified Medicine are also undertaking further analysis of the current 
dataset to interrogate the relationship between genotype and other 
T2DM-associated phenotypes including BMI, c-peptide and lipid profiles. 
At that point in the future, when this further work has done, further more 
sophisticated statistical analysis can take place, making the results seen 
more robust.  
 
Nonetheless, the current work suggests that there is a unique panel of 
SNPs associated with a T2DM phenotype and with poor glycaemic 
control in this population. Of particular interest and worthy of further 
investigation, this study has revealed several SNPs within ABCC8, KCNJ11 
and HNF1α that appear to be associated with good glycaemic control in 
those receiving sulphonylurea therapy, but not in those on other classes 
of anti-diabetic drugs. Although this finding requires further validation, it is 
an exciting discovery and may be useful in assessing response to the 
sulphonylurea drug class, which is associated with poor response rates 


































7.1 Heterogeneity of the diabetic population  
 
Type 2 diabetes mellitus (T2DM) is a multifaceted disease, which arises 
through a clash of genetic and environmental factors, and which is 
reaching epidemic proportions globally (Danaei et al., 2011, Alberti and 
Zimmet, 2014, Zimmet et al., 2014). It is a complicated heterogeneous 
collection of metabolic disorders that includes hyperglycaemia and 
impaired insulin secretion and/or action (Lin and Sun, 2010). There is 
increasing evidence to show that diabetes is far more heterogeneous 
than previously thought. Recent data suggest that merely grouping 
those suffering with this chronic disease as type 1 or type 2 is simplifying 
the broad spectrum of factors at play in the disease, and likely means 
there are far more subgroups prevalent in the increasing numbers of 
those diagnosed (Tuomi et al., 2014). For example, β-cell autoantibodies 
were identified in a subgroup of children and adolescents who 
presented clinically as having T2DM (Reinehr et al., 2006). Furthermore, 
topological analysis of patient similarities revealed that people with 
T2DM can be classified into three distinct groups that predict the 
development of specific diabetic complications (Li et al., 2015). 
 
Given this, the approach to treating T2DM is notoriously complicated 
with the NICE care pathway offering multiple stages of assessment and 
intervention. Stratified or Precision Medicine has offered the hope that 
much of the trial and error approach to the treatment of T2DM may be 
solved by identifying specific biomarkers or drivers of glycaemic control. 
A great deal of research has focused on the identification of genetic 
biomarkers. However, clinical parameters and indeed proteomic or 
metabolomics markers may also be of significant clinical utility. To this 
end, the current study sought to characterize clinical, proteomic and 
genetic markers associated with glycaemic control in the DIASTRAT 
cohort, with particular emphasis on analysis of those receiving 
sulphonylurea therapy, which is an antidiabetic drug class associated 
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with poor response rates and significant adverse events (Aquilante, 
2010). 
 
In the current study, the DIASTRAT cohort were recruited solely from the 
Western Health and Social Care Trust, which covers an area of 4,842 sq. 
km, taking in counties Derry, Tyrone and Fermanagh. Participants were 
recruited from within this region only, with the vast majority being 
recruited from Derry City and surrounding areas, and participants were 
relatively homogenous in terms of ethnicity.  This cohort was almost 
exclusively recruited from secondary care clinics, which suggests an 
advanced stage of disease, but may also raise additional complications 
of comorbidities. Within the DIASTRAT cohort 51% of participants were 
found to have a clinical diagnosis for 5 or more comorbid conditions. The 
association of T2DM and comorbid conditions, and the subsequent risk of 
complication, has been widely reported (Hollander and Kushner, 2010, 
Kim et al., 2012, Pantalone et al., 2015) 
 
The incidence of T2DM increases with age and the condition 
disproportionately affects people aged 65 or older. Consistent with this, 
the mean age of the DIASTRAT cohort was 63. The advancing age of the 
T2DM population and the diagnosed comorbidities discussed above, 
increases the likelihood, and indeed occurrence, of polypharmacy 
(Noale et al., 2016). It is typical that older people are more likely to suffer 
from chronic medical conditions like hypertension, obesity, or 
dyslipidemia that leads to the need for additional drugs (Noale et al., 
2016). In the DIASTRAT study, 14% of participants were on 4 or more 
antidiabetic drugs. However, the scale of the polypharmacy within this 
group is better understood when non-antidiabetic treatments are 
considered. There are some 69% of participants receiving at least 5 
treatments, and 17% of participants receiving at least 10 treatments. 
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The current study has identified several factors of relevance to clinical 
decision making: Firstly, the concomitant prescription of a sulphonylurea 
with an exogenous insulin preparation was associated with higher BMI 
and worsened glycaemic control when compared with those receiving 
either drug in isolation. The co-prescribing of these drugs is not an 
isolated phenomenon in our cohort. Recent work in a Canadian cohort 
of 458 people with T2DM suggested that 18% were on both insulin and 
sulphonylureas for more than one year (Ratzki-Leewing et al., 2017). 
Given that both prescriptions seek to restore circulating insulin levels, it 
appears contradictory to permit long-term administration of both drugs 
in combination. Secondly, the data reveal poor glycaemic control 
among the DIASTRAT cohort, which is countered by excellent lipid 
profiles. Current NICE guidelines are heavily focused on the control of 
cholesterol to prevent the development of cardiovascular complications 
(National Institute for Health and Care Excellence (NICE), 2015). These 
targets are clearly being met within the DIASTRAT cohort, but this is 
potentially at the expense of glycaemic control, which will elevate the 
risk of macrovascular complications independently of cholesterol levels. 
Consistent with this, peripheral protein markers in the DIASTRAT cohort 
were heavily associated with Coronary Artery Disease. 
 
            
7.2 Proteomic markers of glycaemic control 
             
There is a dearth of potential proteomic markers of glycaemic control. 
The key role played by inflammatory processes in diabetes (Wellen and 
Hotamisligil, 2005, Alexandraki et al., 2006, Montane et al., 2014) and in 
obesity-driven insulin resistance (de Luca and Olefsky, 2008, Monteiro 
and Azevedo, 2010, Cavalcante-Silva et al., 2015) is well studied and 
reported. With that in mind, the current study sought to identify protein 
markers of glycaemic control within the DIASTRAT cohort.  
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The results identified an initial 75-protein signature that distinguished 
those with T2DM from apparently healthy controls with 99.2% accuracy. 
While this is indeed interesting, it is not necessarily clinically significant as 
we can already identify those with T2DM via less expensive glucose 
monitoring or biochemical tests. However, the identification of a unique 
protein signature did reveal several important factors about the 
inflammatory processes in this cohort. Firstly, inflammation is macrophage 
driven, consistent with findings that macrophages are present in adipose 
tissue and that obesity can alter the activation status of these cells 
(Donath and Shoelson, 2011). Obesity can promote a chronic low-grade 
inflammation, which is related to parainflammation (Medzhitov, 2008). 
Parainflammation is crucial to the interaction between metabolism and 
inflammation. The dysregulation of this inflammation is linked to insulin 
resistance, through the increase of cytokines like tumor necrosis factor-α 
(TNF-α), and macrophage infiltration into adipose tissue (Thomas and 
Apovian, 2017). There are a plethora of outcomes to this dysregulation, 
including chronic systemic inflammation, metabolic syndrome, obesity-
related insulin resistance, non-alcoholic fatty liver disease and, 
importantly for this study, T2DM (Nikolajczyk et al., 2012, Thomas and 
Apovian, 2017). Also in this cohort CD4+ T cells did not have a primary 
role to play in driving the inflammatory process, contrary to current 
evidence (Shu et al., 2012, Xia et al., 2017). Consistently, protein markers 
poorly expressed in the DIASTRAT cohort were heavily associated with 
CD4+ T cells. Few of those identified have previously been associated 
with disease pathogenesis. Perhaps not surprisingly, a single protein 
marker for glycaemic control could not be identified within this cohort – 
the volume of inflammatory, genetic and environmental factors involved 
in the genesis and progression of this disease meant that this was always 
likely to be the case. However, the work was not without merit. For 
example, proteins that were identified within the DIASTRAT cohort, KIM1 
FGF23, FGF21, were each associated with elevated HbA1c. A finding 
that is hoped can be further validated in larger cohorts in the future. In 
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addition, many of the markers identified here have been implicated in 
development of secondary complications. Therefore, there may be 
significant clinical benefit in screening for these markers in the prediction, 




7.3 Genetic variants associated with T2DM and glycaemic control 
 
The contribution and effect of genetic variants in the development of 
T2DM is wide and varied. The current study sought to investigate the role 
of specific genes previously identified as important in sulphonylurea 
response at a single cell level in the pancreatic β-cell and globally, within 
populations.  
 
The work presented in this thesis confirms a role for both ABCC8 and 
KCNJ11 in the response to sulphonylurea treatment. This is largely 
unsurprising given that these genes encode the protein subunits of the 
KATP channel, the primary target of the sulphonylurea drug class. From a 
mechanistic perspective, silencing of either ABCC8 or KCNJ11 
hampered sulphonylurea-potentiated insulin secretion from β-cell lines. 
Consistently, several SNPs associated with ABCC8 and KCNJ11 were 
found to be significantly associated with glycaemic control in those 
receiving sulphonylureas, but not in those receiving other anti-diabetic 
therapies. These results are consistent with work produced by other 
groups (Meirhaeghe et al., 2001, Zychma et al., 2002, Schroner et al., 
2011, Ragia et al., 2012, Li et al., 2014, Song et al., 2017), but it should still 
be noted that is contradicted by results in other work also 
(Haghvirdizadeh et al., 2015). Going forward, it will be important to 
validate the direct mechanistic impact of these SNPs on insulin release 
via CRISPR/Cas9 studies in isolated β-cell lines and primary islet cells.  
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The association between risk of T2DM, or sulphonylurea response, and 
certain variants has been studied in the past. Variants for each of the 
genes of interest within this work have been highlighted, thus providing 
extra validation for pursuing the prevalence of polymorphisms within 
these genes within the DIASTRAT cohort, and then to define what 
association existed with glycaemic control, particularly in those who 
were prescribed sulphonylureas. There are over 80 common variants for 
T2DM that have already been identified, but which generate a small 
effect, with a minor allele frequency >5%. These variants therefore 
account only for around 10% of heritability of T2DM (Stancakova and 
Laakso, 2016, Fuchsberger et al., 2016).  The results for the DIASTRAT 
cohort showed variants are potentially predictive of glycaemic control 
or are associated with response to sulphonylureas. In an attempt to 
corroborate the conclusions drawn from these results, publically 
available datasets held within the T2D Knowledge Portal 
(http://type2diabetesgenetics.org/home/portalHome) were consulted. 
This work confirmed that several variants identified from the current 
analysis are associated with a variety of traits consistent with a T2DM 
phenotype. Despite the limited sample size, the current work suggests 
that a unique panel of SNPs associated with a T2DM phenotype and with 




7.4 Concluding remarks: integration of clinical and molecular data for  
prediction of glycaemic control in T2DM. 
  
The aims of this work were four-fold: (1) Identify and validate existing 
markers of sulphonylurea response in two pancreatic β-cell lines; (2) 
Establish a biobank of 500 T2DM patients (DIASTRAT cohort) with 
associated clinical, anthropometric, and biochemical data; (3) Conduct 
proteomic screens for novel inflammatory or metabolic markers 
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associated with glycaemic control and sulphonylurea response in the 
DIASTRAT cohort; and (4) assess the prevalence of potentially important 
SNPs among the DIASTRAT cohort and assess the relationship with 
glycaemic control and sulphonylurea response.  
 
To date, T2DM research has tended to focus on either genetic or clinical 
markers of glycaemic control in isolation. However, the use of simple 
clinical information can also provide significant benefit when making 
clinical decisions. Shields et al. (2016) showed that BMI and sex should be 
considered when selecting a sulphonylurea. Their results pointed to 
better glycaemic response in non-obese males when compared to 
obese females.  This example suggests that clinical data may also help 
to stratify patients. The integration of clinical, proteomic and genomic 
information expands the potential for positive patient outcomes and 
cost savings for health services.  
 
The results shown for DIASTRAT do come with caveats, most notable of 
which is the small sample size, which restricts the conclusions that can be 
drawn from the work. However, work is ongoing to expand the project 
into other centres in the UK and validate the results seen here in larger 
secondary cohorts. The observations here that clinical parameters, 
proteomic and genetic markers are differentially expressed in those with 
and without T2DM further reflect the heterogeneity of the disease. The 
current study has identified unique protein and genetic markers that are 
associated with a T2DM phenotype and further identified several novel 
targets for sulphonylurea response. Pending further validation, it is hoped 
that these findings may prove of clinical utility in the treatment of T2DM. 
Furthermore, the work highlights the importance of considering clinical, 
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